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Summary 
 
Inflammatory processes are present in different pathologies including chronic 
inflammatory disorders, neuroinflammatory conditions and cancer. We hypothesized that 
an ideal lentiviral expression system for gene therapy treatments of such diseases could 
make use of the pathological inflammation grade, specific to each pathological condition 
and to the course of the disease, to regulate the transgene expression levels; ideally the 
expression levels of the therapeutic agent would parallel the local inflammatory status and 
therefore might avoid undesirable side effects associated with a constant transgene 
expression. These inflammation-regulated systems might also circumvent drug efficacy 
attenuation due to a continuous exposure to the therapeutic agent. 
Our approach has consisted on the generation of lentiviral vectors (LVs) that contain 
inflammation-regulated promoters to drive transgene expression. Antonio Rodríguez’s 
research group has developed a novel LV system based on the human E-selectin promoter. 
In addition we have also generated other two inflammation-regulated LVs based on 
previous reports: a hybrid promoter based on the human IL-6 promoter plus an enhancer 
region of the human IL-1 promoter and a chimeric promoter based on six NF-κB 
transcription factor binding sites in tandem. We have confirmed their in vitro inducibilities 
in different cell types (immune, endothelial, glia and tumor cells) in response to pro-
inflammatory stimuli such as TNF-α, IL-1 or LPS. 
LVs represent the chosen gene therapy tool to obtain stable and long-lived transgene 
expression in vivo. This study shows that the combination of LVs with inflammation-
inducible promoters allows to monitor inflammatory processes such as those taking place 
in acute inflammation and solid tumor models. Moreover our results indicate that the 
expression of the proper cytokine (either murine IL-10 or IL-12) under these 
inflammation-regulated LV systems constitute an efficient strategy to provide disease-
regulated cytokine expression with therapeutic effects in the mouse model assayed. These 
systems also reduce side effects as cytokine expression is confined to inflammatory sites. 
These inducible promoters might represent excellent systems for the inflammation-
regulated expression of different agents for future clinical applications. 
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Resumen 
 
Los procesos inflamatorios están presentes en diferentes patologías incluyendo 
enfermedades inflamatorias crónicas, neuroinflamación y cáncer. Nuestra hipótesis de 
partida consiste en que un vector lentiviral ideal para el tratamiento con terapia génica 
puede aprovecharse del nivel de inflamación, específico de cada patología y del curso de la 
enfermedad, para regular los niveles de expresión del transgén, de forma que se 
produzcan diferentes niveles de la molécula terapéutica en respuesta al estado 
inflamatorio local y, por lo tanto, se puedan evitar los efectos secundarios asociados.  
Nuestro abordaje ha consistido en el desarrollo de vectores virales que contienen 
promotores inducibles por inflamación para controlar la expresión del transgén. El 
laboratorio del Dr. Antonio Rodríguez ha desarrollado un nuevo sistema lentiviral 
inducible por inflamación basado en el promotor de la Selectina-E humana. Además hemos 
reproducido otros dos sistemas regulados por inflamación previamente descritos: el 
promotor híbrido formado por el promotor de la IL-6 humana unido a la región 
potenciadora del promotor humano de la IL-1 y el promotor quimera basado en seis sitios 
de unión para el factor de transcripción NF-κB en tándem. Hemos validado estos sistemas 
lentivirales inducibles por inflamación in vitro demostrando su inducibilidad en diferentes 
tipos celulares (células del sistema inmune, endoteliales, de la glía y tumorales) en 
respuesta a estímulos inflamatorios como TNF-α, IL-1 y LPS. 
Se han empleado vectores lentivirales ya que representan la mejor estrategia para obtener 
una expresión del transgén estable y duradera in vivo. Este estudio demuestra que la 
combinación de vectores lentivirales con promotores inducibles por inflamación permite 
la monitorización de procesos inflamatorios como los que tienen lugar en los modelos de 
inflamación aguda o durante el desarrollo de tumores sólidos. Además nuestros resultados 
indican que la expresión de citoquinas anti o pro-inflamatorias (IL-10 e IL-12 murinas) 
bajo el control de promotores regulados por inflamación empleando vectores lentivirales, 
constituye una estrategia eficiente para conseguir la expresión de la molécula regulada por 
la propia enfermedad, produciendo un efecto terapéutico en el modelo correspondiente y 
reduciendo los potenciales efectos secundarios. Estos promotores inducibles pueden 
representar excelentes sistemas para la expresión regulada por inflamación de diferentes 
agentes terapéuticos en futuras aplicaciones clínicas. 
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1 Abbreviations 
 
AAV Adeno-associated virus 
ALS Amyotrophic lateral sclerosis
AP-1 Activator protein 1 
APC Antigen-presenting cell 
CARs Chimeric antigen receptors
CD Cluster of differentiation
CLRs C-type lectin receptors 
CMV Cytomegalovirus 
COX2 Cyclooxygenase 2 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4
CTLs Cytotoxic T lymphocytes
DAMPs Damage associated molecular patterns
DC Dendritic cell 
ESEL E-selectin
GM-CSF Granulocyte macrophage colony-stimulating factor
HBV Hepatitis virus B 
HCC Hepatocellular carcinoma
HCV Hepatitis virus C 
HIF1α Hypoxia-inducible factor 1 α
IBD Inflammatory bowel disease
ICAM-1 Intercellular adhesion molecule-1
IFN Interferon
Ig Immunoglobulin 
IL Interleukin 
IP10 Interferon-inducible protein 10
IRES Internal ribosomal entry sites
LLC Lewis lung carcinoma 
LPS Lipopolysaccharide 
LTR Long terminal repeat 
LV Lentiviral vector or lentivector
MALT Mucosa-associated lymphoid tissue
MIG Monokine induced by interferon γ
MMP Matrix metalloproteinase
MOI Multiplicity of infection 
NF-κB Nuclear factor-κB 
NK Natural killer 
NLRs NOD-like receptors 
OEC Olfactory ensheathing cell
OM Olfatory mucosa 
PAMPs Pathogen-associated molecular patterns
PD-1 Programmed cell death 1
PD-L1 Programmed cell death ligand 1
PRRs Pattern recognition receptors 
RA Rheumatoid arthritis 
RIG Retinoic acid-inducible gene
RLU Relative light unit 
ROS Reactive oxygen species
SDF-1 Stromal cell-derived factor-1
SFFV Spleen focus-forming virus
SOD-1 Superoxide dismutase-1
9
  
STAT Signal transducer and activator of transcription 
TLRs Toll-like receptors 
TNF-α Tumor necrosis factor α
VCAM-1 Vascular cell adhesion molecule-1
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2.1 Inflammation 
 
Inflammation is a protective response to damage produced by noxious stimuli such us 
pathogens, chemicals, or physical injury that is intended to recover tissue functionality 
and homeostasis. Classically, inflammatory processes have been classified in acute and 
chronic inflammation1. Acute inflammation is characterized by rapid onset and short 
duration promoting stimulus neutralization followed by resolution of the inflammatory 
process and tissue reparation. In the case of chronic inflammation the duration is longer 
(from days to years) and frequently associated with severe and progressive tissue injury. 
Acute inflammation may progress to chronic when it is not properly resolved; however 
some forms of injury produce chronic inflammation response from the outset. 
 
2.2 Inflammation components 
 
Initially infection or tissue injury signals are detected by local cells, mainly macrophages, 
dendritic cells, mast cells, and others non-professional immune cells such as epithelial 
cells, endothelial cells, and fibroblasts, that express receptors designed to sense the 
presence of infectious pathogens and substances released from dead cells. These receptors 
are called pattern recognition receptors (PRRs) which include transmembrane proteins, 
such as Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), as well as 
cytoplasmic proteins such as retinoic acid-inducible gene (RIG)-I-like receptors and NOD-
like receptors (NLRs)2. They recognize structures conserved among microbial species, 
which are called pathogen-associated molecular patterns (PAMPs). Recent evidence 
indicates that PRRs are also responsible for recognizing endogenous molecules released 
from damaged cells, termed damage associated molecular patterns (DAMPs). The sensing 
of PAMPs or DAMPs (with the exception of some NLRs) by PRRs upregulates the 
transcription of genes involved in the inflammatory responses. These genes encode pro-
inflammatory cytokines, type I interferons (IFNs), chemokines and antimicrobial proteins 
that promote and regulate the subsequent inflammatory response. Vascular changes are 
induced such as vasodilation, increased vascular permeability and endothelium activation 
allowing migration of leukocytes from blood stream and their accumulation in the focus of 
injury together with plasma proteins3,4. Recruited leukocytes are then activated to 
perform their functions, mainly phagocytosis and intracellular destruction of microbes 
and dead cells through reactive oxygen species (ROS) and lysosomal enzymes, liberation 
of effector substances (antimicrobial peptides and elastase) to destroy extracellular 
13
  
pathogens and dead tissues and production of mediators (including cytokines) to amplify 
the inflammatory reaction 5,6.  
Chemical mediators responsible for these processes are numerous and diverse1 (Table I). 
Mediators can be produced by cells located at the site of inflammation or can derive from 
circulating inactive precursors (being the liver the main source) which are activated at the 
site of inflammation (complement proteins, kinins and proteases activated during 
coagulation). Cell-derived mediators of inflammation are produced by tissue macrophages, 
mast cells, activated endothelial cells and recruited leukocytes. Some of them are 
accumulated in intracellular granules and secreted upon cellular activation (e.g., histamine 
and serotonin) and others are de novo synthetized upon stimulation (e.g., prostaglandins, 
leukotrienes or cytokines). 
 
 
2.3 Inflammatory cytokines  
 
Cytokines are polypeptide products of many cell types that are key mediators of 
inflammation and immune responses. The major cytokines in acute inflammation are 
tumor necrosis factor α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6) and chemokines 
(group of chemoattractant cytokines for different subsets of leukocytes). TNF-α and IL-1 
are produced by activated macrophages, mast cells, endothelial cells and some other cell 
types in response to microbial products, immune complexes and T lymphocytes products 
during adaptive immune response. The main role of these cytokines during inflammation 
is activation of endothelium7,8. Activated endothelial cells promote inflammation by 
displaying different combinations of adhesion molecules for leukocyte recruitment 
including E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1). In combination with the release of chemokines9 they 
promote leukocyte adhesion and extravasation to the inflammation site. Both TNF-α and 
IL-1 are activators of the classical nuclear factor-κB (NF-κB) pathway10. IL-6 plays an 
important role on acquired immune response by stimulation of both antibody production 
and effector T-cell development 11. 
Although these cytokines are secreted locally, they may enter into circulation and cause or 
participate in systemic reactions such us fever (TNF-α, IL-1, and IL-6), hepatic synthesis of 
acute-phase proteins (IL-6 and IL-1) and leukocyte proliferation and release from bone 
marrow (TNF-α, IL-1, and IL-6). 
Other important cytokines during chronic inflammation are IFN-γ and IL-12. Classical 
macrophage activation by either microbe endotoxins or cytokines such as IFN-γ induces 
Th1 cell activation and release of cytokines, particularly IFN-γ, involved in activation of 
14
  
microbicide activities. IL-12 is primarily produced by classically activated macrophages 
and crucial for Th1 differentiation and cytotoxic responses, ultimately leading to the 
production of IFN-γ12. 
 
 
Table I. Actions and sources of the principal mediators of inflammation 
Mediator Source (s) Actions 
 
Cell-Derived 
 
Histamine Mast cells, basophils, 
platelets 
Vasodilation, increased vascular permeability, 
endothelial activation 
 
Serotonin Platelets Vasoconstriction 
 
Prostaglandins Mast cells, leukocytes Vasodilation, pain, fever 
 
Leukotrienes Mast cells, leukocytes Increased vascular permeability, chemotaxis, leukocyte 
adhesion and activation 
 
Platelet-activating factor Leukocytes, mast cells Vasodilation, increased vascular permeability, 
leukocyte adhesion, chemotaxis, degranulation, 
oxidative burst 
 
Reactive oxygen species 
 
Leukocytes Killing of microbes, tissue damage 
Nitric oxide Endothelium,  
Macrophages 
 
Vascular smooth muscle relaxation; killing of microbes 
 
Cytokines  
(TNF, IL-1, IL-6) 
Macrophages, 
endothelial cells,  
mast cells 
Local: endothelial activation (expression of adhesion 
molecules). 
Systemic: fever, metabolic abnormalities, hypotension 
(shock) 
 
Chemokines Leukocytes, activated 
macrophages 
Chemotaxis, leukocyte activation 
 
 
Plasma Protein-Derived 
 
Complement Plasma (produced in 
liver) 
Leukocyte chemotaxis and activation, direct target 
killing (MAC) vasodilation (mast cell stimulation) 
 
Kinins Plasma (produced in 
liver) 
Increased vascular permeability, smooth muscle 
contraction, vasodilation, pain 
 
Proteases activated 
during coagulation 
 
Plasma (produced in 
liver) 
Endothelial activation, leukocyte recruitment 
MAC= Membrane attack complex 
Adapted from Robbins Basic Pathology 9th Edition 
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2.4 Anti-inflammatory mechanisms 
 
Several mechanisms counteract inflammatory mediators and function to limit or terminate 
an inflammatory response that otherwise could be uncontrolled and harmful. Activated 
macrophages and other cells secrete interleukin-10 (IL-10), whose major functions are to 
down-regulate the responses of activated macrophages, providing a negative feedback 
loop and supress antigen presenting cell (APC) activation13. Transforming growth factor β 
(TGF-β) is another anti-inflammatory cytokine which is also a mediator of fibrosis for 
tissue repair after inflammation14. In addition lipoxines and complement regulatory 
proteins limit the inflammatory process at different levels15.  
 
2.5 Para-inflammation 
 
Recently, chronic inflammatory states that are not caused by the classical instigators of 
inflammation (i.e. infection and injury) have been defined as chronic systemic 
inflammation or para-inflammation. This kind of inflammation seems to be associated 
with tissue malfunctions16. Sustained malfunctions can result from mutations or 
environmental factors that generate a chronic low-grade inflammation which is partially 
responsible for chronic inflammatory conditions associated with modern human diseases 
such as cardiovascular, neurodegenerative or metabolic conditions. 
 
2.6  Inflammatory reactions and disorders 
 
2.6.1 Acute inflammation pathology 
 
Acute inflammatory reactions are triggered by a variety of stimuli such as infections, 
trauma, tissue necrosis and foreign bodies. However, the mechanisms involved in the 
elimination of microbes and dead cells are also capable of damaging normal tissues, 
causing pathologies associated with inflammation. Once leukocytes are activated their 
effector mechanisms (enzymes and ROS) do not distinguish between offender and host 
and secrete many cytokines which further stimulate inflammation with important 
systemic effects.  
Organ functions are often compromised as a consequence of acute responses such as 
glomerulonephritis or acute respiratory distress syndrome17. Acute inflammatory reaction 
plays also a role in acute transplant rejection. In addition, severe infections (sepsis), 
generally caused by bacteria, induce the production of several cytokines, mainly TNF-α, IL-
16
  
12 and IL-1, in response to large amounts of bacterial toxins that may cause a septic 
shock18. 
 
2.6.2 Chronic inflammation pathology 
 
Chronic disorders can arise under different circumstances19 and are characterized by 
episodes of relapse and remission that often involve superposition of acute inflammation 
on top of the inflammation already present. In persistent infections difficult to eradicate, 
such us tuberculosis, syphilis or during some viral and fungi infections, the inflammatory 
response contributes more to the pathologic process than does the microbe itself. In 
addition, prolonged exposure to toxic agents can induce chronic inflammation, tissue 
injury and fibrosis. 
When the inflammatory response is inappropriately directed against self-tissues, as in 
certain autoimmune diseases20 such as rheumatoid arthritis (RA), inflammatory bowel 
disease (IBD) or psoriasis generates hypersensitivity reactions. Immune responses against 
environmental substances are the cause of allergic diseases, such as bronchial asthma.  
Finally, as already mentioned, milder forms of chronic inflammation (para-inflammation) 
may be important for the pathogenesis of neurodegenerative disorders (Alzheimer 
disease), atherosclerosis, metabolic syndrome and the associated type 2 diabetes 16. Many 
of these chronic conditions (RA, IBD, atherosclerosis and others) share the activation of 
NF-κB pathway as a pivotal feature 21. 
 
2.6.3 Cancer-related inflammation 
 
In the 19th century the physician Rudolf Virchow provided the first indication of a possible 
link between inflammation and cancer by reporting the presence of leukocytes within 
tumor masses22. Nowadays the role of inflammation in different steps of tumorigenesis is 
generally accepted23,24. Firstly, inflammatory conditions increase the risk of developing 
many types of cancer in different settings. Persistent infections promote cancer 
development and progression such as gastric cancer and mucosa-associated lymphoid 
tissue (MALT) lymphoma associated with Helicobacter pylori infection or hepatocellular 
carcinoma (HCC) associated with Hepatitis virus B or C (HBV or HCV) infection25. 
Autoimmune diseases are another type of chronic inflammation that precedes tumor 
development, as in the case of IBD which increases the risk of colorectal cancer 26. 
Second, inflammation caused by exposure to noxious environmental or dietary substances 
is a tumor promoter as well. Obesity promotes tumorigenesis in liver and pancreas27 and it 
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has been shown that tobacco smoke in addition to its high carcinogenic content promotes 
cancer due to its ability to trigger chronic inflammation 28. 
Third, inflammatory microenvironment associated to tumors (called tumor-promoting 
inflammation) has been revealed as an essential component that enhances 
neoangiogenesis, promotes tumor progression and metastatic spread, causes local 
immunosuppression and augments genomic instability. The generation of a cancer-related 
inflammation can follow two pathways 24, an extrinsic pathway in which inflammatory or 
infectious conditions promote cancer development, and an intrinsic pathway activated by 
genetic events that cause neoplasia. Signaling pathways involved in inflammation operate 
downstream of oncogenic mutations, such as RAS and MYC family members, and induce 
transcriptional programs leading to tumor microenvironment remodeling, leukocytes 
recruitment, tumor-promoting chemokines and cytokines expression and angiogenic 
switch induction29,30. The two pathways converge, resulting in the activation of 
transcription factors in tumor cells, mainly NF-κB 31 and signal transducer and activator of 
transcription 3 (STAT3) 32,33, but also others such as hypoxia-inducible factor 1 α (HIF1α) 
34 or activator protein 1 (AP-1) 35. These transcription factors coordinate the production of 
inflammatory mediators including cytokines, chemokines and cyclooxygenase 2 (COX2). 
These factors recruit and activate leukocytes, mainly cells of the myelomonocytic lineage, 
and activate the same key transcription factors in inflammatory cells, stromal cells and 
tumor cells, creating a cancer-related inflammatory microenvironment. Pro-inflammatory 
cytokines IL-1, IL-6, and TNF-α36-39 have been recognized as key elements in these 
processes. 
 
2.7  Inflammatory disease treatments 
 
Traditionally, treatment for inflammatory diseases consisted in the administration of 
broad-spectrum immune regulators, such as glucocorticoids, methotrexate, azathioprine 
or 6-mercaptopurine that block leukocyte function systemically but causes important side 
effects. However, the therapeutic success obtained by targeted inhibition of TNF-α in RA 
patients in the early 1990s 40 pushed research efforts towards the development of 
selective inhibitors or blocking agents rather than broad immune-suppressors. Given the 
fundamental roles of cytokines in the development and pathogenesis of many 
inflammatory diseases, treatments based on the selective targeting of cytokine activities 
have shown beneficial for patients suffering inflammatory diseases; Table II summarizes 
the cytokine inhibition-based strategies for TNF-α, IL6-R, IL-1 and combined inhibition of 
IL-12/IL-23 and the responsiveness level of each chronic inflammatory disease treated41; 
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it highlights how different inflammatory pathologies respond to inhibition of the same 
cytokine (being the most prominent example inhibition of  TNF-α) and how each cytokine 
inhibition independently works for a particular inflammatory disease. Several approaches 
can be used to inhibit a given cytokine signaling: the cytokine can be blocked by specific 
monoclonal antibodies or sequestered by adding  soluble cytokine receptors; the cytokine 
receptor can be also blocked by monoclonal antibodies or by receptor antagonists that 
compete with the ligand for the receptor binding site 42. Another strategy to regulate and 
control chronic inflammatory processes is the administration of immune modulating 
cytokines, being the use IFN-β for the treatment of multiple sclerosis the most successful 
example 43-45. However important limitations still exist as these therapies do not abrogate 
the concomitant use of steroids or immunosuppressive drugs, and a significant percentage 
of patients do not respond to these new therapies. Moreover, keeping the balance between 
blocking the pathological inflammatory responses while simultaneously maintaining the 
ability to control infections is extremely important; for instance, it has been reported an 
increased susceptibility to infections by the systemic blockade of soluble and membrane-
bound TNF-α using neutralizing antibodies such as infliximab 46,47. 
 
Table II. Efficacy of cytokine inhibition in chronic inflammatory diseases. 
The chart shows strong clinical efficacy of inhibition of each cytokine confirmed in randomized 
clinical trials of various chronic inflammatory diseases (CIDs) (or several independent 
observational studies in case of low prevalence diseases) (dark green), preliminary data on clinical 
efficacy (light green), no or mild clinical efficacy or no data on efficacy (gray) and disease-
aggravating effect (red). IL-12/23, combined inhibition of interleukin-12 and interleukin-23 by 
targeting p40. 
 
CID 
 
TNF IL-6R IL-1 IL-12/23 
Rheumatoid arthritis   
Giant cell arthritis   
JIA/AID   
Gout   
Crohn’s disease   
Ulcerative colitis   
Psoriasis    
Psoriatic arthritis   
Ankylosing spondylitis   
Multiple sclerosis   
 
 
Drugs 
Adalimumab
Certolizumab
Etanercept 
Golimumab 
Infliximab 
Tocilizumab
Sarilumab* 
Anakinra
Canakinumab
Rilonacept 
Ustekinumab 
Briakinumab*
 
IL-6R=IL-6 receptor; JIA=juvenile idiopathic arthritis; AID=auto-inflammatory disease including 
Still’s disease. Asterisks indicate drugs that are not approved to date.  
Adapted from Schett G. et al. Nat Med. 2013. 
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2.8  Interleukin-10 
 
Altering the cytokine network is a common therapeutic strategy for treatments of 
inflammatory diseases as it has been explained. One way to regulate the inflammatory 
cytokine activity is to administer anti-inflammatory cytokines, such as IL-10. The IL-10 
cytokine family together with the closely related IFN family forms the larger class II 
cytokine family13. IL-10 was identified by Mosmann and colleagues in 1989 48. The human 
IL-10 is a homodimer with a molecular mass of 37 KDa, each monomer consisting of 160 
amino acids. The human IL-10 gene is located on chromosome 1 and encodes for 5 exons 
(5.1 kb) 49. Murine and human IL-10 exhibit a nucleotide homology of about 80% and their 
structures and functions have been extensively studied 50,51.  
IL-10 is expressed by cells of the innate and adaptive immune system including dendritic 
cells (DC), macrophages, mast cells, natural killer (NK) cells, eosinophils, neutrophils, CD4+ 
and CD8+ T cells, and B cells 52,53. IL-10 targets various cells types in the body by binding to 
a heterodimeric receptor formed by two chains, IL-10R1 and IL-10R2. The IL-10R2 chain 
is ubiquitously expressed whereas the IL-10R1 chain is mainly expressed on leukocytes 54, 
making IL-10 the only family member that primarily target these cells. IL-10R1 and IL-
10R2 are associated with Jak1 and Tyk2 respectively55,56; although STAT3 is the key 
downstream transcription factor (Figure 2.1), STAT1 and sometimes STAT5 can be 
activated57,58. 
Most studied function of IL-10 is the prevention of tissue damage caused by infections and 
inflammation; it regulates and represses the expression of pro-inflammatory cytokines 
during the recovery phase of infections and reduces the tissue damage caused by these 
cytokines 59,60. IL-10 inhibits inflammatory responses from innate and adaptive immunity, 
and prevents the lesions in tissues caused by exacerbated adaptive immune responses; it 
is thus a central cytokine during the resolution phase of inflammation.  
IL-10 interferes with the production of inflammatory mediators by polymorphonuclear 
neutrophils, monocytes, and macrophages, such as inflammatory cytokines (IL-6, IL-1 and 
TNF-α) and chemokines as well as upregulates the expression of molecules that amplify 
the anti-inflammatory effect of IL-10 (IL-1 receptor agonist and soluble TNF-α receptor) 61. 
This anti-inflammatory role is illustrated by IL-10-deficient mice that develop chronic IBD 
owing to an inappropriate innate immune response to intestinal bacterial antigens62. 
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Figure 2.1 
Immunoregulatory and stimulatory effects of interleukin 10 
(A) IL-10 interacts with IL10R expressed on monocytes, macrophages, dendritic cells, CD4+ T cells, 
and polymorphonuclear neutrophils (PMN). STAT3 is the transcriptional factor largely involved in 
the inhibitory action of IL-10 including the inhibition of NF-κB. IL-10 inhibits numerous 
inflammatory and antigen-presenting functions and stimulates other responses in immune cells. 
(B) IL-10 interacts with CD8+ T cells, B cells and NK cells, in which they stimulate NF-κB and AP-1, 
in addition to STAT3. This leads to cytotoxic activity of CD8+ T cells and NK cells, and to B cell 
activation. AA=arachidonic acid. DC=dendritic cell. MMP=matrix metalloproteinases. RNI=reactive 
nitrogen intermediates. ROI=reactive oxygen intermediates. Adapted from Mege JL. et al. Lancet, 
2006. 
 
IL-10 regulates adaptive immune responses through its effects on APCs and T cells. In 
APCs, IL-10 can directly or indirectly suppress TLR signaling 63,64 impeding APC activation. 
IL-10 inhibits production of IL-12 and IL-18, as well as reduces expression of MHC class II 
molecules and costimulatory molecules, therefore inhibiting their ability to present 
antigens to T cells65. Additionally, IL-10 impairs differentiation of monocyte-derived 
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dendritic cells, induces plasmacytoid dendritic cell apoptosis, and alters the migration of 
dendritic cells by modulating surface expression of chemokine receptors. IL-10 directly 
affects the function of CD4+ T cells by inhibiting the expression of IL-2, TNF-α, IL-5, 
chemokine receptor CXCR4, and the response to stromal cell-derived factor-1 (SDF-1). 
Activation of T cells in the presence of IL-10 can induce non-responsiveness or anergy that 
cannot be reversed by IL-2 stimulation66. 
In addition of the profound anti-inflammatory effects of IL-10, it can promote humoral 
immune responses by enhancing the expression of MHC class II molecules on B cells, 
inducing immunoglobulin production (Ig) and increasing B-cell survival 67-69. This effect on 
B cells may account for the presence of high circulating levels of antibodies such as IgA, 
associated with overproduction of IL-10 in clinical situations. Furthermore, IL-10 activates 
mast cells in vitro70 and enhances CD8+ T and NK cell activities in vivo 71-74. It is interesting 
to note that IL-10 activates NF-κB and AP-1 in CD8+ T cells but inhibits these transcription 
factors in monocytes and CD4+ T cells65 (Figure 2.1).  
 
2.8.1 IL-10-based therapies for inflammatory diseases 
 
Based on the comprehension of IL-10 role in inflammation and its effective reduction of 
pro-inflammatory cytokine activity in animal models of diseases such as sepsis, stroke, 
multiple sclerosis and other chronic inflammatory disorders75-78, a variety of clinical 
studies were undertaken using systemic administration of recombinant IL-10 to treat 
psoriasis, Crohn´s disease or RA 79. Despite of being well tolerated and the encouraging 
early results observed80-82, larger blinded studies showed only modest therapeutic 
benefits 79. Interestingly, it has been reported immune stimulatory effects when high doses 
of IL-10 were employed80,83,84. On the other hand, it has been shown that high or 
dysregulated levels of IL-10 may result in chronic infection 61,69,85,86. Globally these results 
suggest that local IL-10 administration at the right site, dose and time might be effective 
for inflammatory disease therapies, avoiding or reducing potential side effects derived 
from systemic treatments. 
 
2.9   Cancer immunotherapy 
 
Although nowadays is accepted the role of tumor-promoting inflammation, on the other 
hand, immunosuppression allows cancer cells to evade immunological destruction, in 
particular by T and B lymphocytes, macrophages and NKs, and is considered a cancer 
hallmark87. This highlights the dual role of immune system in cancer that both antagonizes 
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and enhances tumor development and progression, unified in a conceptual framework 
called “cancer immunoediting” 88. 
 
 
Figure 2.2 
Steps and potential therapies along the cancer-immunity cycle 
The numerous factors that come into play in the cancer-immunity cycle provide a wide range of 
potential therapeutic targets. This figure highlights examples of some of the therapies currently 
under preclinical or clinical evaluation. Key highlights include vaccines to improve cancer antigen 
presentation, anti-CTLA4 and IL-12 therapies that can primarily promote T cell priming and 
activation, anti-VEGF therapies to favor T cell infiltration, improved recognition of cancer by T cells 
using CARs and anti-PD-L1 or anti-PD-1 antibodies that can primarily promote killing of cancer 
cells. Targeted therapies are aimed to promote the release of cancer cell antigens. Although not 
developed as immunotherapies, chemotherapy and radiation therapy also produce this effect. 
Anti-CTLA4=anti-cytotoxic T-lymphocyte-associated protein 4 antibodies, anti-PD-L1 and anti-PD-
1=anti-programmed cell death ligand 1 and anti-programmed cell death 1 antibodies, anti-
VEGF=anti-vascular endothelial growth factor, CAR = chimeric antigen receptor. 
Adapted from Chen DS. et al. Cell 2013. 
 
Initially cancer treatment has made use exclusively of relatively nonspecific cytotoxics and 
cytostatics (chemotherapies). These drugs remain the backbone of current treatments, but 
they are limited by a narrow therapeutic index, significant toxicities and frequently 
acquired resistance. More recently, an improved understanding of cancer pathogenesis 
has made possible new approaches resulting in mechanism-based therapeutics. They can 
be classified in targeted agents, which aim to inhibit molecular pathways that are crucial 
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for tumor growth and maintenance, and cancer immunotherapy, consisting in stimulation 
of the host immune response to allow a long-lived tumor recognition and destruction 89. 
Anti-cancer immunity can be enhanced throughout the different steps of interaction 
between immunity and cancer development 90, such as cancer antigens recognition and 
presentation, priming and activation of effector T cell responses, T cell tumor infiltration 
and finally, T cell recognition and killing of cancer cells (Figure 2.2). Two examples have 
shown the potential of cancer immunotherapy. First, the successful treatment of patients 
with metastatic melanoma by employing the anti-cytotoxic T-lymphocyte-associated 
protein 4 (anti-CTLA-4) monoclonal antibody 91. CTLA-4 is a key T cell negative regulator 
that prevents activation and expansion of T cells after APC interaction; thereby it controls 
the immune response progress and attenuates the chances of chronic autoimmune 
inflammation 92. This negative regulation can be overcome by using this blocking antibody. 
The second example are the anti-programmed cell death ligand 1 (PD-L1) and anti-
programmed cell death 1 (PD-1) antibodies. PD-L1 is a distal immune modulator 
expressed in many tumors (in cancer and tumor-infiltrating T cells) that binds to PD-1 
expressed on activated effector T cells and blocks the secretion or production of cytotoxic 
mediators required for cell killing 93,94. A number of immunotherapies that target different 
PD-1 or PDL-1 interactions are under development 95 and they are reporting encouraging 
results in a broad range of cancer types. 
 
2.10 Interleukin-12  
 
IL-12 is a heterodimeric cytokine composed of two subunits (p35 and p40) covalently 
linked by a disulfide bridge 96,97. Both subunits are encoded by to independently regulated 
genes on the human chromosomes 3 and 5 respectively and co-expression yields to the 
formation of the biologically active p70 heterodimer98.  IL-12 is primarily produced by 
macrophages, dendritic cells, neutrophils and B cells12. When IL-12 is secreted, it engages 
the IL-12 receptor (IL12R), also formed by two subunits (β1 and β2) and mostly expressed 
on activated T and NK cells, dendritic cells and macrophages 99-102. IL12-IL12R interaction 
induces tyrosine phosphorylation of Jak2 and Tyk2, triggering the phosphorylation and 
activation of STAT4, ultimately leading to the production of IFN-γ, principal mediator of 
IL-12 function 103. 
IL-12 mainly targets T and NK cells and induces IFN-γ production by these cells, therefore 
enhancing both innate and adaptive responses. Macrophages activated by IFN-γ produce 
nitric oxide synthase and subsequently release active nitrogen species. This results in an 
enhancement of phagocytic function and local inflammation104. IL-12 crucially favors the 
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differentiation of naïve T cells into Th1 cells and impedes Th2 differentiation105,106. 
Additionally, IL-12 increases NK cells and CD8 cytotoxic T lymphocytes (CTLs) 
proliferation and cytotoxic activity. Moreover, in the presence of IL-12 B cells are 
prompted to secrete antibody isotypes associated with Th1 responses 107 (Figure 2.3). 
 
 
Figure 2.3 
IL-12 role in cancer therapy 
Overview of the biological properties of IL-12 contributing to its anti-tumor activity. Activated APCs 
produce IL-12 that induces CD8+ T cells and NK cytotoxic effect. B cells are prompted to secrete 
antibodies. IL-12 crucially contributes to the skew of naïve T cells in Th1 cells. Subsequent IFN-γ 
production enhances both innate and adaptive responses in addition to its anti-angiogenic effect 
and myeloid-derived suppressor cells reprogramming.  APC=antigen presenting cell, NK=natural 
killer cell, Tc=cytotoxic T lymphocyte, Th=T helper lymphocyte, IP-10=interferon-inducible protein 
10, MIG=monokine induced by interferon γ.  
Adapted from Lasek W. et al. Cancer Immunol Immunother, 2014. 
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2.10.1   IL-12 cancer therapy 
 
The anti-tumor effect of IL-12 108 has been known for many years. IL-12 induces tumor 
infiltration, proliferation and activation of effector immune cells (macrophages, NK and T 
cells), and also inhibits tumor angiogenesis mainly through IFN-γ dependent production of 
antiangiogenic factors such as interferon-inducible protein 10 (IP10) 109 and monokine 
induced by interferon-γ (MIG). In addition, IL-12 promotes reprogramming of myeloid-
derived suppressor cells within the tumor110 (Figure 2.3). Several studies have 
demonstrated the anti-tumor and anti-metastatic activities of IL-12 in rodent preclinical 
models, including melanomas, mammary carcinomas, colon carcinoma, renal carcinoma 
and sarcomas111, suggesting its therapeutic use as an anti-cancer agent. However, most 
clinical trials involving IL-12, with the exception of results obtained in cutaneous T cell 
lymphoma variants, non-Hodgkin´s lymphoma and in AIDS-related Kaposi sarcoma, have 
been unsuccessful and reported unimpressive results112. Importantly, IL-12 systemic 
administration is associated with marked toxic side effects, such as flu-like symptoms, 
toxic effects on the bone marrow and liver and hematologic toxicity (neutropenia and 
thrombocytopenia); this prompted the investigation into new methods of IL-12 delivery to 
avoid unacceptable toxicity, and enhance IL-12 anti-tumor activity113. As an alternative, 
clinical trials based on intratumoral IL-12 expression have proven that local production of 
IL-12 inside a tumor can stimulate tumor infiltration by effector immune cells and in some 
cases it is followed by tumor regression. 
 
2.11  Gene therapy with lentiviral vectors 
 
Gene therapy involves the use of nucleic acids (DNA or RNA) for the treatment, cure or 
prevention of human diseases, using different tools including naked oligonucleotides, viral 
and non-viral vectors. Viral vectors represent highly effective means for the delivery of 
therapeutic genes, and the scientific knowledge acquired in the field have allowed the 
generation of new improved vector versions, already tested in clinical trials 114. Lentiviral 
vectors (also called lentivectors, LVs) which are derived from lentiviruses115-117 are 
currently employed in both basic and clinical research. Lentiviruses belong to the 
Retroviridae family, and LVs as other retroviral vectors can integrate into the host cell 
genome (up to 10 kb); however and contrary to other oncoretroviral vectors, LVs allow 
gene delivery into not only dividing but also quiescent cells. Retroviral vectors do not 
integrate viral sequences that encode for packaging proteins (gag and pol), thus 
minimizing the risk of cytotoxic T lymphocyte activity onto vector-transduced cells. In 
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addition LVs (mainly derived from HIV-1) cause very low inflammatory response in vivo. 
In summary all these features make them a powerful and reliable tool for gene therapy. 
Several safety concerns have been improved in the latest generation of HIV-1-based 
vectors. All accessory genes (among them 6 of 9 genes encoding for virulence factors) and 
the regulatory tat gene are deleted118,119 ensuring that the parental virus cannot be 
reconstituted. The remaining viral sequences essential for virion production are split into 
three different helper vectors, to maximize the number of recombination events required 
to generate a replication-competent virus. Altogether these features reduce greatly the 
putative generation of replication-competent lentiviruses. Finally, the 3´ long terminal 
repeat (LTR) sequence has been partially deleted to eliminate the viral LTR 
enhancer/promoter activity, creating the so-called self-inactivating (SIN) LTR 120 reducing 
the risk of host gene activation. As a consequence of all these modifications, these 
lentiviral particles can undergo only one single round of transduction and the integrated 
proviral DNA will express only the transgene of interest. These safety improvements in LV 
engineering have encouraged employing them in clinical trials. LVs have been employed in 
ex vivo121-130, and more recently, in vivo131 strategies with excellent clinical results. In 
addition, their low immunogenicity compared to other commonly used viral vectors, such 
as adenoviral or adeno-associated viral vectors (AAV), make them ideal vectors for the 
treatment of inflammatory diseases 132-135. 
 
2.11.1   IL-10 gene therapy 
  
Studies in animal models have shown that gene therapy is an alternative for the local 
treatment of chronic inflammatory diseases as it has the potential to be more effective, 
better tolerated, and more specific than conventional pharmacological treatments 136. As 
discussed previously, IL-10 is a good candidate to regulate inflammatory cytokine activity 
due to its broad spectrum of anti-inflammatory activities. As a consequence, the 
therapeutic effect of IL-10 expression has been tested in preclinical models under different 
gene therapy strategies, both in vivo and ex vivo. IL-10 has been expressed by employing 
different viral vectors (AAV, γ-retroviral vectors and LVs) and in different animal models 
mimicking inflammatory disorders such as autoimmune syndromes137, RA138, 
neuroinflammation139,140 and allograft rejection141. The results have confirmed its anti-
inflammatory potential and its putative use for the treatment of inflammatory diseases. 
However, future gene therapy treatments for chronic inflammatory diseases must 
overcome one important limitation, the relapse and remission alternation that 
characterize these pathologies. Transgene expression should parallel the course of the 
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disease itself, matching the varying pathological conditions and thereby avoiding 
undesirable secondary effects. 
 
2.11.2   IL-12 gene therapy 
 
Gene therapy could also be a good alternative strategy for IL-12-based cancer therapy, as 
gene transfer methods can be designed to confine IL-12 production to the tumor 
environment, preventing systemic toxicity142. Several vectors derived from viruses, such 
as adenovirus143, AAV144, retrovirus145 and herpes simplex virus146, have been developed to 
transfer IL-12 genes locally to the tumor site. These preclinical experiments have shown 
encouraging results, not only by IL-12 expression by itself but also when it is used in 
combination with other anti-tumor strategies. In addition, the virus-mimicking effect of 
these viral vectors should trigger an IFN-mediated response, which has been proven to be 
absolutely required for the efficient anti-tumoral effect of IL-12 147. 
Again, an ideal vector system should be disease-regulated, expressing high levels of the 
transgene only when and where the therapeutic effect of the transgene is required, 
preventing the toxicity that may be associated with constitutive and systemic expression 
of the transgene, as is the case of the known IL-12-based therapies. Thus, a major 
challenge in the treatment of cancer using IL-12 is the development of expression systems 
restricted to and tightly regulated by the tumor environment, in order to confine 
transgene expression to the tumor site. 
 
2.11.3   Disease-regulated promoters for gene therapy 
 
Currently, viral promoters are the most frequently used for transgene expression. Initially 
they produce very high and constant expression of the transgene and as a consequence the 
therapeutic molecule can be released and spread throughout the organism increasing the 
risk of potential side effects. Moreover, these strong viral promoters are commonly 
silenced inside the cell, causing transient expression in vivo 148-151. In addition, even if high 
expression of the transgene were successful, there might be an adaptive response to the 
constant high concentration of transgene protein, counteracting its therapeutic effect. 
Thus, there is a need of developing accurate regulation systems for gene therapy. Several 
vectors driven by drug-controlled promoters have been developed to achieve regulated 
transgene expression such as those based on the tetracycline-regulated (Tet)152 and the 
rapamycin-regulated dimerizer systems153,154; however, these approaches require 
continuous monitoring of the disease to achieve optimal efficacy, and this is further 
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complicated in the case of the unpredictable, relapsing course of  inflammatory conditions. 
An ideal vector system would therefore be disease-regulated, expressing high levels of 
therapeutic agent during relapses and lower levels during remission phases of the disease, 
allowing the confinement of the therapeutic molecule and avoiding systemic toxic side 
effects. 
Several viral expression systems that respond to inflammatory stimuli in vivo have been 
devised155. The first was based on a two component adenoviral expression system in 
which the promoter of complement factor 3 drives transcription of the HIV transactivator 
of transcription (Tat)156. However, the immunogenicity of Tat has been implicated in 
central nervous system disorders. Subsequently, van de Loo et al. 157 developed a hybrid 
inflammation-inducible adenoviral expression system, consisting of the human IL-6 
promoter fused to the enhancer region of the human IL-1 promoter. Additionally, an 
inflammation-inducible expression system based on serotype 5 adeno-associated virus 
(AAV) has been developed by employing a chimeric promoter based on NF-κB-binding 
sites158. More recently, different inducible promoters by tissue-specific transcription 
factors have been developed to employ LVs for in vivo bioimaging 159. 
Concluding, inflammation-inducible systems combined with the long term transgene 
expression capacity of LVs might represent an important improvement that would fulfil 
the requirements for an effective and safe gene therapy agent for clinical applications. 
 
 
2.12 Development and in vivo validation of inflammation-regulated 
lentiviral expression systems 
 
As has been explained, cytokines are key mediators of inflammation and immune 
responses, being TNF-α, IL-1 and IL-6 the main cytokines involved in the first steps of 
inflammation, thus we hypothesized that they could be expression-inductors for 
inflammation-regulated lentiviral expression systems. 
Antonio Rodríguez laboratory have previously generated a novel inflammation-regulated 
lentiviral expression system based on the E-selectin promoter (ESELp) that is induced 
upon acute inflammation. E-selectin is rapidly and transiently expressed in response to 
early pro-inflammatory cytokines (TNF-α, IL-1), and is not expressed under basal 
conditions, making its promoter a good candidate for the design of inflammation-
regulated gene therapy vectors160. During my thesis work I have also generated LVs 
incorporating other previously described inflammation-inducible promoters, such as the 
human IL-6 promoter fused to the enhancer region of the human IL-1 promoter (IL1-
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IL6p)157 and a chimeric promoter based on six NFκB-binding sites (NFκBp) and the 
minimal cytomegalovirus (CMV) promoter158. I have studied in vitro the inducibilty of all 
these promoters in different primary cultures, cell lines and tumor cell lines, in response 
to inflammatory stimuli (TNF-α, IL-1 or LPS). In addition I have cloned murine IL-10 gene 
under the control of these promoters to generate inflammation-inducible lentivectors to 
produce IL-10 and I studied its anti-inflammatory effect in a zymosan-induced 
inflammation model.  
Besides, our inflammation-responsive lentivectors were employed to study the activation 
of inflammatory responses when olfactory mucosa (OM) of amyotrophic lateral sclerosis 
(ALS) patients is co-cultured with human spinal cord neurons161. 
Finally I have studied the expression pattern of our inflammation-inducible lentivector 
sytems in a syngeneic tumor model162, showing that murine IL-12 expressed is able to 
trigger anti-tumor responses (data not published). 
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3 Objectives 
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There are three main objectives in this project: 
 
i. Generation of inflammation-inducible lentivector systems to express luciferase, 
and murine IL-10 and IL-12. 
 
ii. Analysis of promoter activity and cytokine expression in vitro. 
 
iii. Study of inflammation-regulated transgene expression and therapeutic potential in 
vivo.  
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4 Materials, methods and results 
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4.1 IL-10 released by a new inflammation-regulated lentiviral system 
efficiently attenuates zymosan-induced arthritis 
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4.1.1 Introduction 
 
Chronic inflammatory diseases are characterized by episodes of relapse and remission. 
Altering the cytokine network is a common therapeutic strategy in inflammatory diseases. 
One way to regulate inflammatory cytokine activity is to administer anti-inflammatory 
cytokines, such as interleukin-10 (IL-10). Compared with other anti-inflammatory 
molecules such as IL-4 or IL-13, IL-10 has a broader spectrum of anti-inflammatory 
activities, inhibiting the production of several pro-inflammatory cytokines (e.g. IL-1, IL-2, 
IL-6, IL-8 and TNF-α) and inducing the production of anti-inflammatory agents (such as IL-
1 receptor antagonist). IL-10 also suppresses nitric oxide release in lymphocytes163. Local 
administration of recombinant IL-10 effectively reduces pro-inflammatory cytokine 
activity in animal models of diseases such as sepsis, stroke, multiple sclerosis and chronic 
inflammatory disorders75-78. 
Studies of inflammatory flare-up reactions in animal models have shown the applicability 
and viability of local gene therapy in arthritis164. Ideally, treatments for chronic 
inflammatory diseases should parallel the course of the disease itself, matching the 
varying pathological conditions and thereby avoiding undesirable secondary effects. An 
ideal vector system would therefore be disease-regulated, expressing high levels of anti-
inflammatory agents during relapses and lower levels during remission phases of the 
disease. 
Several viral expression systems that respond to inflammatory stimuli in vivo have been 
devised155. Van de Loo et al.157 developed a hybrid inflammation-inducible adenoviral 
expression system, consisting of the human IL-6 promoter fused to the enhancer region of 
the human IL-1 promoter. The therapeutic efficacy of adenoviral systems is, however, 
compromised by the induction of an adenovirus-mediated immune response and by the 
rapid loss of transgene expression due to the episomal localization of the viral genomes. 
More recently, an inflammation-inducible expression system based on serotype 5 adeno-
associated virus has been developed by employing a chimeric promoter based on NF-κB 
binding sites158. However, although the non-pathogenicity of adeno-associated viruses 
makes them promising candidates for long term gene therapy, under some circumstances 
they too can cause an inflammatory response in the host133-135. A potentially more 
appropriate system for gene therapy in chronic inflammatory processes would be 
lentiviral vectors, since they can infect both dividing and quiescent cells, provide long term 
expression, and display low immunogenicity165. 
Currently, the most frequently used promoters for transgene expression are viral, but 
these strong promoters are usually silenced, and result in only transient expression in 
39
  
vivo. Moreover, even if high expression of the transgene were successful, the constant high 
levels of anti-inflammatory molecules might increase the risk of infection, as already 
observed with anti-TNF-α and anti-IL-1 treatment of patients with rheumatoid arthritis166-
169. In addition, there might be an adaptive response to the constant high concentration of 
transgene protein, counteracting its therapeutic effect.  
TNF-α and IL-1 are early-induced pro-inflammatory cytokines that act locally on vascular 
endothelium to induce the expression of adhesion molecules, including selectins and 
ligands for leukocyte integrins, which participate in the capture and recruitment of blood 
cells170. The selectins are a family of three type-I cell surface glycoproteins (E-, L- and P-
selectin) involved in chronic and acute inflammation. E-selectin (ESEL) is rapidly and 
transiently expressed in response to inflammatory cytokines such as TNF-α and IL-1, and 
is not expressed under basal conditions except in skin microvessels171. The promoter of 
human ESEL has been used for in vitro gene delivery in recombinant retroviral and 
adenoviral vectors172,173 and for in vivo delivery in non-viral vectors174-176. Here we report 
the development of a lentiviral expression system based on the ESEL promoter (ESELp). 
We show that ESELp-driven transgene expression is induced in response to pro-
inflammatory cytokines in cell culture, and is regulated in vivo during chronic paw 
inflammation. This long term expression system shows low basal activity during remission 
and high expression during the acute inflammatory response. The lentiviral vector system 
drives in vivo expression of the anti-inflammatory cytokine IL-10 at levels sufficient to 
efficiently attenuate repetitive local acute inflammation episodes induced by yeast cell 
wall glucans (zymosan) injection. This attenuation is also observed when the lentiviral 
vector system is administered after zymosan injection. Therefore, this new expression 
system fulfils the requirements for a disease-regulated on/off system, suggesting potential 
use for auto-regulated treatment of chronic inflammatory diseases. 
My personal contribution in this work consisted in: 
First, the generation of the following pHRSIN contructs: Spleen focus-forming virus 
promoter (SFFVp)-mIL10, ESELp-mIL10, 6xNFκBp-Luc and IL1IL6p-Luc. Second, the 
analysis of the in vitro response of these promoters upon pro-inflammatory stimulation 
(TNF-α plus IL-1 or LPS). Third, in vivo local transduction followed by zymosan-induced 
acute inflammation model, determination of luciferase activity in tissues, comparative 
study of the different inflammation-regulated systems by in vivo imaging determination of 
luciferase activity, quantification of local and serum IL-10 expression levels and 
therapeutic effect determination. And forth, in vivo inflammation model in response to 
zymosan injection followed by local lentiviral transduction, luciferase activity monitoring 
by in vivo imaging and therapeutic effect determination.  
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Administration of anti-inflammatory cytokines is a com-
mon therapeutic strategy in chronic inflammatory dis-
eases. Gene therapy is an efficient method for delivering 
therapeutic molecules to target cells. Expression of the cell 
adhesion molecule E-selectin (ESEL), which is expressed 
in the early stages of inflammation, is controlled by 
proinflammatory cytokines, making its promoter a good 
candidate for the design of inflammation-regulated gene 
therapy vectors. This study describes an ESEL promoter 
(ESELp)-based lentiviral vector (LV) that drives localized 
transgene expression during inflammation. Mouse matri-
gel plug assays with ESELp-transduced endothelial cells 
showed that systemic lipopolysaccharide (LPS) admin-
istration selectively induces ESELp-controlled luciferase 
expression in vivo. Inflammation-specific induction was 
confirmed in a mouse model of arthritis, showing that 
this LV is repeatedly induced early in acute inflammation 
episodes and is downregulated during remission. More-
over, the local acute inflammatory response in this ani-
mal model was efficiently blocked by expression of the 
anti-inflammatory cytokine interleukin-10 (IL10) driven 
by our LV system. This inflammation-regulated expres-
sion system has potential application in the design of 
new strategies for the local treatment of chronic inflam-
matory diseases such as cardiovascular and autoimmune 
diseases.
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IntroductIon
Chronic inflammatory diseases are characterized by episodes 
of relapse and remission that often involve superposition of 
acute inflammation on top of the inflammation already present. 
Altering the cytokine network is a common therapeutic strategy 
in inflammatory diseases. Therapies based on natural cytokines 
are very promising as they are more effective, better tolerated, 
and more specific than pharmacological treatments.1 One way 
to regulate inflammatory cytokine activity is to administer anti-
inflammatory cytokines, such as interleukin-10 (IL10). Compared 
with other anti-inflammatory molecules such as IL4 or IL13, IL10 
has a broader spectrum of anti-inflammatory activities, inhibiting 
the production of several proinflammatory cytokines [e.g., IL1, 
IL2, IL6, IL8, and tumor necrosis factor-α (TNF-α)] and inducing 
the production of anti-inflammatory agents (such as IL1 recep-
tor antagonist). IL10 also suppresses nitric oxide release in lym-
phocytes.2 Local administration of recombinant IL10 effectively 
reduces proinflammatory cytokine activity in animal models of 
diseases such as sepsis, stroke, multiple sclerosis, and chronic 
inflammatory disorders.3–6
Studies of inflammatory flare-up reactions in animal models 
have shown the applicability and viability of local gene therapy 
in arthritis.7 Ideally, treatments for chronic inflammatory diseases 
should parallel the course of the disease itself, matching the vary-
ing pathological conditions and thereby avoiding undesirable 
secondary effects. An ideal vector system would therefore be dis-
ease-regulated, expressing high levels of anti-inflammatory agents 
during relapses and lower levels during remission phases of the 
disease.
Several viral expression systems that respond to inflammatory 
stimuli in vivo have been devised.8 The first was based on a two-
component adenoviral expression system in which the promoter 
of complement factor 3 drives transcription of the HIV trans-
activator of transcription (Tat).9 However, the immunogenicity 
of Tat has been implicated in central nervous system disorders. 
Subsequently, van de Loo et al.10 developed a hybrid inflammation-
inducible adenoviral expression system, consisting of the human 
IL6 promoter fused to the enhancer region of the human IL1 
promoter. The therapeutic efficacy of adenoviral systems is, how-
ever, compromised by the induction of an adenovirus- mediated 
immune response and by the rapid loss of transgene expres-
sion due to the episomal localization of the viral genomes. More 
recently, an inflammation-inducible expression system based on 
serotype 5 adeno-associated virus (AAV) has been developed by 
employing a chimeric promoter based on NF-kB-binding sites.11 
However, although the nonpathogenicity of AAVs makes them 
promising candidates for long-term gene therapy, under some cir-
cumstances they too can cause an inflammatory response in the 
host.12–14 A potentially more appropriate system for gene therapy 
in chronic inflammatory processes would be lentiviral vectors 
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(LVs), since they can infect both dividing and quiescent cells, pro-
vide long-term expression, and display low immunogenicity.15
Currently, the most frequently used promoters used for trans-
gene expression are viral, but these strong promoters are usually 
silenced, and result in only transient expression in vivo. Moreover, 
even if high expression of the transgene were successful, the con-
stant high levels of anti-inflammatory molecules might increase 
the risk of infection, as already observed with anti-TNF-α and 
anti-IL1 treatment of patients with rheumatoid arthritis (RA).16–19 
In addition, there might be an adaptive response to the constant 
high concentration of transgene protein, counteracting its thera-
peutic effect. Several vectors driven by drug-controlled promoters 
have been developed to achieve regulated transgene expression; 
however, this approach requires constant monitoring of the dis-
ease to achieve optimal efficacy, and this is further complicated by 
the unpredictable, relapsing course of the disease.
TNF-α and IL1 are early induced proinflammatory cytokines 
that act locally on vascular endothelium to induce the expression 
of adhesion molecules, including selectins and ligands for leuko-
cyte integrins, which participate in the capture and recruitment 
of blood cells.20 The selectins are a family of three type-I cell sur-
face glycoproteins (E-, L-, and P-selectin) involved in chronic and 
acute inflammation. E-selectin (ESEL) is rapidly and transiently 
expressed in response to inflammatory cytokines such as TNF-α 
and IL1, and is not expressed under basal conditions except in 
skin microvessels.21 The promoter of human ESEL has been used 
for in vitro gene delivery in recombinant retroviral and adenoviral 
vectors22,23 and for in vivo delivery in nonviral vectors.24–26 Here, 
we report the development of a lentiviral expression system based 
on the ESEL promoter (ESELp). We show that ESELp-driven 
transgene expression is induced in response to proinflammatory 
cytokines in cell culture, and is regulated in vivo during chronic 
paw inflammation. This long-term expression system shows 
low basal activity during remission and high expression dur-
ing the acute inflammatory response. The LV system drives in 
vivo expression of the anti-inflammatory cytokine IL10 at levels 
sufficient to efficiently attenuate repetitive local acute inflamma-
tion episodes induced by zymosan injection. This attenuation is 
also observed when the LV system is administered after zymo-
san injection. Therefore, this new expression system fulfills the 
requirements for a disease-regulated on/off system, suggesting 
potential use for autoregulated treatment of chronic inflamma-
tory diseases.
results
eselp-driven transgene expression is 
efficiently activated by proinflammatory cytokines 
in lentivirus-transduced endothelial cells
To assess the ability of lentivectors to efficiently transduce endothe-
lial cells, we infected mouse or human primary endothelial cell 
cultures [mouse lung endothelial cells (MLEC) and human umbil-
ical vein endothelial cells] with a LV encoding green florescent 
protein (GFP) under the control of the constitutive SFFV viral 
promoter (LV-SFFVp-GFP). In addition, we infected immortal-
ized MLEC (iMLEC).27 GFP expression was analyzed after 48 
hours, and the efficiency of transduction was close to 100% in all 
cases (Supplementary Figure S1).
Since ESEL is the earliest endothelium-specific adhesion mol-
ecule induced by proinflammatory cytokines, we tested whether 
the ESELp might be a useful tool for achieving targeted transgene 
expression at sites of inflammation. We generated a LV encoding 
GFP under the control of ESELp (LV-ESELp-GFP; Supplementary 
Figure S2) and infected iMLEC and human umbilical vein 
endothelial cells. Treatment of infected cells with TNF-α strongly 
increased GFP expression in both cell types, paralleling the 
expression of endogenous ESEL (Figure 1a,b). In contrast, GFP 
expression from the constitutively active LV-SFFVp-GFP vector 
was not modified by TNF-α treatment (Supplementary Figure 
S3). The potent induction by TNF-α of endogenous ESEL in vitro 
is greatly enhanced by preincubation with the proangiogenic fac-
tor vascular endothelial growth factor (VEGF).28 We therefore 
preincubated infected cells for 24 hours with VEGF and then with 
TNF-α for different periods. As in the case of endogenous ESEL, 
VEGF pretreatment potentiated TNF-α-induced ESELp-driven 
expression of GFP; induction of GFP expression peaked at 6 hours 
both in VEGF and in vehicle pretreated cells, and declined after 12 
hours (Supplementary Figure 4a).
As VSV-pseudotyped LVs have a broad host range, we tested 
the ESELp activity in non endothelial immortalized and primary 
cells susceptible to be infected after intraplantar administration 
by employing a lentivector containing the luciferase reporter gene 
under the control of the ESELp (LV-ESELp-Luc; Supplementary 
Figure S2). Treatment of infected cells with proinflammatory 
cytokines increased luciferase expression in all cell types assayed 
(Figure 1c–f). However, only in the case of stimulated LV-ESELp 
transduced endothelial cells the level of luciferase was similar to 
that observed in LV-SFFVp transduced cells (Figure 1c). In the 
rest of cell types we found a low basal level of luciferase expression 
and modest induction upon stimulation (Figure 4d–f).
We next investigated whether LV-ESELp could be activated 
by an inflammatory milieu. Injection of mice with lipopolysac-
charide (LPS) induces the release of proinflammatory cytokines, 
resulting in activation of the endothelium and the expression of 
additional proinflammatory factors and cell-specific adhesion 
molecules that participate in the inflammatory response.27 To 
test the effect of these inflammatory mediators on LV-ESELp, we 
transduced endothelial cells with LV-ESELp-Luc and treated these 
cells with culture supernatant from LPS-activated macrophages.29 
The cytokine-containing supernatant increased luciferase activity 
in iMLEC transduced with LV-ESELp-Luc but had no effect on 
cells transduced with LV-SFFVp-Luc (Supplementary Figure 4b). 
LV-ESELp-Luc driven luciferase activity was also increased by 
treatment with VEGF plus TNF-α, but direct treatment with LPS 
did not modify luciferase activity in endothelial cells driven by 
either SFFVp or ESELp (data not shown).
eselp-driven transgene expression is induced by 
proinflammatory cytokines in a mouse subcutaneous 
matrigel model
The inducibility of LV-ESELp-Luc by inflammatory mediators was 
further investigated by subcutaneous matrigel experiments in mice. 
iMLEC were transduced with LV-SFFVp-Luc or LV-ESELp-Luc, 
and, after 24 hours, cells were embedded in VEGF-containing matri-
gel and injected subcutaneously into syngenic mice.  Forty-eight 
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hours later, mice were treated with LPS [intraperitoneal (i.p.)], and 
luciferase activity in matrigel plugs was monitored by in vivo opti-
cal bioluminescence imaging. LPS administration led to similar 
increases in serum IL6 levels in all mice, but luciferase activity was 
increased only in LV-ESELp-Luc matrigel implants, thus confirm-
ing the selectivity of ESELp induction by inflammatory cytokines in 
vivo (Figure 2 and Supplementary Figure S5).
eselp-driven transgene expression is modulated 
by proinflammatory cytokines in a mouse model of 
chronic inflammation
We next addressed the inducibility of the LV system in a mouse 
model of RA, a disease characterized by chronic inflammation of 
the joints which leads to destruction of cartilage and bone. We used 
a zymosan-induced arthritis (ZIA) model, in which intraplantar 
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administration of zymosan, a glucan obtained from yeast cell 
wall, induces the secretion of inflammatory ILs.30 Intraplantar 
injection of zymosan causes pronounced, dose-dependent edema. 
This inflammatory response is time-dependent and can last up 
to 14 days following zymosan administration. LV-SFFVp-Luc 
or LV-ESELp-Luc was injected subcutaneously into both hind 
paws 1 week before zymosan administration to allow sufficient 
time for integration of the vector genome. After 1 week the right 
paw was injected with zymosan and the left paw with physi-
ological saline solution. Luciferase expression was monitored by 
imaging of luciferase bioluminescence every 3–4 days over the 
first 2 weeks, when the signal intensity started to decrease, with 
additional measurements after 20 and 30 days. Compared with 
control paws, the inflamed paws showed a notable induction of 
ESELp-driven luciferase expression 4 days after zymosan injec-
tion, reaching a maximum after 7 days and decreasing from this 
point (Figure 3a–c). In contrast, paws injected with SFFVp-Luc 
showed no differences in luciferase expression upon injection 
with zymosan (Figure 3a–c). Comparable progression of ZIA in 
LV-SFFVp-Luc and LV-ESELp-Luc-injected paws was confirmed 
by measuring paw diameter (Figure 3d). In addition, inflamma-
tion was measured by bioluminescence after i.p. administration 
of luminol, which allows quantitative longitudinal monitoring of 
myeloperoxidase (MPO) system activity31 (Figure 3e). LV injec-
tion by itself produced no inflammatory reaction that could con-
tribute to ZIA, since luminol reactions were only observed in 
zymosan-treated paws.
It has been demonstrated that the majority of transduced cells 
after lentivector foot pad administration are dendritic cells (DCs) 
(90% CD11c+ cells) which can migrate to the draining lymph nodes 
and spleen.32 To test whether locally infected cells were migrating 
and luciferase was expressed in these organs, lymph nodes, spleen 
and liver were extracted from LV-transduced animals 5 days after 
zymosan administration. Total tissue homogenates from these 
organs were employed to measure the luciferase activity. The 
results showed that only very low-luciferase activity was detected 
in the popliteal lymph node draining the paw infected with the 
luciferase-bearing LV (Figure 3f,g). Although we cannot rule out 
that LV particles may reach these and other organs, this result sug-
gests that transgene expression remains restricted to the paw after 
zymosan injection.
To identify the uncharacterized 10% of transduced cells, we 
performed double immunostaining in cross-sections of paraffin-
embedded transduced paws. Our preliminary data indicate that 
transgenes are expressed in transduced endothelial cells in vivo 
(data not shown); however further experiments would need to be 
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performed to confirm these data and investigate whether other 
cell types are contributing to the overall transgene expression in 
vivo.
eselp-driven transgene expression in vivo responds 
to inflammation flare-ups
An important aim in gene therapy is the development of expres-
sion systems which can be switched on and off on demand. Such 
vectors would allow cessation of transgene expression upon reso-
lution of the pathological process, and its restoration should the 
disorder reactivate. We therefore wanted to determine whether 
our lentiviral ESELp-driven expression system is modulated by 
the inflammatory conditions induced by zymosan. We monitored 
the inflamed paws after the first injection of zymosan by weekly 
measurement of the bioluminescence produced in response to i.p. 
administration of luminol. After one month, no detectable bio-
luminescence signal was generated in the paws, and correspond-
ingly control and zymosan-injected paws showed no differences in 
ESELp-driven luciferase activity (day 30, Figure 4a). At this point, 
we reactivated the inflammation by administering a second zymo-
san injection to the same paw, and monitored SFFVp- and ESELp-
controlled luciferase expression by bioluminescence. The new 
inflammatory process again led to an increase in ESELp-driven 
transgene expression in the zymosan-injected paws, whereas no 
apparent changes were observed in paws infected with LV-SFFVp-
Luc (Figure 4a,b and Supplementary Figure S6a). The acute 
inflammatory reaction induced by the second zymosan  injection 
was similar in LV-SFFVp-Luc and LV-ESELp-Luc-infected mice, 
as estimated by paw diameter and luminol bioluminescence 
(Figure 4c and Supplementary Figure S6b). These data indicate 
that the ESELp-driven lentiviral expression system has the poten-
tial to selectively target inflammatory tissues and can be reinduced 
by acute inflammatory episodes.
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Figure 3 the e-selectin promoter (eselp)-based lentivector drives 
local transgene expression at inflammatory sites. Mice received an 
intraplantar injection of either LV-SFFVp-Luc or LV-ESELp-Luc in both 
hind paws. After 1 week, mice received intraplantar injections of 180 μg 
zymosan in the right paw and saline solution in the left paw (as a 
negative control for inflammation). In vivo luciferase activity was deter-
mined by bioluminescence at different times after zymosan injection. 
(a) Fold induction of in vivo luciferase activity (flux) in zymosan- and 
saline-injected paws at the indicated times. (b) Scatter plot showing in 
vivo luciferase activity (flux) of control and zymosan-induced arthritis 
(ZIA)-treated paws at day 7 (P < 0.0016; n ≥ 8). (k) Representative bio-
luminescence images of paws infected with the indicated vectors and 
treated with saline (c) or zymosan (ZIA) for 7 days. (d) Graph showing 
the diameters (mm) of mouse hind paws infected with the indicated 
vectors and treated with saline (control) or zymosan (ZIA) for 7 days 
(mean ± SEM; n ≥ 8). **P < 0.01 and ***P < 0.001. (f,g) Luciferase activ-
ity detected in tissues from mice locally transduced with the indicated 
lentiviral vector (LV). Total tissue homogenates from liver, spleen, and 
the indicated lymph nodes were employed to measure luciferase activity 
(n = 4), expressed as RLU (relative light units) per microgram of protein 
(μg). LV, lentiviral vector.
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Figure 4 expression of the e-selectin promoter (eselp)-based 
 lentiviral system is regulated by the level of inflammation in vivo. 
(a) One month after the first zymosan injection, when the inflammation 
had receded, hind paws were reinjected with saline or 180 μg zymosan 
to reactivate inflammation. The graph shows fold induction of in vivo 
luciferase activity measured by bioluminescence in zymosan and saline 
reinjected paws of mice at the indicated times. (b) Scatter plot showing 
in vivo luciferase activity (flux) of control and zymosan-induced arthritis 
(ZIA)-treated paws 7 days after the second zymosan boost (P = 0.0027; 
n = 7). (c) The graph shows the diameters (mean ± SEM; n ≥ 8) of mouse 
hind paws infected with the indicated vectors, measured 7 days after 
the second treatment with saline (control) or zymosan (ZIA). **P < 0.01 
and ***P < 0.001.
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comparative study of transgene expression under 
different inflammation-inducible expression systems
As other viral expression systems that respond to inflammatory 
stimuli have been described, we decided to compare the tran-
scriptional inducibility of ESELp with two other inflammation-
inducible promoters: a NF-kB responsive promoter (NFkBp) 
and a hybrid promoter based on the human IL6 promoter 
fused to the enhancer region of the human IL1 promoter (IL1-
IL6p).10,11 After replacing ESELp with either NFkBp or IL1-IL6p 
and generating the corresponding luciferase-containing LVs, 
we employed them to transduce different cell lines. We found 
that LV-NFkBp displayed the highest luciferase activity in non 
endothelial cells (Figure 5a,b); however, in endothelial cells 
LV-ESELp and LV-NFkBp showed similar basal luciferase activ-
ity (Figure 5a,c). Upon stimulation, LV-ESELp was induced in 
all the cell types tested (Figure 6a–c), displaying the highest 
luciferase activity in endothelial cells (Figure 5c). In the case of 
LV-IL1-IL6p, it showed the highest induction in RAW cells after 
treatment with LPS, displaying luciferase units similar to those 
already published.10
Next, we compared these inflammation-inducible systems 
in vivo. For this, LV-ESELp-Luc, LV-NFkBp-Luc or LV-IL1-
IL6p-Luc was injected subcutaneously into both hind paws and 
1 week later the right paw was injected with zymosan and the 
left paw with physiological saline solution. Luciferase expres-
sion was monitored by imaging of luciferase bioluminescence 4 
days after zymosan injection. As shown in Figure 5d, LV-NFkBp 
displayed very high-luciferase basal activity that was further 
increased after zymosan injection. LV-IL1IL6p displayed the 
lowest luciferase activity and the modest induction observed has 
no statistical significance. Once again, LV-ESELp showed a low 
basal activity which was significantly increased after zymosan 
administration.
eselp-driven Il10 expression attenuates local acute 
inflammation in vivo
Since IL10 shows potential as an anti-arthritic agent which coun-
teracts the actions of proinflammatory molecules, we used the 
inflammation-regulated LV-ESELp system to express this cytokine. 
Cells infected with LV-driving expression of IL10 (LV-ESELp-
IL10) released this IL into the culture medium (Supplementary 
Table S1). To test the efficacy of lentiviral-driven IL10 expression 
in vivo, we injected LV-ESELp-IL10 subcutaneously into the right 
hind paw and LV-ESELp-Luc into the left hind paw of the same 
animal, so that each mouse served as its own control. Another 
group of animals was similarly administered with LV-SFFVp-
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IL10 and LV-SFFVp-Luc. One week later, ZIA was induced in 
both hind paws, and MPO (luminol) and luciferase activities 
were monitored by imaging of bioluminescence every other day 
until inflammation remission began (10 days). Compared with 
the luciferase-expressing inflamed paws, the IL10-expressing 
paws showed a notable reduction in MPO activity, by 90% and 
70% 3 days after zymosan injection in the case of LV-SFFVp and 
LV-ESELp, respectively (Figure 6a and Supplementary Figure 
S7). This was accompanied by corresponding reductions in paw 
swelling (Figure 6b).
To test the reactivation of the system, we administered a sec-
ond zymosan injection after remission of the first acute episode, 
and monitored luciferase and MPO activity by bioluminescence. 
The second acute inflammatory episode was again attenuated in 
the IL10-expressing paws (Figure 6c,d). The smaller attenuation 
observed correlated with the lower degree of inflammation (MPO 
activity) after a repeated zymosan administration (Figure 4). 
These results show that the anti-inflammatory effect obtained by 
low and transient level of IL10 expressed under LV-ESELp was 
similar to that observed after the high and constant level of IL10 
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zymosan in both hind paws. (a) Myeloperoxidase (MPO) activity was measured by bioluminescence at different times after zymosan injection, 
and the percentage of  relative MPO activity was calculated; 100% = MPO activity in paws injected with LV-ESELp-Luc or LV-SFFVp-Luc (*P < 0.05 
and **P < 0.01; n > 5). (b) Paw diameters measured 3 days after the first zymosan injection (*P < 0.05; n > 5). (c) After remission of the first 
acute inflammation, hind paws were reinjected with zymosan (180 μg per paw) to reactivate inflammation, and MPO activity was measured by 
bioluminescence at different times (n = 4). (d) The scatter plot shows in vivo MPO activity (flux) of zymosan-induced arthritis (ZIA)-treated paws 
6 days after the second bout. (e,f) IL10 level present in (e) footpad supernatant and (f) serum from the indicated mice 5 days after the first 
zymosan bout was measured by ELISA (mean ± SEM; n ≥ 4). *P < 0.05 and ***P < 0.001 versus control; ns, not significant P value. LV, lentiviral 
vector.
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released by the LV-SFFVp. Therefore, the expression of IL10 under 
the LV-ESELp would avoid the side effects associated with a pro-
longed release of IL10.
Locally released IL10 might reach the blood stream, raising its 
serum level and therefore increasing the risk of infection. To test 
this, we measured IL10 paw and serum levels in the two animal 
groups 5 days after the first zymosan bout. We found that both 
LV-SFFVp-IL10 and LV-ESELp-IL10 increased the local amount 
of IL10 (Figure 6e); however, only the injection of LV-SFFVp-
IL10 significantly raised IL10 serum level which might cause 
immunosuppression and put the animals at risk of opportunis-
tic infections (Figure 6f). Therefore, these results suggest that 
LV-ESELp-IL10 local administration does not increase suscepti-
bility to infections.
As the local environment in the animal paw is different after 
zymosan injection, we wondered whether our lentiviral system 
was also effective when it was administered after zymosan injec-
tion. We injected LV-ESELp-IL10 subcutaneously into the right 
hind paw and LV-ESELp-Luc into the left hind paw of the same 
animal 1 day after zymosan administration. Another group of 
animals was similarly administered with LV-SFFVp-IL10 and 
LV-SFFVp-Luc. We monitored luciferase activity and found the 
peak at day 7 after zymosan injection (Figure 7a). At that time 
there was a clear swelling reduction in the IL10-expressing paws 
in both groups which was maintained at least for two more days 
(Figure 7b). These results showed that LV-ESELp also works when 
it is administered after the initiation of inflammation; therefore, it 
might be useful as a therapeutic tool after detecting a new inflam-
matory episode.
dIscussIon
The inflammatory response is precisely controlled by the expres-
sion of cytokines whose local levels are directly related to the 
severity of the process. A major challenge in the treatment of 
chronic inflammatory diseases is the development of an expres-
sion system that is tightly regulated by the variable levels of these 
cytokines. This study describes a long-term lentiviral expres-
sion system based on the ESELp, and which is locally induced by 
inflammatory stimuli in direct correlation with the intensity and 
duration of the inflammatory response.
Studies in animal models have shown that gene therapy is an 
alternative for the local treatment of chronic inflammatory dis-
eases. One of the critical factors in gene transfer is the type of vec-
tor employed. Nonviral vectors commonly yield low gene transfer 
efficiency.33,34 Among the viral vectors, adenoviruses are the most 
widely used, but they are poor candidates for the treatment of 
chronic inflammatory diseases because of the immune response 
associated with their application and the rapid loss of transgene 
expression due to lack of persistence of the viral genomes.35,36 AAV 
have emerged as a very promising alternative, since although AAV 
vectors have limited cargo capacity, they stably transduce host 
cells and show low immunogenicity. However, recent studies have 
reported an inflammatory response after AAV application.12–14 
In addition, technical limitations limit the scalability of AAV 
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Figure 7 therapeutic effect of e-selectin promoter (eselp)-Il10 local administration. Mice received intraplantar injections of 180-μg zymosan 
in both hind paws. The next day, one group of mice received an intraplantar injection of LV-ESELp-Luc in the left hind paw and LV-ESELp-IL10 in the 
right one. A second group received similar intraplantar injections of LV-SFFVp-Luc and LV-SFFVp-IL10. (a) In vivo luciferase activity was determined by 
bioluminescence after zymosan injection in both animal groups. (b) Paw diameters measured (top) 7 and (bottom) 9 days after the zymosan injec-
tion. The graph shows the diameters (mean ± SEM; n = 5) of mouse hind paws infected with the indicated vectors. *P < 0.05 and **P < 0.01 versus 
control. LV, lentiviral vector.
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vectors, making it difficult to produce adequate viral titers.37–39 As 
an alternative, lentivirus-derived expression systems have been 
employed in animal models of neuroinflammation.40 Lentivectors 
not only infect dividing and quiescent cells, but they also provide 
long-term expression and show low immunogenicity. In addition, 
the biosafety profile of LVs has been improved significantly by 
minimizing the regions of homology between vector and helper 
sequences (split configuration), and by using heterologous pro-
moters.41 Furthermore, the use of vesicular stomatitis virus glyco-
protein confers efficient transduction in a wide range of cell types 
from many species, and allows high titers of the lentiviral particles 
for clinical applications.42,43 Our study suggests that lentivectors 
may also be a valuable alternative in the treatment of chronic 
inflammatory diseases.
Several inflammation-inducible systems have been described 
recently, all of which are based on chimeric promoters. The pre-
cise in vivo regulation of these tailored promoters is still unknown. 
Our expression system is based on the proximal promoter region 
that controls the expression of the ESEL gene. This gene is par-
ticularly attractive as it is induced early and transiently upon 
inflammation and its promoter region contains the binding sites 
for transcription factors induced by the early induced proinflam-
matory cytokines TNF-α and IL1. Compared to other described 
expression systems, the ESELp-based system shows the high-
est transcriptional activity in endothelial cells. In addition, our 
expression system is highly induced in endothelial cells by the 
early induced proinflammatory cytokines TNF-α and IL1. These 
results are important as activated endothelium plays an important 
role in inflammation initiation. We tested our expression system 
in an experimental model of chronic inflammation by administer-
ing repeated local injections of zymosan. ESELp-driven transgene 
expression is rapidly induced after zymosan administration, coin-
ciding with the peak of inflammation 7 days after the first treat-
ment, and is maintained until inflammation recedes. Compared to 
other inflammation-inducible systems, the ESELp-based is char-
acterized by a low basal activity that after zymosan administration 
increased to levels similar to those observed with a strong viral 
promoter. The other expression systems analyzed showed either 
very high basal activity (NFkB-based system) or very low induc-
ibility after inflammation (IL1-IL6p-based system). Our results 
show that ESELp-dependent transgene expression increases sev-
eral fold, correlating with the severity of inflammation in the ani-
mal system tested. Future experiments will enable more detailed 
comparison of how these expression systems perform in gene 
transfer models.
Since chronic inflammatory diseases are characterized by 
flare-ups and remission phases, it was important to test whether 
the promoter was silenced in vivo and whether transgene expres-
sion could be reinduced after a second zymosan boost. Transgene 
expression again correlated with inflammatory status after a sec-
ond zymosan boost, showing no evidence of promoter silencing. 
We therefore consider the ESELp a valuable tool for the devel-
opment of gene expression systems for the treatment of chronic 
inflammatory diseases. The use of ESELp-based gene delivery sys-
tems to selectively express anti-inflammatory agents in arthritis-
affected joints might eliminate some of the problems of tolerability 
and compliance associated with systemic drug therapies.
One important issue in locally applied gene therapy is to study 
the putative migration of transduced cells in vivo. In this regard, it 
has been demonstrated that LV injection into the mouse footpad 
transduces DCs which are able to migrate to the draining lymph 
nodes and spleen.32 However, we only detected residual luciferase 
activity in the popliteal lymph nodes draining the infected paw 
suggesting that transduced DCs remain in the local inflammatory 
focus (Figure 3f,g). This is in agreement with previously pub-
lished results showing that IL10 transgene expression modulates 
DC maturation.44,45 The authors observed that DCs transduced 
with adenoviral vectors expressing IL10 maintained an immature 
state characterized by low MHC class II, CD86, and IL12 expres-
sion. The immaturity might affect to their migratory ability which 
would support our in vivo results. Further experiments should be 
performed to further characterize the impact of IL10 expression 
on DC migration in vivo.
The occurrence of unpredictable relapses complicates the 
treatment of chronic inflammatory diseases. RA, the most fre-
quent inflammatory rheumatic disorder, is a paradigm of chronic 
inflammatory diseases characterized by an imbalance of pro- and 
anti-inflammatory molecules. Although systemic administration 
of anti-inflammatory agents is beneficial to patients with chronic 
RA, these treatments are limited by loss of efficiency and relapse 
after treatment cessation. There are also significant side effects 
associated with a prolonged systemic imbalance of the natural 
inflammatory response.46,47 Viral vectors are promising candidates 
for gene therapy for local treatment of RA, and several clinical tri-
als are underway.48 However, there is still a need to develop new 
therapeutic approaches that provide prolonged remission from 
disease with limited side-effects by targeting anti-inflammatory 
mediators to the diseased joints. The use of disease-regulated pro-
moters to drive transgene expression might provide therapeutic 
levels of the anti-inflammatory agent exclusively during flare-ups. 
In addition, administration of virus directly into arthritic joints 
should avoid the side-effects associated with systemic administra-
tion and increase the site-specific effects of the therapeutic agent.
It has been shown that local administration of recombinant 
IL10 effectively reduces proinflammatory cytokine activity in sev-
eral animal models of human diseases; however, constant high 
levels of anti-inflammatory molecules might increase the risk of 
infection, therefore prolonged administration of IL10 is limited 
by associated side-effects. Our study demonstrates that activa-
tion of the LV-ESELp lentiviral expression system is regulated by 
the local level of inflammation. Moreover, the LV-ESELp system 
drives inflammation-regulated IL10 expression at levels sufficient 
to reduce acute inflammation induced by zymosan with no effect 
in the IL10 serum levels. Although the LV-ESELp system releases 
considerably lower local concentrations of IL10 than the constitu-
tive expression vector LV-SFFVp, it is noteworthy that regulated 
IL10 expression is as effective as constant expression in reduc-
ing inflammation in vivo. Furthermore, the inducible system is 
switched off during remission of the inflammation, thus avoiding 
the risks associated with a sustained release of IL10. Altogether, 
these results suggest that local administration of LV-ESELp-IL10 
should not increase animal susceptibility to opportunistic infec-
tions. As expected, the levels of inflammation and transgene 
induction are lower after the second bout than observed at disease 
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onset. This endogenously regulated system for the local expression 
of anti-inflammatory molecules provides a potential new approach 
for the local treatment of chronic inflammatory diseases.
MaterIals and Methods
Plasmid constructs. The human ESELp (–940;+40) (ESELp) was amplified 
from human genomic DNA by PCR. The PCR product was cloned into the 
pHRSIN HIV-derived transfer vector to replace the ubiquitously expressed 
spleen forming Focus virus promoter, SFFVp. Firefly luciferase cDNA was 
PCR amplified from a commercially available plasmid (pGL3 Basic).
The NFkB chimeric promoter (NFkBp) was generated by annealing 
sense and antisense oligonucleotides and direct cloning into pBlueScript 
in the following order: HindIII-EcoRI minimal CMV promoter (sense 5′ 
AGCTTGTAGGCGTGTACGGTGGAGGTCTATATAAGCAGAGCTCG 
3′; antisense 5′ AATTCGAGCTCTGCTTATATAGACCTCCACCGTACA 
CGCCTACA 3′), XhoI-3xNFkB-HindIII (sense 5′ TCGAGGGACTTTCC 
ACAAGGGGACTTTCCACAAGGGGACTTTCC 3′; antisense 5′ AGCTGG 
AAAGTCCCCTTGTGGAAAGTCCCCTTGTGGAAAGTCCC 3′) and
KpnI-MluI-3xNFkB-XhoI (sense 5′ CACGCGTGGGACTTT 
CCACAAGGGGACTTTCCAC AAGGGGACTTTCC 3′; antisense 5′ 
TCGAGGAA AGTCCCCTTGTGG AAAGTCCCCTTGTGGAAAGTCC 
CACGCGTGGTAC 3′). The IL1-IL6 hybrid promoter (IL1-IL6p) was 
generated by cloning the PCR products containing the human IL1 
enhancer (–3,690; –2,720) and the human IL6 promoter (–172;+12) 
into pBlueScript. The PCR primers employed were MluI-IL1-fwd 
(5′ CCACGCGTGATCCAAGAGGGAGAAGAAGC 3′), XbaI-IL1-
rv (5′ GGTCTAGACTGATGCTTTCGCTCGAGGG 3′), IL6-fwd 
(5′ GGCTTAGCGCTAGCCTCAATGAC 3′) and BamHI-IL6-rv (5′ 
GGGGATCCGAGACTCTAATATTGAGAC TCATGGG 3′). The ESELp 
sequence was removed from pHRSIN-ESELp-Luc-IRES-GFP by MluI 
and BamHI digestion and replaced by either NFkBp or IL1-IL6p.
The IL10 coding sequence was amplified by PCR using cDNA 
generated from total RNA extracted from LPS-treated RAW cells. The 
PCR products were directly cloned into the SIN-BX plasmid to generate 
the bicistronic cassettes. The luciferase-IRES-GFP and IL10-IRES-GFP 
inserts were cloned into the pHRSIN-SFFVp and pHRSIN-ESELp transfer 
plasmids. The sequences of all plasmids were confirmed and are available 
in our lab websites (http://www.rodriguezlab.com or http://www.lablife.
org/labs/947).
Lentivirus production and titration. HEK-293 cells were transiently trans-
fected by the calcium phosphate method. For viral particle production, the 
indicated pHRSIN transfer plasmid was cotransfected with two helper 
plasmids (8.9 and pMD2-G). Supernatants were collected 48 hours after 
transient transfection and cell debris was removed by centrifugation (10 
minutes, 740 x g, 4 °C). Viral particles were concentrated by ultracentrifu-
gation in a swing bucket rotor for 2 hours at 121,986 x g, 4 °C (Ultraclear 
Tubes, SW28 rotor and Optima L-100 XP Ultracentrifuge; Beckman 
Coulter, Fullerton, CA). After removal of the supernatant, viral particles 
were resuspended in phosphate-buffered saline (PBS) and stored at –80 °C 
until use.
Total viral content was determined by quantitative PCR.49 The con-
centration of transducing units was calculated by infecting 50,000 Jurkat 
cells (in a p96 plate), with 1, 0.1, and 0.01 μl (duplicates) of concentrated 
viral supernatant. After 12 hours, viruses were removed and cells were 
suspended in PBS and analyzed by flow cytometry (FACS Canto HTS; 
Beckton Dickinson, Franklin Lakes, NJ); the number of infective particles/
μl was calculated from the percentage of GFP+ cells.
Cell culture, transient transfection, and transduction. HEK-293 (ATCC 
#CRL-1573), RAW 264.7 (ATCC #TIB-71) cells were grown in Dulbecco’s 
modified Eagle’s medium (Bio-Whittaker; Lonza, Walkersville, MD) sup-
plemented with 10% fetal bovine serum (FBS; Sigma-Aldrich, St Louis, 
MO) and L-glutamine plus  antibiotics (100 U/ml penicillin and 100 μg/ml 
streptomycin). Jurkat cells were  cultured in RPMI medium (RPMI; Bio-
Whittaker, Lonza) containing 10% FBS and L-glutamine plus antibiotics. 
Mouse embryonic fibroblasts (MEFs) were derived from wild-type mice, 
immortalized with SV40 T large antigen using standard protocols (iMEFs), 
and grown in Dulbecco’s modified Eagle’s medium supplemented with 
10% FBS plus antibiotics. Elicited peritoneal macrophages were obtained 
from male mice 4 days after intraperitoneal administration of 1 ml of 10% 
thioglycolate broth. Peritoneal macrophages were seeded at densities of 
0.5–1.0 × 106 cells in 24-multiwell plates in RPMI supplemented with 10% 
FBS and antibiotics for 12 hours and transduced. Mouse granulocyte-mac-
rophage colony-stimulating factor bone marrow-derived DCs were gener-
ated using granulocyte-macrophage colony-stimulating factor-containing 
media by standard protocols. DCs cultured in the presence of granulocyte-
macrophage colony-stimulating factor were transduced at day 5 of culture. 
Primary cultures of human umbilical vein endothelial cells and MLEC were 
isolated and maintained as described.50 iMLEC were grown in Dulbecco’s 
modified Eagle’s medium F-12 (Bio-Whittaker, Lonza) supplemented with 
10% FBS, L-glutamine plus antibiotics (100 U/ml penicillin and 100 μg/ml 
streptomycin), and 50 μg/ml ECGF.27 Cells were transduced for 5 hours 
at the indicated multiplicity of infection, washed with PBS and serum-
deprived for 12 hours before stimulation with the indicated reagents. After 
stimulation, cells were trypsinized and harvested for further analysis.
Flow cytometry, ELISA, and luciferase assay. GFP expression was ana-
lyzed by flow cytometry (FACScanto, BD Biosciences, Franklin Lakes, 
NJ) of harvested cells washed with PBS. For footpad cytokine extraction, 
each one was cut into small pieces in 0.2 ml RPMI with 10% FBS and were 
incubated for 45 minutes at 37 °C to allow cytokine release. Cytokine-
containing media were collected and centrifuged at 2,000g for 20 minutes. 
Footpad or cell culture supernatants were collected for cytokine detection 
by employing commercial ELISA kits (Quantikine immune assays; R&D 
Systems, Minneapolis, MN) and measured in a Benchmark Plus microplate 
spectrophotometer (Bio-Rad, Hercules, CA). To determine luciferase 
activity, transduced cells were collected after stimulation, washed with 
PBS, lysed, and analyzed in an AutoLumat LB953 luminometer (Berthold 
Technologies, Bad Wildbad, Germany). Results are expressed in relative 
light units. For tissue luciferase assays, 1 ml of reporter lysis buffer was 
added to 100 mg of each sample and homogenized at 4 °C using a tissue 
grinder. Tissue homogenates were centrifuged for 10 minutes at 12,800xg 
at 4 °C. Supernatants were saved and employed for luciferase (20 μl) and 
protein quantification (Bradford; Bio-Rad). Reporter gene expression is 
shown as relative light units/μg of protein.
Animals. Four-week-old male and female C57/BL6 mice (Charles River, 
Burlington, MA) were fed lab chow and kept on a 12 hours light/dark 
cycle. The animals were cared for according to the CNIC Animal Facility 
guidelines for the care and use of laboratory animals.
In vivo optical bioluminescence imaging. Bioluminescent imaging analy-
sis was conducted with the IVIS 200 in vivo imaging system (Caliper, 
Hopkinton, MA). Mice were i.p. injected with 150 mg/kg firefly luciferin 
(Promega, Madison, WI) 15 minutes before imaging and anesthetized 
with isoflurane during the procedure. Photons emitted from live mice 
were acquired as photons per s/cm2 per steradian, using Living Imaging 
3.0 (Caliper). For photon quantification, a region of interest was manually 
selected and kept constant within each experiment.
In vivo matrigel plug assay. iMLEC transduced with lentiviral particles 
containing luciferase cDNA were embedded in matrigel (Sigma) which was 
implanted subcutaneously in the chest of mice. After 24 hours, lipopoly-
ssaccharide (40 mg/ml LPS from Escherichia coli; Sigma) was intraperi-
toneally injected and blood samples were obtained 4-6 hours later to 
determine serum cytokine levels (IL6) by ELISA. Bioluminescence due to 
luciferase activity was monitored (see above) 24, 48, and 72 hours after LPS 
treatment.
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ZIA animal model. Viral particles (2 × 107 transducing units) were injected 
into each hind paw of the mouse. After 1 week, the left paw was injected 
with saline solution (30 μl) and arthritis was induced in the right paw 
by intraplantar administration of 180 μg zymosan.30 Luciferase expres-
sion was monitored over one month using the IVIS 200 system (Caliper). 
Inflammation was determined by paw diameter and by monitoring the 
luminescence after i.p. administration of luminol (Sigma).31
Statistical analysis. Data were analyzed for statistical significance using 
GraphPad Prism (version 5.01). Data shown in Figure 2 were analyzed by 
one-way ANOVA followed by Newman–Keuls multiple comparison test. 
Data from ZIA experiments were analyzed by t-test. Statistical significance 
was assigned at P < 0.05. SEM, standard error of the mean; SD, standard 
deviation.
suPPleMentarY MaterIal
Figure S1. Endothelial cells are efficiently infected by lentivectors in 
vitro.
Figure S2. Lentiviral vectors containing the human E-selectin pro-
moter sequence.
Figure S3. Constitutive GFP expression driven by the SFFVp viral pro-
moter is not affected by TNF-treatment.
Figure S4. ESELp-based lentiviral system is induced by an inflamma-
tory milieu in endothelial cells.
Figure S5. In vivo optical bioluminescence images of luciferase activ-
ity from a representative experiment of the ESELp-driven transgene 
expression induced by proinflammatory cytokines in a mouse subcuta-
neous matrigel model.
Figure S6. Inflammation induced by the second zymosan 
administration.
Figure S7. IL10 release from the SFFVp lentiviral system in vivo.
Table S1. IL10 release by LV-transduced cells.
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4.2.1 Introduction 
 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder of unknown origin 
characterized by progressive degeneration of upper motor neurons in the motor cortex 
and lower motor neurons in the brainstem and the spinal cord, initiating in mid-age life177. 
It results in muscle paralysis and ultimately death due to respiratory failure, most 
commonly within 3 to 5 years of diagnosis178. Approximately 90% of ALS patients are 
considered sporadic (sALS) as they appear to occur randomly throughout the community, 
whereas the remaining 10% are familial (fALS) cases179, showing autosomal dominant 
inheritance in the majority of instances. Of these, ∼12% are associated with mutations in 
the Cu/Zn superoxide dismutase (SOD-1) gene180, which seem to confer toxic gain of an 
unknown function rather than loss of normal SOD1 activity181. Recently, a large GGGGCC 
repeat expansion in the first intron of the C9orf72 gene has been reported to be the most 
common genetic cause of ALS, accounting for approximately 40% of fALS and 7% of 
sALS182-184. While several pathogenic processes for the motor neuron degeneration 
observed in ALS have been proposed, one of the most prevailing hypotheses supports a 
non cell-autonomous process: neighbouring astrocytes are thought to play a major role in 
disease progression185-190. The molecular mechanisms underlying neuronal death in ALS 
are presently not fully determined and appear to be multifactorial and among others, 
neuroinflammation191 have been proposed to be involved. Evidence of inflammation is 
observed in post mortem tissue192-195, in cerebrospinal fluid (CSF)196,197 and in blood 
samples198 from fALS and sALS patients. These observations are in agreement with 
previous observations of neuroinflammation in rodent models of ALS199,200. In transgenic 
mice expressing mutant SOD-1, increased levels of Toll-like receptors (TLRs) are 
detected201. Microglial neurotoxic inflammatory responses have been suggested to be 
facilitated via TLR2 202. In addition, it has been shown that mutant SOD-1 binds to CD14, 
which is a co-receptor of TLR2 and TLR4, and that the microglial activation mediated by 
mutant SOD-1 can be attenuated using TLR2, TLR4 and CD14 blocking antibodies203. In 
accordance, Casula et al. have reported an upregulation of TLR2 and TLR4 as well as other 
pro-inflammatory molecules such as Receptor for Advanced Glycation End products 
(RAGE) and High Mobility Group protein B1 (HMGB1) in reactive glia in the spinal cord of 
sALS victims194. One unanswered question, however, is whether these correlative 
observations reflect a causal relationship, with inflammatory activation provoking ALS, or 
alternatively, ALS pathology triggering inflammatory responses. 
There is a need for patient-derived cell models that are relevant and robust enough to 
produce the cells required for molecular and functional analyses. In this study we have 
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explored an alternative patient-derived neural model for the study of sALS disease: 
primary olfactory mucosa (OM) cultures derived from sporadic ALS patients. The OM is 
easily accessible for non-invasive biopsy in human adults204. Either biopsied tissue or 
derived primary cultures have been shown to exhibit alterations in Rett’s syndrome, 
Alzheimer’s disease, fragile X syndrome, schizophrenia, Parkinson’s disease and bipolar 
disorder with respect to healthy donors205-210. OM derived primary cultures contain 
several types of extraepithelial cells including multipotent stem cells211-214 as well as 
olfactory ensheathing glia215 which normally support the growth of primary olfactory 
axons from the neuroepithelium in the nasal cavity to the brain216. These glia are present 
both in the peripheral as well as the central nervous system, and share characteristics of 
both astrocytes as well as Schwann cells. Moreover, olfactory mucosa-derived ensheathing 
glia have been used for therapeutic purposes in spinal cord injury217,218 and even in ALS219. 
The fact that olfactory mucosa transplants exhibit regenerative capacity in spinal cord218, 
led us to speculate that the interaction of OM derived cells with spinal cord-derived motor 
neurons may recapitulate the non-cell autonomous properties described for ALS. It is 
conceivable that olfactory ensheathing cells (OECs) may share some similar characteristics 
of inflammatory cells, providing a degree of immunological protection against infections in 
the olfactory system. Indeed microarray analysis has revealed that, relative to astrocytes 
and Schwann cells, OECs express higher levels of a number of innate immune factors, 
including lysozymes, chemokines and monocyte chemotactic proteins, suggestive of 
functions in modulating neuroinflammation220. OECs have also been demonstrated to 
express Toll-like receptors and possess the cellular machinery to respond to certain 
bacterial ligands221,222. 
Another interesting aspect of using olfactory mucosa cells to model ALS is that it has been 
proposed that chemosensory impairment is an early symptom of many neurodegenerative 
diseases223,224, including ALS225,226. Notably, disease-specific alterations in gene expression, 
protein expression and cell function have previously been found in primary olfactory 
mucosa cultures derived from patients with schizophrenia and Parkinson’s disease227 as 
well as spastic paraplegia228. In this study, we propose the use of olfactory mucosa to 
model ALS, demonstrating their negative effect over motor neuron survival and 
morphology as well as the activation of inflammatory responses as a consequence of this 
deleterious interaction. 
My personal effort in this work has been the expertise with the inflammation-responsive 
LVs which were employed to detect the inflammatory response when OM cells from ALS 
patients are co-cultured with human spinal cord neurons. 
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Abstract
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease which currently has no cure. Research using rodent ALS models
transgenic for mutant superoxide dismutase 1 (SOD1) has implicated that glial–neuronal interactions play a major role in the destruction of
motor neurons, but the generality of this mechanism is not clear as SOD1 mutations only account for less than 2% of all ALS cases. Recently,
this hypothesis was backed up by observation of similar effects using astrocytes derived from post-mortem spinal cord tissue of ALS patients
which did not carry SOD1 mutations. However, such necropsy samples may not be easy to obtain and may not always yield viable cell cultures.
Here, we have analysed olfactory mucosa (OM) cells, which can be easily isolated from living ALS patients. Disease-specific changes observed
when ALS OM cells were co-cultured with human spinal cord neurons included decreased neuronal viability, aberrant neuronal morphology and
altered glial inflammatory responses. Our results show the potential of OM cells as new cell models for ALS.
Keywords: olfactory mucosa amyotrophic lateral sclerosis non-cell autonomous toxicity
SOD-1 neurotoxicity inflammation-responsive promoter
Introduction
Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, is a
neurodegenerative disorder of unknown origin characterized by pro-
gressive degeneration of upper motor neurons in the motor cortex
and lower motor neurons in the brainstem and the spinal cord, initiat-
ing in mid-age life [1]. It results in muscle paralysis and ultimately
death because of respiratory failure, most commonly within 3–
5 years of diagnosis [2].
The classical division of ALS into familial or sporadic types has
been made depending on patient family history. Approximately, 90%
of ALS patients are considered sporadic (sALS) as they appear to
occur randomly throughout the community, whereas the remaining
10% are familial (fALS) cases [3], showing autosomal dominant
inheritance in the majority of instances. Of these, ~12% are associ-
ated with mutations in the Cu/Zn superoxide dismutase (SOD-1) gene
[4], which seem to confer toxic gain of an unknown function rather
than loss of normal SOD1 activity [5]. Other genes, including TARDBP
(TAR DNA-binding protein 43) [6], FUS (fused in sarcoma) [7, 8] and
angiogenin (ANG) [9] have also been implicated in fALS. Recently, a
large GGGGCC repeat expansion in the first intron of the C9orf72 gene
has been reported to be the most common genetic cause of ALS,
accounting for approximately 40% of fALS and 7% of sALS [10–12].
Sporadic and familial ALS cases are however, clinically indistinguish-
able, suggesting similar underlying pathophysiological mechanisms
of neurodegeneration.
While several pathogenic processes for the motor neuron degen-
eration observed in ALS have been proposed, one of the most
prevailing hypotheses supports a non-cell autonomous process:
neighbouring astrocytes are thought to play a major role in disease
progression [13–18]. Nevertheless, the basis for the specificity of
astrocytes and other glial cells in the selective degeneration of
motor neurons remains unclear. Indeed, the molecular mechanisms
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underlying neuronal death in ALS are presently not fully determined
and appear to be multifactorial. Glutamate excitotoxicity, mitochon-
drial dysfunction [19], accumulation of intracellular protein aggre-
gates [20], oxidative stress [21], hypoxia [22, 23], alterations in
RNA metabolism [24], impaired axonal transport [25], growth factor
deficiency [26] and neuroinflammation [27] have all been proposed
to be involved.
Evidence of inflammation is observed in post-mortem tissue
[28–31], in cerebrospinal fluid [32, 33] and in blood samples [34]
from fALS and sALS patients. These observations are in agreement
with previous observations of neuroinflammation in rodent models of
ALS [35, 36]. In transgenic mice expressing mutant SOD-1, increased
levels of toll-like receptors (TLRs) are detected [37]. Microglial neuro-
toxic inflammatory responses have been suggested to be facilitated
via TLR2 [38]. In addition, it has been shown that mutant SOD-1
binds to CD14, which is a co-receptor of TLR2 and TLR4, and that the
microglial activation mediated by mutant SOD-1 can be attenuated
using TLR2, TLR4 and CD14 blocking antibodies [39]. In accordance,
Casula et al. have reported an up-regulation of TLR2 and TLR4 as well
as other pro-inflammatory molecules such as Receptor for Advanced
Glycation End products and High Mobility Group protein B1 in reactive
glia in the spinal cord of sALS victims [30]. One unanswered question,
however, is whether these correlative observations reflect a causal
relationship, with inflammatory activation provoking ALS, or alterna-
tively, ALS pathology triggering inflammatory responses.
A large amount of ALS research has made use of in vitro and
in vivo models based on overexpression of genes with mutations
linked to familial ALS. However, as 90% of ALS cases are sporadic, it
is difficult to ascertain how representative these models are with
respect to the human disease. This highlights one of the main obsta-
cles currently limiting the study also of other neurological diseases:
the need for patient-derived cell models that are relevant and robust
enough to produce the large quantities of cells required for molecular
and functional analyses. Current efforts on developing sALS models
have used patient-derived samples from post-mortem brain, spinal
cord and muscle [28, 40]. More recently, sALS patient-derived cell
cultures have been developed including astrocytes differentiated from
neural progenitor cells obtained from spinal cord necropsies [41], and
induced pluripotent stem cells [42, 43]. All these models represent
various degrees of compromise between relevance for understanding
disease aetiology and suitability for diagnostics and drug discovery.
In this study, we have explored an alternative patient-derived neu-
ral model for the study of sALS disease: primary olfactory mucosa
(OM) cultures derived from sporadic ALS patients. The OM is easily
accessible for non-invasive biopsy in human adults [44]. Either biop-
sied tissue or derived primary cultures have been shown to exhibit
alterations in Rett’s syndrome, Alzheimer’s disease, fragile X syn-
drome, schizophrenia, Parkinson’s disease and bipolar disorder with
respect to healthy donors [45–50]. OM-derived primary cultures con-
tain several types of extraepithelial cells including multipotent stem
cells [51–54] as well as olfactory ensheathing glia [55] which nor-
mally support the growth of primary olfactory axons from the neu-
roepithelium in the nasal cavity to the brain [56]. These glia are
present both in the peripheral as well as the central nervous system,
and share characteristics of both astrocytes as well as Schwann cells.
Moreover, OM-derived ensheathing glia have been used for therapeu-
tic purposes in spinal cord injury [57, 58] and even in ALS [59–61].
The fact that OM transplants exhibit regenerative capacity in spinal
cord [58], led us to speculate that the interaction of OM-derived cells
with spinal cord-derived motor neurons may recapitulate the non-cell
autonomous properties described for ALS.
It is conceivable that olfactory ensheathing cells (OECs) may
share some similar characteristics of inflammatory cells, providing a
degree of immunological protection against infections in the olfactory
system. Indeed, microarray analysis has revealed that, relative to as-
trocytes and Schwann cells, OECs express higher levels of a number
of innate immune factors, including lysozymes, chemokines and
monocyte chemotactic proteins, suggestive of functions in modulat-
ing neuroinflammation [62]. OECs have also been demonstrated to
express TLRs and possess the cellular machinery to respond to cer-
tain bacterial ligands [63, 64].
Another interesting aspect of using OM cells to model ALS is that
it has been proposed that chemosensory impairment is an early
symptom of many neurodegenerative diseases [65, 66], including
ALS [67, 68]. The mucus covering olfactory epithelium has been
shown to contain reduced levels of growth factors that may be related
to this reduction in olfactory capacity [68]. Thus, this olfactory dys-
function suggests that mucosa neuroepithelium components might
also be affected in neurodegenerative disorders, supporting their use
as disease models. Notably, disease-specific alterations in gene
expression, protein expression and cell function have previously been
found in primary OM cultures derived from patients with schizophre-
nia and Parkinson’s disease [69] as well as spastic paraplegia [70].
In this study, we propose the use of OM to model ALS, demon-
strating their negative effect over motor neuron survival and morphol-
ogy as well as the activation of inflammatory responses as a
consequence of this deleterious interaction.
Materials and methods
Reagents and antibodies
All media such as Hank’s balanced salt solution (HBSS), HBSS supple-
mented with Ca2+ and Mg2+, DMEM, DMEM:F12 and Neurobasal med-
ium as well as other cell culture reagents including L-Glutamine,
TrypLE, bovine pituitary extract, B-27 supplement, N-2 supplement were
purchased from Gibco, Life Technologies (Barcelona, Spain).
Other special reagents used were: trypsin, penicillin, streptomycin,
bovine serum albumin, trypan blue, retinoic acid and lipopolysaccharide
(LPS), all purchased from Sigma-Aldrich (St. Louis, MO, USA); DNase-I
(Roche, Mannheim, Germany); foetal calf serum (FCS, Hyclone, Logan,
UT, USA); forskolin (Alomone, Jerusalem, Israel); primocin (InvivoGen,
San Diego, CA, USA); carboxyfluoresceinsuccinimidyl ester (CFSE,
Molecular Probes/Life Technologies, Eugene, OR, USA); brain-derived
neurotrophic factor (BDNF, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), forskolin (Alomone Labs, Jerusalem, Israel); Smoothened agonist
(SAG, Merck/Calbiochem, Darmstadt, Germany); Fluoromount-G (South-
ern Biotech, Birmingham, AL, USA); matrigel (BD Biosciences/Pharmin-
gen, Madrid, Spain) and DAPI (Calbiochem, Nottingham, UK).
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1285
J. Cell. Mol. Med. Vol 19, No 6, 2015
58
The antibodies against the following proteins were used: bIII-tubulin
[71]; S100b, SOD-1 and GAPDH (from Sigma-Aldrich); GFAP and nestin
(from Chemicon, Temecula, CA, USA, now part of Merk-Millipore,
Darmstadt, Germany); vimentin (Boehringer, Ingelheim, Germany); p75
and neuroligin (from Santa Cruz Biotechonology). The secondary anti-
bodies used were anti-rabbit, antimouse and anti-goat Alexa 555, and
Alexa 488 (Molecular Probes/Life Technologies) for immunofluores-
cence and peroxidase-labelled secondary antibodies (Sigma-Aldrich) for
Western blot.
Culture of patient-derived OM
Human OM primary cultures were obtained and cultured as previously
described [72]. OM primary cultures were derived from human nasal
endoscopic biopsies that were carried out by otolaryngologists (E. Scola
and J. Medina) at the Gregorio Mara~non Hospital, Madrid. Written
informed consent was obtained from all healthy or ALS patients, and
the study was approved by the Gregorio Mara~non Hospital ethics com-
mittee. Pre- and post-nasal biopsy olfaction was evaluated in ALS
patients and controls, according to the Barcelona Smell Test-24 (BAST-
24), previously validated for the Spanish population [73]. No significant
changes were found between the ALS patient group and controls, either
before or after nasal biopsy. Briefly, tissue samples were kept at 4°C in
HBSS until processing by disaggregation with 0.05% trypsin in HBSS
for 20 min, inactivation with one volume of FCS, followed by a 5 min.
treatment with 0.01% DNAse-1 in HBSS supplemented with Ca2+ and
Mg2+, after which the cell pellet was finally resuspended in ME medium:
DMEM:F12 (1:1), 10% FCS, 2 mM glutamine, 20 lg/ml bovine pituitary
extract, 2 lM forskolin, 50 lg/ml primocin. Unless specified, OM cells
were grown as adherent monolayer cultures in ME medium.
Immunofluorescence assay
Immunofluorescence analysis was performed as previously described
[68] using the primary and secondary antibodies detailed above and fol-
lowed by 10 min. incubation with DAPI (1/500). Coverslips were
mounted with Fluoromount-G according to the provider’s guidelines.
Representative images were taken with an Axiovert200 (Zeiss, Oberko-
chen, Germany) inverted microscope coupled to a CCD camera using
Metavue 5.07 software (Universal Imaging, Bedford Hills, NY, USA).
Neuronal survival assay
Preparation of frozen stocks of differentiated neurons from human foe-
tal spinal cord neural precursors was as previously described [76]. For
co-cultures with patient-derived glia, OM samples were first seeded in
six-well plates (105 cells per well). After 24 hrs, differentiated neurons
were thawed out and labelled with 25 lM CFSE in PBS containing 1%
bovine serum albumin, for 15 min. at 37°C. After labelling, cells were
diluted with 5 ml of neuronal medium [DMEM:F12 supplemented with
B-27 (20 ll/ml), N-2 (10 ll/ml), streptomycin (100 U/ml) and penicillin
(100 lg/ml)]. The cells were then centrifuged and resuspended in 3 ml
of neuronal medium at 37°C. The percentage of live neurons was deter-
mined by trypan blue exclusion and the labelled cells were seeded in
neuronal medium over OM monolayers at a neuron:OM ratio of 1:6. Cul-
ture medium was changed partially three times per week. After 2 weeks
of co-culture cells were detached with TrypLE, washed with PBS and
resuspended in 200 ll PBS for flow cytometry analysis. The total num-
ber of CFSE-positive cells was counted in 110 ll of each sample using
a FACS CantoII flow cytometer (Becton Dickinson Biosciences, San
Jose, CA, USA) and the results analysed using FlowJo software (Tree-
Star Inc., Ashland, OR, USA).
Olfactory mucosa survival assay
Olfactory mucosa cells were seeded in six-well plates (105 cells/well).
After 24 hrs, ME culture medium was substituted for neuronal medium
(DMEM:F12 supplemented with 20 ll/ml B-27, 10 ll/ml N-2, 100 U/ml
streptomycin and 100 lg/ml penicillin) after which the medium was
renewed partially three times per week. Twenty-three days after seeding,
cells were collected and the total number of surviving cells was counted
in a FACS CantoII flow cytometer (Becton Dickinson Biosciences) and
the results analysed using FlowJo software (TreeStar Inc.).
Neuronal morphology assay
Differentiation of human foetal spinal cord neural precursors along the
motor neuron lineage was carried out by culturing them in Neurobasal
medium supplemented with N-2 (5 ll/ml), BDNF (50 ng/ml), retinoic
acid (100 nM), Forskolin (5 lM) and streptomycin/penicillin (100 U/ml
and 100 lg/ml, respectively) during the first 4 days and Neurobasal
medium similarly supplemented with N-2, BDNF, retinoic acid, strepto-
mycin/penicillin, and SAG (100 nM) for up to 3 weeks.
A subconfluent culture of OM cells was grown on round coverslips
in 24 multi-well plates and differentiated neurons were seeded on top
(5 9 103 neurons per well) in Neurobasal medium supplemented with
N-2 (5 ll/ml) and streptomycin/penicillin (100 U/ml and 100 lg/ml,
respectively). The medium was changed partially three times per week.
After 2 weeks of co-culture, cells were fixed with paraformaldehyde and
immunofluorescence analysis was performed as previously described
[75] using 195 antiserum specific for bIII-tubulin [71] diluted 1:3000
during 1 hr followed by incubation with anti-rabbit Alexa 555 and DAPI.
Representative images were taken and morphological quantification was
performed by scoring a minimum of 15 bIII-tubulin-positive cells in at
least nine random fields per condition into different morphologies:neu-
ronal, when the cells exhibited filamentous bIII-tubulin staining and the
length of the longest neurite was at least four times that of the longest
axis of the nucleus; non-neuronal, when the bIII-tubulin stain was dif-
fuse, cytoplasm was more expanded and its longer part was smaller
than four times the size of longest axis of its corresponding nucleus.
Cells not matching either morphology were discarded from the analysis.
Lentivector production and titration
The viral vectors used to express wild-type and mutant SOD-1 were
LentiSOD1wt and LentiSOD1G37R [18]. The inflammation-responsive
lentivectors LV-NFjBp-luc, LV-ESELECp-luc, LV-IL1-IL6p-luc encode the
luciferase-IRES-GFP reporter construct under the control of 69 NFjB,
E-selectin and IL1-IL6 hybrid promoters, respectively; the LV-SFFVp-luc
lentivector encodes the same reporter under the control of the SFFV
constitutive promoter [74]. Lentiviral stocks were produced as previ-
ously described [75]. Vector titre was determined in OM cells by
1286 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
59
infection with serial dilutions of the viral supernatants and the number
of transduced cells determined 48 hrs post-infection by flow cytometry
(FACSCalibur, BD Biosciences) using GFP expression.
fALS cell model
The foetal human primary astrocyte cell line, HA1800, was obtained
from ScienCell Research Laboratories (Carlsbad, CA, USA) and was cul-
tured according to the provider’s instructions. These cells were infected
with LentiSOD1wt and LentiSOD1G37R [18] before each experiment.
Innate immune response assay
Astrocytes and OM cells were infected with the indicated lentivectors
2 days after the treatment under study. For LPS stimulation, 24 hrs
before treatment, cells were subjected to serum starvation by incubation
overnight in DMEM containing 2% FCS to minimize interference by
serum-borne factors. Cells were then cultured in the presence of LPS
(500 ng/ml) in DMEM containing 2% FCS for the indicated period.
For co-culture, subconfluent spinal cord neural precursors were
seeded in 96 multi-well plates coated with matrigel and differentiated
along the motor neuron lineage by culture in Neurobasal medium sup-
plemented with N-2 (5 ll/ml), BDNF (50 ng/ml), retinoic acid (100 nM),
Forskolin (5 lM) and streptomycin/penicillin (100 U/ml and 100 lg/ml,
respectively) during first 4 days and Neurobasal medium similarly sup-
plemented with N-2, BDNF, retinoic acid, streptomycin/penicillin, and
SAG (100 nM) during the last 5 days. Thereafter, OM cells and human
astrocytes expressing SOD-1 (where indicated) and harbouring lucifer-
ase reporter constructs, were seeded on top of the neurons at a density
of 7000 per well in Neurobasal medium supplemented with N-2 (5 ll/
ml) and penicillin/streptomycin (100 U/ml and 100 lg/ml, respectively).
Medium was changed every 2 days and luciferase assays were per-
formed at the time indicated for each experiment.
Luciferase assay
Cells were washed with PBS and frozen at 80°C. Luciferase activity
was measured with an AutoLumat LB953 luminometer (Berthold
Technologies, Bad Wildbad, Germany) using a commercially available
assay system (E1501; Promega, Madison, WI, USA) following the
manufacturer’s instructions. All treatments were performed in
triplicate. Normalized luciferase activity represented in the graphs was
the result of dividing the relative light unit (RLU) values obtained for
each inflammation-responsive vector by the mean RLU value obtained
for the constitutive SFFV promoter vector under the same conditions.
Western blot assay
Cells were collected, washed and resuspended in lysis buffer (50 mM
Tris-HCl pH 7.5; 300 mM NaCl; 0.5% sodium dodecyl sulphate and 1%
Triton X-100) and incubated for 15 min. at 95°C. Protein concentration
of the extracts was measured using the Dc protein assay kit (Bio-Rad,
Hercules, CA, USA) and 30 lg of each cell extract was resolved by elec-
trophoresis in 12% polyacrylamide gels in the presence of sodium
dodecyl sulphate. After electrophoresis, proteins were transferred to
nitrocellulose membranes which were blocked with 10% low-fat milk in
PBS-T (0.3% TWEEN 20 in PBS) and incubated overnight at 4°C with
specific primary antibody against SOD-1 (1:1000) and anti-GAPDH anti-
body (1:5000). After washing, membranes were incubated with peroxi-
dase-labelled secondary antibodies and the immunoreactive proteins
were visualized using the enhanced chemiluminescence detection kit
Western Lightning Plus-ECL (PerkinElmer, Waltham, MA, USA) following
the supplier’s instructions.
Statistical analysis
Statistical comparison of the data sets was performed with Student’s
t-test. The differences are given with their corresponding P-value, which
is the probability that the observed result could occur merely by chance
under the null hypothesis.
Results
Co-culture of neurons with ALS mucosa cells
diminishes their survival
As a result of the fact that the majority of ALS cases are not
associated with a known mutation [21], our first goal was to gen-
erate an ALS cell bank based on sporadic cases. Numerous stud-
ies have highlighted the relevance of glial cells in ALS
pathogenesis [13–18] and therefore we concentrated on OM as it
is a source of glia that can be obtained from living patients via a
small nasal endoscopic biopsy [72]. We generated a bank of OM
from eight healthy donors and seven ALS patients (Table 1). In
this study, we used culture conditions optimized to enrich for the
growth of glia cells [72]; we successfully obtained primary cul-
tures from all of the patients and did not detect any difference in
the efficiency, survival, growth rates, life span or antigenic mark-
ers in samples derived from ALS patients compared to those from
healthy donors (Figs S1 and S2, and Table 1). All cells were simi-
lar in their expression of the antigenic markers GFAP, vimentin,
S100b, neuroligin, nestin and the low affinity NGF receptor p75
(Fig. S2), all of which are characteristic of OECs. However, as a
cautionary note, our previous work has demonstrated that these
immunocytochemical properties do not clearly distinguish OECs
from other cell types such as fibroblasts or gliomas [72]. To test
whether these biopsy-derived glia exhibit disease-specific neurotox-
icity similar to that observed for spinal cord astrocytes derived
from ALS patient cadavers, we co-cultured them with differentiated
post-mitotic human spinal cord neurons [76] which we pre-
labelled with CFSE to facilitate quantification. The neurons were
plated over OM monolayers at a neuron:OM ratio of 1:6 (Fig. 1A)
and after 2 weeks of co-culture, cells were harvested and the total
number of surviving neurons was counted by flow cytometry. We
observed that neuronal survival was significantly higher when the
neurons were co-cultured with OM derived from healthy donors
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1287
J. Cell. Mol. Med. Vol 19, No 6, 2015
60
compared to when they were co-cultured with OM from ALS
patients (Fig. 1B).
Neuron morphology is aberrant in
co-cultures with OM from ALS patients
In addition to diminished survival when spinal cord neurons were
co-cultured with OM cells from ALS patients, we observed that the
morphology of the surviving cells was significantly affected (Fig. 2).
While neurons grown over control OM cells preserved their typical
morphology with a small cell body and long neuritis positive for
strong fibrillar bIII-tubulin staining (Fig. 2A, upper row), neurons
grown over OM cells from ALS patients often displayed aberrant
morphologies, exhibiting wider cell bodies and retracted neurites
with less fibrillar and more diffuse bIII-tubulin staining (Fig. 2A,
lower row). As OM cells may express low levels bIII-tubulin [72],
we optimized the bIII-tubulin staining sensitivity to exclusively label
CFSE-positive cells. For morphometric analysis, cells were scored
as neuronal if the length of the longest neurite was at least four
times that of the longest axis of the nucleus. Based on this crite-
rion, the data showed a significant reduction in the percentage of
cells with neuronal morphology when the neurons were co-cultured
with OM from ALS patients compared to when they were co-cul-
tured with OM from healthy donors. We thus concluded that co-
culture with OM derived from ALS patients not only reduced
neuronal survival but also modified the morphology of surviving
cells.
Table 1 Information about olfactory mucosa donors
Patient Gender Age
Maximum
cell passage
Number of cells/
mm2 for confluence
C1 Male 26 10 260
C2 Male 36 >10 364
C3 Female 51 >10 260
C16 Male 20 >10 260
C17 Female 25 >10 260
C18 Female 22 >10 260
C19 Male 29 >10 260
C20 Female 30 >10 364
ALS1 Male 57 >10 208
ALS3 Male 72 9 364
ALS4 Male 48 >10 208
ALS5 Male 36 10 208
ALS6 Female 61 >10 260
ALS7 Male 40 >10 364
ALS8 Male 39 >10 364
A
B
Fig. 1 Spinal cord neuron survival after
co-culture with olfactory mucosa (OM).
(A) Scheme of the procedure using flow
cytometry to study the survival of CFSE-
labelled spinal cord neurons after co-cul-
ture with OM cells from healthy control or
ALS donors. (B) Flow cytometry quantifi-
cation of the number of CFSE-labelled sur-
viving neurons after 2 weeks of co-culture
with OM cells or in the absence of these
cells (none). The left graph shows means
and standard errors of the mean (SEM) of
three independent assays of each OM
sample. Samples are ordered by ascend-
ing patient age within each group (control
and ALS). The right graph represents the
combined mean and SEM of the control
or ALS groups with the P-value for com-
parison of the means.
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Glial inflammatory response to LPS is
not altered in ALS
Mounting evidence suggests that neuroinflammation plays an
important role in the degeneration of motor neurons in ALS [77].
It has been demonstrated that reactive astrocytes and microglia
can release pro-inflammatory factors such as cytokines and
chemokines, which are harmful to neighbouring neurons [78]. To
test whether OM cells from ALS patients have an altered pro-
inflammatory state and/or a modified response to inflammatory
stimuli, we transduced OM cells with three different inflamma-
tion-regulated lentivector systems [74]. As a control, OM cells
were transduced with the same reporter cassette (luciferase-
IRES-GFP) under the control of a constitutively promoter
(SFFVp). We first transduced OM cells from healthy donors and
challenged them with a pro-inflammatory stimulus, LPS. We
observed efficient activation of the inflammation-regulated pro-
moters (NFjBp, IL1/IL6p and ESELp) after LPS treatment for 6
and 27 hrs (Fig. 3A). As the largest responses to LPS were
obtained with the NFjB and E-selectin promoters, we selected
these reporters for subsequent experiments.
Our next goal was to ascertain if abnormal pro-inflammatory
innate responses in ALS glia play a role in their toxicity to motor
neurons. For this, we used the inflammation-inducible expression
systems to first analyse human astrocytes overexpressing
SOD1G37R, a previously published genetic model of ALS; in this
model, the authors showed that co-culture with these modified
astrocytes was deleterious to mouse motor neurons [18]. We
thus compared astrocytes expressing either wild-type SOD1 or
the mutant SOD1G37R to control astrocytes (non-transduced) after
LPS treatment for 6 hrs (Fig. 3B and C). Luciferase activities
were lower in astrocytes than in OM cells, indicating less pro-
inflammatory response in this cell type. In addition, NFjBp and
ESELp reporter activity did not increase in astrocytes expressing
either wt SOD1 or mutant SOD1G37R; overall luciferase activity
was actually lower in transduced astrocytes compared to that
observed in control astrocytes. In the case of NFjBp, reporter
activity was significantly higher in the presence of mutant SOD1
than in the presence of wild-type SOD1. In addition, LPS chal-
lenge induced a significant increase in luciferase activity in pres-
ence of mutant SOD1, but not in the presence of wild-type
SOD1 (Fig. 3B). A similar effect was observed using the ESELp
A
B
Fig. 2Morphology of the surviving spinal
cord neurons after co-culture with olfac-
tory mucosa (OM). (A) Representative
immunofluorescence images of the surviv-
ing spinal cord neurons labelled for bIII-
tubulin after 2 weeks of co-culture over
monolayers of OM from four different
healthy control donors (upper row) and
four different ALS patients (lower row).
Nuclei were labelled with DAPI. (B) Mor-
phometric quantification of spinal cord
neurons after co-culture over OM cells.
CFSE-labelled cells were classified as:
neuronal if they exhibited filamentous bIII-
tubulin staining and the length of the lon-
gest neurite was at least four times the
length of the longest axis of the nucleus;
non-neuronal if they exhibited diffuse bIII-
tubulin staining and all neurites were
shorter than four times the length of the
longest axis of the nucleus. A minimum of
15 neurons in at least nine random fields
were scored for each OM sample. Graphs
represent the percentage of cells exhibit-
ing each morphology, showing means and
standard errors of the mean of eight dif-
ferent controls and seven different ALS
OM samples with the P-value for compari-
son of the means. The scale bar repre-
sents 50 lm.
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reporter although the differences were not statistically significant
(Fig. 3B).
We next used these inflammation-inducible reporter systems
to study the inflammatory response in OM cells from healthy
donors and ALS patients (Fig. 3D). Although we observed effi-
cient activation of both NFjBp (Fig. 3D) and ESELp (Fig. 3E)
reporters in response to LPS treatment, no significant differences
between ALS and healthy samples were observed, either in basal
conditions or after LPS exposure. Thus, our results indicate that
there is no alteration of the inflammatory response in OM cells
from ALS samples.
Olfactory mucosa from ALS patients shows
increased inflammatory response in
co-cultures with spinal cord neurons
We next posed the question if the altered inflammatory response
described for ALS might be a consequence, rather than the cause, of
the abnormal interaction between neurons and glia. To address this
issue, we co-cultured human astrocytes, either unmodified (control),
or overexpressing wild-type SOD1 or mutant SOD1G37R with differen-
tiated human spinal cord neurons (Fig. 4A and B). As we had
observed the largest response using the NFjBp reporter previously
(Fig. 3), we employed it to study the effects of only neuronal co-cul-
ture on the astrocytes (Fig. 4A). Under basal conditions (in the
absence of neurons), the SOD1-overexpressing astrocytes showed lit-
tle change in reporter activity compared to unmodified astrocytes;
neuronal co-culture significantly increased the luciferase activity in
astrocytes overexpressing wild-type SOD1, and this increase was
even greater in those overexpressing mutant SOD1G37R (Fig. 4A).
Western blot analysis confirmed similar levels of expression of wild-
type or mutant SOD1, ruling out the possibility that the different sen-
sitivities to the neurons were because of different SOD1 levels. These
results are consistent with the idea of the accumulation of wild-type
SOD1 in sporadic ALS patients [79] to adopt an abnormal pathogenic
conformation which may be exacerbated by overexpression or by cer-
tain point mutations.
We next applied the same methodology to measure the NFjB-
mediated response in OM samples derived from healthy donors and
ALS patients (Fig. 4C). Again, a significant increase in reporter activ-
ity was observed when the cells were co-cultured with spinal cord
neurons, with the OM cells from ALS patients showing higher lucifer-
ase activity than those from healthy donors (Fig. 4C). As increased
reporter activity in the ALS group is not observed in the absence of
co-culture with neurons, we conclude that the altered glial inflamma-
tory response in ALS is likely to be a consequence, rather than a
cause, of neuronal death, which may liberate inflammatory cytokines
which in turn activate NFjB-mediated responses.
Discussion
Multiple lines of evidence have shown the immune system, includ-
ing astrocytes and microglia, to be deleterious for motor neurons
in ALS. Reactive astrocytes and microglia may release pro-inflam-
matory factors such as cytokines and chemokines which are harm-
ful for the neighbouring cells [78]. However, their role as the
primary cause of the disease remains undetermined. Our data indi-
cate that there is no increased innate immune response of glia in
ALS: using the established model of SOD1 overexpression in
human astrocytes, we did not observe increased pro-inflammatory
response after LPS treatment and this result is similar when OM
cells from healthy donors and those from ALS patients are com-
pared. However, co-culture with motor neurons increases glial sen-
sitivity to pro-inflammatory stimuli in ALS: we observed augmented
NFjB-dependent reporter activity both in the SOD1-overexpressing
astrocyte model as well as in OM cells from ALS patients. These
results indicate that alterations in the innate immune response of
glia in ALS might be a consequence of their interaction with dam-
aged neurons rather than the cause of initial neuronal damage.
Nevertheless, once sensitized, the modified pro-inflammatory
response of glia in ALS could further worsen the state of neigh-
bouring neurons. In agreement with this concept, previous work
using a SOD1 transgenic mouse model demonstrated that microglia
and T cells initially slow disease progression, but at later stages
after accumulation of SOD1 protein, contribute to acceleration of
the disease [80]. Moreover, it has been shown in both ALS patients
as well as in mouse models that activation of microglia and astro-
cytes takes place only after distal axon degeneration [40].
Fig. 3 Study of the inflammatory response in ALS cell models. Cells were transduced with reporter lentivectors encoding the luciferase gene under
the control of three inflammation-responsive promoters (NFjBp, an artificial promoter containing multiple NF-jB binding sites; IL1/IL6p, consisting
of the human IL-6 promoter fused to the enhancer region of the human IL-1 promoter; or ESELp, the human E-selectin promoter) or the constitutive
spleen focus-forming virus promoter (SFFVp). Normalized luciferase activity was obtained by dividing the luciferase activity measured in relative light
units (RLU) for each inflammation-responsive promoter by the mean activity of the SFFVp reporter in the same conditions. Graphs represent means
and standard errors of the mean (SEM) of three independent samples. (A) Reporter activities in untreated control olfactory mucosa (OM) cells
(Basal) or after challenge with LPS (500 ng/ml) for either 6 or 27 hrs. (B) Reporter activities in control human astrocytes or those overexpressing
SOD1wt or SOD1G37R either without (Basal) or with LPS challenge for 6 hrs. Comparison of mean luciferase activities (corresponding P-values are
shown) after LPS treatment of astrocytes overexpressing SODG37R with those overexpressing SODwt revealed a significant increase using the NFjBp
reporter; this effect was similar using the ESELp reporter, although not statistically significant. (C) Western blot analysis of SOD1 expression in the
human astrocyte ALS cell models used in B. (D) The left graph shows luciferase activities of the NFjBp reporter in OM cells from eight control
donors and seven ALS patients either without (Basal) or with LPS challenge for 6 hrs. Samples are ordered by ascending patient age within each
group (control and ALS). The right graph represents the combined mean and SEM of the control or ALS groups. (E) Similar study to that shown in
D but using the ESELp reporter.
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The use of OM to model ALS offers certain advantages over other
cell models. The non-invasive and relatively simple nasal biopsy pro-
cedure provides a patient-derived source of living cells that can be
easily expanded to perform molecular analysis and functional assays.
Samples can be collected not only from patients showing genetic link-
age but also from sporadic cases which represent the majority of ALS
victims and are more difficult to model. Most importantly, in view that
sporadic ALS patients may show wide variability in disease aetiology
and responses to therapy, OM cells can be obtained from living
patients, offering the future possibility of personalized in vitro drug
screening prior to treatment of the patient. Presently, the majority of
patient-derived sALS models originate from post-mortem tissue
[28, 40, 41], placing limitations on the average cellular lifespan and
not offering any benefit to the donor. The advent of induced pluripo-
tent stem cells generated from sALS patients offers an expandable
cell model that can be obtained from living patients [42], but this
involves a complex, time-consuming and expensive protocol. On the
contrary, OM cell culture is a relatively simple and reproducible tech-
nique which can yield long-lived cultures without the need for genetic
manipulations which could generate undesired non-disease-related
alterations. Furthermore, OM cultures avoid the necessity for
inefficient, complex and expensive protocols to differentiate neural
precursors as they provide a direct source of neural cells, which, as
we have observed in the present study, recapitulate ALS-specific hall-
marks. Firstly, we observed that compared to healthy donor OM cells,
co-culture with those derived from ALS patients results in reduced
survival and aberrant morphology of spinal cord neurons, in agree-
ment with the deleterious effect of ALS glia on co-cultured neurons
previously reported [14–18]. This may be because of the generation
of a toxic factor and/or decreased trophic support by the glia [26].
The latter is particularly relevant in view of the fact that our controls
show that neurons exhibit drastically reduced survival in the absence
of mucosa cells (control samples ‘none’ in Fig. 1B and [72]). Sec-
ondly, we observed good correlation between the effects obtained
with OM cells from ALS patients and those from a previously pub-
lished ALS model using SOD1-expressing astrocytes [18]. While LPS
challenge did not result in increased NFjB-mediated response in ALS
samples, when OM cells or astrocytes were co-cultured with neurons,
an augmented sensitivity was observed in ALS samples that was not
detected in the absence of neurons. These data indicate that while
there may be no alteration of the innate immune response in cells
from ALS patients, the differential death of neurons after co-culture
A B
C
Fig. 4 Study of the inflammatory response in ALS cell models co-cultured with spinal cord neurons. Cells were transduced with reporter lentivectors
encoding the luciferase gene under the control of an artificial promoter containing multiple NF-jB binding sites (NFjBp) or the constitutive spleen
focus-forming virus promoter (SFFVp). Normalized luciferase activity was obtained by dividing the luciferase activity measured in relative light units
(RLU) for each inflammation-responsive promoter by the mean activity of the SFFVp reporter in the same conditions. Graphs represent means and
standard errors of the mean (SEM) of three independent samples. (A) Reporter activities in control human astrocytes or those overexpressing
SOD1wt or SOD1G37R cultured either alone (Basal) or with spinal cord neurons for 5 days (Neurons). (B) Western blot analysis of SOD1 expression
in the human astrocyte ALS cell models used in A. (C) The left graph shows reporter activities in olfactory mucosa cells from eight control donors
and seven ALS patients cultured either alone (Basal) or with spinal cord neurons for 1 day. Samples are ordered by ascending patient age within
each group (control and ALS). The right graph represents the combined mean and SEM of the control or ALS groups with the P-value for compari-
son of the means.
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with ALS-derived samples may trigger an inflammatory process
including activation of NF-jB pathways. Consistent with this, NF-jB
activation has previously been observed in spinal cord astrocytes in
ALS patients as well as in TDP-43 animal models where it was also
demonstrated that the inhibition of NF-jB with Withaferin A reduced
denervation in neuromuscular junctions [81, 82].
Although important advances in ALS research have been made
using mutated SOD1-expressing astrocytes, this model has the disad-
vantage that it only represents a small fraction of genetic cases of the
disease. Furthermore, transduction by the SOD1 transgene may result
in overexpression the protein at non-physiological levels or generate
other disease-unrelated artefacts such as insertional mutagenesis. In
the present study, to achieve a completely human model, we have
examined the effect of patient OM on motor neurons derived from
human foetal spinal cord. In further work, it would be interesting to
compare their effect on rodent motor neuron primary cultures, which
can be prepared cells that are more fully committed to the motor neu-
ron lineage [83, 84]. To facilitate such studies, the relative homogene-
ity of response to different ALS OM samples with respect to controls
may permit the use of pooled patient cells or perhaps even immortal-
ized cell lines to generate more user-friendly cell models for ALS. Val-
idation of OM as a cell model for ALS offers a new versatile tool to
accelerate research and therapeutic development for this presently
incurable devastating disease. Detailed characterization of OM cell
models opens up the possibility of correlating genetic and functional
differences which will facilitate the identification of more cellular com-
ponents implicated in the disease process.
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4.3.1 Introduction 
 
Precancerous and malignant cells can induce an immune response that results in the 
destruction of transformed cells, a process known as immune surveillance. However, 
immune surveillance is not always successful, resulting in “edited” tumors. Immunoediting 
is mediated by an immune selection pressure favoring the development of less 
immunogenic tumors, which escape recognition by the immune system. Therefore, the 
immune system has the capacity either to block tumor development and impair 
established tumors, or to promote carcinogenesis, tumor progression and metastasis. 
Which of these conditions prevails depends on the balance between the pro-tumor and 
anti-tumor mediators of both innate and adaptive immunity229. This balance is strongly 
regulated by the tumor microenvironment, which is characterized, among other traits, by 
inflammation. Nowadays, the role of inflammation in cancer is controversial. On one hand, 
several immune pro-tumor effector mechanisms are upregulated by chronic inflammation, 
therefore endorsing the hypothesis of a pro-tumorigenic chronic inflammation, which 
seems to produce an immune suppressive and tumor-friendly environment, promoting 
carcinogenesis and tumor growth230. On the other hand, inflammation is also necessary to 
create an environment that promotes the induction of anti-tumor immunity by the 
recruitment and activation of several immune effector cells90. 
IL-12 is a heterodimeric cytokine composed of two subunits (p35 and p40) covalently 
linked by a disulfide bridge primarily produced by macrophages, dendritic cells, 
neutrophils and B cells. When IL-12 is secreted, it engages the IL-12 receptor (IL12R), also 
formed by two subunits (β1 and β2) and mostly expressed on activated T and NK cells, 
dendritic cells and macrophages. IL12-IL12R interaction induces tyrosine phosphorylation 
of Jak2 and Tyk2, triggering the phosphorylation and activation of STAT4, ultimately 
leading to the production of IFN-γ, principal mediator of IL-12 function. IL-12 is crucial for 
Th1 differentiation and cytotoxic responses12. For many years the anti-tumor effect of IL-
12 has been known108, it induces tumor infiltration, proliferation and activation of effector 
immune cells (macrophages, NK and T cells), and also inhibits tumor angiogenesis mainly 
through IFN-γ-dependent production of anti-angiogenic factors such as IP10109. 
Several studies have demonstrated the anti-tumor activity of IL-12 in preclinical models, 
suggesting its therapeutic use as an anti-cancer agent. However, clinical trials involving IL-
12 have been unsuccessful due to the toxic side effects associated with its systemic 
administration, prompting investigation into new methods of IL-12 delivery designed to 
avoid unacceptable toxicity113. In this context, gene therapy seems to be a good alternative 
strategy, as gene transfer methods can be designed to confine IL-12 production to the 
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tumor environment, preventing systemic toxicity142. Several vectors derived from 
viruses143-146, as well as non-viral vectors231 have been developed to transfer IL-12 genes 
locally to the tumor site, offering encouraging results in preclinical experiences, not only 
by itself but also when used in combination with other anti-tumor strategies. In addition, 
the virus-mimicking effect of these viral vectors should trigger an interferon (IFN)-
mediated response, which has proven to be absolutely required for the efficient anti-
tumoral effect of IL-12147. 
An appropriate system for gene therapy in chronic inflammatory processes such as cancer 
could be a lentivector-based expression system, since lentivectors can infect both dividing 
and quiescent cells, provide long term expression and display low immunogenicity. 
Moreover, an ideal vector system should be disease-regulated, expressing high levels of 
the transgene only when and where the therapeutic effect of the transgene is required, 
preventing the toxicity that may be associated with constitutive and systemic expression 
of the transgene. We have generated a novel inflammation-regulated lentiviral expression 
system based on the E-selectin promoter (ESELp) that is induced rapidly and transiently 
upon acute inflammation in response to early pro-inflammatory cytokines (TNF-α, IL1), 
making this promoter a good candidate for the design of inflammation-regulated gene 
therapy vectors160. We have also generated lentivectors incorporating other previously 
described inflammation-inducible promoters, such as the human IL-6 promoter fused to 
the enhancer region of the human IL-1 promoter (IL1-IL6p)157 and a chimeric promoter 
based on NFκB-binding sites (NFκBp)158. Since bioactive IL-12 is a heterodimer composed 
of two subunits, p40 and p35, and it has been shown that p40 homodimers are potent IL-
12 antagonists232, it is important to develop a system that ensures equimolecular 
expression of both IL-12 subunits to maximize the therapeutic effects of IL-12. In this 
work we have cloned and expressed both murine IL-12 subunits as a single coding 
sequence which is processed into separate subunits during translation by the self-cleaving 
property of the 2A peptide (P2A), thereby guaranteeing their stoichiometric expression, to 
transduce murine tumor cell lines commonly employed in syngeneic tumor models.  In 
addition, these IL-12 genes are expressed in lentiviral vectors under the control of 
different inflammation-inducible promoters to confine their expression to inflammation 
foci. We confirmed the inducibility of these systems in vitro and in vivo and demonstrated 
the successful expression of both IL-12 subunits and the release of bioactive IL-12 upon 
pro-inflammatory stimulation. 
My personal contribution has been the characterization of the transduced tumor cell lines 
with our inflammation-inducible LVs upon pro-inflammatory stimulation in vitro and after 
subcutaneous implantation in vivo. 
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Efﬁcient expression of bioactive murine IL12 as a self-
processing P2A polypeptide driven by inﬂammation-regulated
promoters in tumor cell lines
C Lorenzo1,3,4, G Pérez-Chacón2,4, G Garaulet1,4, Z Mallorquín1, JM Zapata2 and A Rodríguez1
Interleukin 12 (IL12) is a heterodimeric proinﬂammatory cytokine that has shown promise as an anticancer agent. However, despite
encouraging results in animal models, clinical trials involving IL12 have been unsuccessful due to toxic side effects associated with
its systemic administration, prompting investigation into new delivery methods to conﬁne IL12 expression to the tumor
environment. In this study we used the self-cleaving property of the 2A peptide to express both codon-optimized murine IL12
subunits (muIL12opt) as a self-processing polypeptide (muIL12opt-P2A). We cloned muIL12opt-P2A driven by different
inﬂammation-induced lentiviral expression systems to transduce murine tumor cell lines commonly employed in syngeneic tumor
models. We conﬁrmed the inducibility of these systems in vitro and in vivo and demonstrated the successful expression of both IL12
subunits and the release of bioactive IL12 upon proinﬂammatory stimulation in vitro. Therefore, IL12 release driven by these
inﬂammation-regulated expression systems might be useful not only to address the impact of IL12 expression in the tumor
environment but also to achieve a local IL12 release controlled by the inﬂammation state of the tumor, thus avoiding toxic side
effects associated with systemic administration.
Cancer Gene Therapy advance online publication, 9 October 2015; doi:10.1038/cgt.2015.53
INTRODUCTION
Precancerous and malignant cells can induce an immune
response that results in the destruction of transformed cells, a
process known as immune surveillance. However, immune
surveillance is not always successful, resulting in ‘edited’ tumors.
Immunoediting is mediated by an immune selection pressure
favoring the development of less immunogenic tumors, which
escape recognition by the immune system. Therefore, the immune
system has the capacity either to block tumor development and
impair established tumors, or to promote carcinogenesis, tumor
progression, and metastasis. Which of these conditions prevails
depends on the balance between the protumor and antitumor
mediators of both innate and adaptive immunity.1 This balance is
strongly regulated by the tumor microenvironment, which is
characterized, among other traits, by inﬂammation. Nowadays, the
role of inﬂammation in cancer is controversial. On the one hand,
several immune protumor effector mechanisms are upregulated
by chronic inﬂammation, therefore endorsing the hypothesis of a
protumorigenic chronic inﬂammation, which seems to produce an
immune suppressive and tumor-friendly environment, promoting
carcinogenesis and tumor growth.2 On the other hand, inﬂamma-
tion is also necessary to create an environment that promotes the
induction of antitumor immunity, by the recruitment and
activation of several immune effector cells.3
Interleukin 12 (IL12) is a heterodimeric cytokine composed of two
subunits (p35 and p40) covalently linked by a disulﬁde bridge
primarily produced by macrophages, dendritic cells, neutrophils,
and B cells. When IL12 is secreted, it engages the IL12 receptor
(IL12R), also formed by two subunits (β1 and β2) and mostly
expressed on activated T and NK cells, dendritic cells, and
macrophages. IL12–IL12R interaction induces tyrosine phosphoryla-
tion of Jak2 and Tyk2, triggering the phosphorylation and activation
of STAT4, ultimately leading to the production of interferon (IFN)-γ,
principal mediator of IL12 function. IL12 is one of the main
proinﬂammatory cytokines, being crucial for Th1 differentiation and
cytotoxic responses. It induces the production of IFN-γ by T and NK
cells, in addition to the proliferation and activation of these immune
cells.4 For many years the antitumor effect of IL12 5 has been
known, and its enhancement of antitumor immunity by acting as a
bridge between innate and adaptive immune responses. IL12
induces tumor inﬁltration, proliferation, and activation of effector
immune cells (macrophages, NK, and T cells), and also inhibits
tumor angiogenesis mainly through IFN-γ-dependent production of
antiangiogenic factors such as IP10.6
Several studies have demonstrated the antitumor activity of
IL12 in preclinical models, suggesting its therapeutic use as an
anticancer agent. However, clinical trials involving IL12 have been
unsuccessful due to the toxic side effects associated with its
systemic administration, prompting investigation into new meth-
ods of IL12 delivery designed to avoid unacceptable toxicity.7 In
this context, gene therapy seems to be a good alternative
strategy, as gene transfer methods can be designed to conﬁne
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IL12 production to the tumor environment, preventing systemic
toxicity.8 Several vectors derived from viruses, such as
adenovirus,9 adeno-associated virus,10 retrovirus,11 and herpes
simplex virus,12 as well as non-viral vectors13 have been
developed to transfer IL12 genes locally to the tumor site, offering
encouraging results in preclinical experiences, not only by itself
but also when used in combination with other antitumor
strategies. In addition, the virus-mimicking effect of these viral
vectors should trigger an IFN-mediated response, which has
proven to be absolutely required for the efﬁcient antitumoral
effect of IL12, as recently demonstrated by Melero and co-workers
using a Semliki forest virus derived vector.14
An appropriate system for gene therapy in chronic inﬂamma-
tory processes such as cancer could be a lentivector-based
expression system, since lentivectors can infect both dividing and
quiescent cells, provide long-term expression, and display low
immunogenicity. Moreover, an ideal vector system should be
disease-regulated, expressing high levels of the transgene only
when and where the therapeutic effect of the transgene is
required, preventing the toxicity that may be associated with
constitutive and systemic expression of the transgene. We have
generated a novel inﬂammation-regulated lentiviral expression
system based on the E-selectin promoter (ESELp) that is induced
upon acute inﬂammation. E-selectin is rapidly and transiently
expressed in response to early proinﬂammatory cytokines (tumor
necrosis factor-α (TNF-α), IL1), and is not expressed under basal
conditions, making its promoter a good candidate for the design
of inﬂammation-regulated gene therapy vectors.15 We have also
generated lentivectors incorporating other previously described
inﬂammation-inducible promoters, such as the human IL6
promoter fused to the enhancer region of the human IL1
promoter (IL1–IL6p)16 and a chimeric promoter based on NFkB-
binding sites (NFkBp).17 Indeed, we have recently demonstrated
that expressing the anti-inﬂammatory cytokine IL10 with these
inﬂammation-regulated lentiviral expression systems efﬁciently
attenuates zymosan-induced inﬂammation.15 Since bioactive IL12
is a heterodimer composed of two subunits, p40 and p35, and it
has been shown that p40 homodimers are potent IL12
antagonists,18 it is important to develop a system that ensures
equimolecular expression of both IL12 subunits to maximize the
therapeutic effects of IL12. In this work we have cloned and
expressed both murine IL12 subunits as a single coding sequence
which is processed into separate subunits during translation by
the self-cleaving property of the 2A peptide P2A, thereby
guaranteeing their stoichiometric expression. In addition, these
IL12 genes are expressed in lentiviral vectors under the control of
different inﬂammation-inducible promoters to conﬁne their
expression to inﬂammation foci. We have studied the inducibility
of the inﬂammation-regulated lentiviral systems and bioactive
IL12 production using HEK-293 cells, tumorigenic Lewis lung
carcinoma (LLC) cells, and melanoma B16-F10 cells.
MATERIALS AND METHODS
Plasmid constructs
The 19 amino acid 2A region of the picornavirus PTV1 (porcine
teschovirus-1), P2A, was generated using the complementary oligonu-
cleotides 2A-1 (5′-GATCCGGAGCCACGAACTTCTCTCTGTTAAAGCAAGCAG
GAGACGT GGAAGAAAACCCCGGTCCT-3′) and 2A-2 (5′-CTAGAGG
ACCGGGGTTTTCTTCCACGTCTCCTGCTTGCTTTAACAGAGA GAAGTTCGTGG
CTCCG-3′) (Sigma-Aldrich, St Louis, MO, USA). These were annealed to
form a duplex with 5′ overhang ends and directly cloned into BamHI–
XbaI-digested pBlueScript to generate the pBS-P2A construct. The murine
codon-optimized p35 subunit cDNA (mup35opt) was polymerase chain
reaction (PCR) ampliﬁed from the AG250-DPmuIL12opt plasmid19 using
the oligonucleotides 5′- CGCTCTTCTAGACATGTGCCAGTCGCGCTACCT
CCTCTTC-3′, which added a XbaI site (underlined) upstream to the start
codon (bold), and 5′-GCGAGAGCGGCCGCTTATCAGGCGGAACTCAGGTA
GCCCATC-3′, which retained the stop codon (bold) and added a NotI site
(underlined) immediately downstream to the coding region. The
mup35opt PCR product was further cloned into the XbaI and NotI
pBS-P2A to create pBS-P2A-mup35opt. The mup40opt subunit was also
ampliﬁed from the AG250-DPmuIL12opt plasmid using the oligonucleo-
tides 5′-CGCTCTGGATCCGCCACCATGTGCCCGCAGAAGCTG ACCATCTCC
-3′, which added a BamHI site (underlined) upstream to the start codon
(bold), and 5′-CGCAGAAGATCTAATGGA CCGGACCCTGCAGGGGACGC-3′,
which removed the stop codon and generated a BglII site (underlined)
next to the last p40 codon. The mup40opt PCR product was directly
cloned into a pGEMT vector (Promega, Madison, WI, USA) to generate the
pGEMT-mup40opt construct. Next, the P2A-mup35opt sequence was
cloned into the pGEMT-mup40opt, using BglII and NotI restriction sites,
obtaining the single ORF mup40opt-P2A-mup35opt encoding for the
muIL12opt-P2A. Finally, the mup40opt-P2A-mup35opt cassette was
cloned into the BamHI–NotI digested pHRSIN HIV 1-derived transfer
vectors, including the ones containing an inﬂammation-induced promo-
ter (ESELp, IL1–IL6p or NFkBp) and the one containing a constitutive viral
promoter (SFFVp).15 All plasmid sequences were conﬁrmed by
sequencing.
Cell culture
Human embryonic kidney (HEK-293; ATCC #CRL-1573; Teddington, UK),
murine LLC (ATCC #CRL-1642), murine melanoma (B16-F10; ATCC #CRL-
-6475), and RAW 264.7 (ATCC#TIB-71) cell lines were grown in Dulbecco´s
modiﬁed Eagle's medium supplemented with 10% fetal bovine serum
(Sigma-Aldrich) and L-glutamine (2 mM) plus antibiotics (100 Uml− 1
penicillin and 100 μgml− 1 streptomycin). After serum starvation (2% fetal
bovine serum O/N), RAW cells were incubated with lipopolysaccharide
(2 μgml− 1) for 24 h.
Transient transfection, Brefeldin A treatment and western blot
HEK-293 cells were seeded in p100 plates and were transiently transfected
by the calcium phosphate method.20 Each plate was transfected with
30 μg total DNA, containing 19 μg of a carrier DNA (pBlueScript), 1 μg of a
reporter plasmid (pEGFP-N3; Clontech, Mountain View, CA, USA), and 10 μg
of either pHRSIN-SFFVp-muIL12opt-P2A plasmid, AG250-DPmuIL12opt
(positive control) or a pHRSIN-SFFVp construct encoding a non-IL12
related transgene (negative control). After 48 h, the culture media was
collected and stored at − 70 °C. Fresh culture medium containing the
protein transport inhibitor Brefeldin A (BD GolgiPlug, BD Biosciences, San
Jose, CA, USA; cat. #555029) was added to the transfected cells. After 6 h of
treatment, transfected cells were harvested and lysed with Laemmli buffer
for western blot analysis. In brief, protein samples were separated on 12%
polyacrylamide gels under reducing conditions and transferred to
nitrocellulose membranes (Whatman). After blocking the membranes with
5% w/v skimmed milk in TBS-T (0.05% Tween-Tris buffered saline) for 1 h at
room temperature, the blots were incubated overnight at 4 °C with the
corresponding ﬁrst antibody solution: anti-mouse IL12 antibody (0.1%, v/v;
R&D Systems, Minneapolis, MN, USA; cat. #AF-419-NA), rabbit polyclonal
anti-2A peptide (0.05%, v/v; Millipore, Billerica, MA, USA; cat. #ABS31);
mouse monoclonal anti-β-tubulin (0.1%, v/v; Sigma-Aldrich; cat. #T6074),
in TBS-T with 5% skimmed milk. After several washes with TBS-T, blots
were incubated with peroxidase-labeled goat anti-rabbit or anti-mouse
IgG (0.02%, v/v; Pierce, Grand Island, NY, USA; cat. #4160 and #31430,
respectively) in TBS-T with 5% skimmed milk for 1 h at room temperature.
The blots were then washed again with TBS-T and membrane-bound
antibody was detected with enhanced chemiluminescence detection
reagent (GE Healthcare, Pittsburgh, PA, USA).
Second-generation lentivector production and titration
HEK-293 cells were transiently transfected by the calcium phosphate
method.20 For viral particle production, the indicated pHRSIN HIV 1-derived
transfer vector was cotransfected with two helper plasmids, the 8.91
packaging vector21 and pMD2-G (VSV-G containing plasmid; Addgene,
Cambridge, MA, USA). Supernatants were collected 48 h after transient
transfection and cell debris was removed by centrifugation (10min, 740g,
4 °C). Viral particles were concentrated by ultracentrifugation in a swing
bucket rotor for 2 h at 121, 986g at 4 °C (Ultraclear Tubes, SW28 rotor and
L8–70 Ultracentrifuge; Beckman Coulter, Brea, CA, USA). After supernatant
removal, viral particles were resuspended in phosphate-buffered (PBS) and
stored at − 70 °C. Total viral content was determined by quantitative PCR.22
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Transduction and induction assay
LLC, B16-F10, and HEK-293 cells were seeded in six-well plates (5×105 cells
per well) and transduced for 5 h with different lentiviral particles at the
indicated multiplicity of infection. They were then passaged into 24-well
plates and incubated for 12 h under serum deprivation (0.5% fetal bovine
serum for LLC and 2% fetal bovine serum for B16-F10 and HEK-293)
before proinﬂammatory stimulation with TNF-α (100 ngml− 1) and IL1β
(10 ngml− 1) (Peprotech, London, UK). After 6 h of stimulation, super-
natants were collected and cells were lysed for further analysis. Each
experiment was performed at least three times.
Luciferase assay
To determine luciferase activity, cells transduced with the luciferase-
containing viral particles (pHRSIN-LUC) were collected after stimulation,
washed with PBS, and lysed with Reporter Lysis Buffer (RLB; Promega).
Supernatants were saved and employed to measure luciferase activity in a
20/20N luminometer (Turner BioSystems, Sunnyvale, CA, USA) and for
protein quantiﬁcation (Bradford; Bio-Rad, Hercules, CA, USA). Reporter
gene expression is shown as relative light units per microgram of protein.
Lymphoblast proliferation assay
Spleens from C57/BL6 mice (n = 4) were mechanically processed and
mononuclear murine cells were isolated by density gradient centrifuga-
tion (Lympholyte-M; Cedarlane Laboratories, Burlington, NC, USA).
Splenocytes were resuspended in RPMI 1640 medium supplemented
with 10% FCS, 50 μM 2-mercaptoethanol (2-ME), 100 Uml − 1 penicillin,
100 μg ml − 1 streptomycin, and 2mM L-glutamine and incubated in 96-
well plates (5×104 cells per well) with concanavalin A (ConA, 4 μg ml − 1)
for 30 h at 37 °C. After this incubation, different amounts of codon-
optimized murine IL12 were added and cell survival (proliferation)
was determined 48 h later using the CellTiter-Glo Luminescent Cell
Viability Assay (Promega). Recombinant muIL12 (Peprotech) was used as
a positive control.
Interferon gamma release
Splenocytes from C57/BL6 mice (n=3) were isolated as described above
and subsequently incubated for 30 h in the presence of ConA (4 μgml− 1),
washed with PBS, and cultured in 96-well plates (5×104 cells per well) in
triplicates with different amounts of codon-optimized murine IL12. After
48 h supernatants were harvested and stored at − 20 °C until use. In
parallel, cell viability in these conditions was measured using the CellTiter-
Glo Luminescent Cell Viability Assay. Recombinant muIL12 (Peprotech; cat.
#210-12) was used as a positive control. Supernatant from cells cultured in
the absence of ConA was used as a negative control of interferon
production.
Enzyme-linked immunosorbent assay
Cell culture supernatants were collected for IL12 and IFN-γ detection by
employing mouse IL12 ELISA Kit (Thermo Scientiﬁc, Grand Island, NY,
USA; cat. #EMIL 122) and mouse IFNγ Quantikine ELISA Kit (R&D
Systems; cat. #MIF00), respectively. Samples were measured in a
microplate spectrophotometer (xMark; Bio-Rad) following the manufac-
turer’s recommendations.
Animals
Six-week-old female C57/BL6 mice (Charles River, Burlington, MA, USA)
were fed lab chow and kept on a 12 h light/dark cycle. The animals were
cared for according to the UAM Animal Facility guidelines for the care and
use of laboratory animals.
Statistical analysis
Prism 5 for Windows (GraphPad Software; version 5.03) was employed for
statistical analysis. Data shown in Figures 1–4 were analyzed by t-test
(unpaired, two-tailed test) compared with control or untreated samples.
Data shown in Figure 5 were analyzed by one-way ANOVA followed by
Newman–Keuls multiple comparison test. EC50 was calculated by
Gaddum/Schild EC50 shift. Statistical signiﬁcance was assigned at
Po0.05. s.d., standard deviation.
RESULTS
Generation of muIL12opt-P2A self-processing construct
As human IL12 is inactive in mice and mouse IL12 is active in both
humans and mice,23 we decided to clone codon-optimized murine
IL12 subunits (muIL12opt)19 as a single coding sequence and
employ the self-cleaving property of the P2A peptide to express
this heterodimeric cytokine as a self-processing polypeptide. A
similar strategy has been successfully employed with bovine24 and
ovine25 IL12. The 2A peptide was ﬁrst discovered in the foot-and-
mouth disease virus.26 It allows the coordinated co-expression of
multiple proteins from a single transcript and, even more
importantly, enables the co-expression of the two IL12 subunits
in stoichiometric amounts.27 In brief, we ﬁrst designed the 2A
coding oligonucleotides for the porcine teschovirus-1 2A peptide
(P2A), annealed them, and cloned them into a plasmid.
Furthermore, we performed PCR ampliﬁcation of the sequences
encoding the murine IL12 subunits, p35 and p40, from a codon-
optimized muIL12-containing construct (muIL12opt)19 (Figure 1a,
top). Next, both PCR products were subcloned into different
intermediary plasmids to ﬁnally generate the single ORF p40-P2A-
p35 coding for the codon-optimized self-cleaving murine IL12
(muIL12opt-P2A). This cDNA cassette was further cloned into a HIV
1-derived transfer vector (pHRSIN) under the transcriptional
control of the constitutive viral promoter from spleen focus
forming virus (SFFVp) (Figure 1a, bottom).
Efﬁcient murine IL12 expression
To assess whether we had successfully cloned murine IL12 and if
the interleukin was correctly expressed, we ﬁrst performed a
transient transfection experiment in HEK-293 cells. For this
experiment, we employed the pHRSIN transfer vector that
contains the muIL12opt-P2A cassette under the control of SFFVp.
As a positive control, we used the parental codon-optimized
muIL12-containing construct (muIL12opt). In addition, we
employed a pHRSIN-SFFVp construct encoding a non-IL12 related
transgene as a negative control. Cells were transfected by the
calcium phosphate method with one of these pHRSIN-based
constructs. To test whether IL12 was successfully released, the
culture medium collected from transfected cells was analyzed by
enzyme-linked immunosorbent assay (Figure 1b). To conﬁrm the
correct expression of both IL12 subunits, we analyzed the
transfected cells by western blotting. Since IL12 is a secreted
cytokine, to detect it in cell extracts, intracellular protein transport
must be blocked to accumulate IL12 within the Golgi complex.28
Thus, after collecting the culture medium 48 h post-transfection,
cells were treated with Brefeldin A, a protein transport inhibitor
that blocks protein release. After treatment, cells were harvested
and total cell extracts were analyzed by western blotting using an
anti-IL12 antibody that recognizes both IL12 subunits, p40 and
p35 (Figure 1c). As a protein loading control we used an antibody
speciﬁc for β-tubulin. These cell extracts were also tested for P2A
expression by employing an anti-2A peptide antibody. As
expected, we were able to detect the P2A peptide fused to p40
subunit only in the total cell extracts from cells transfected with
the muIL12opt-P2A-containing construct (last lane). As CMV
promoters are more transcriptionally active than SFFVp, lower
IL12 levels were expressed when the lentivector was employed
(Figure 1b and c). These results show that muIL12opt-P2A is
successfully expressed and efﬁciently released. They also suggest
that the P2A sequence does not interfere with the heterodimeric
conformation of IL12.
Inducibility of the inﬂammation-regulated promoters in human
and murine tumor cell lines
Since we want to express the muIL12opt-P2A transgene under the
control of inﬂammation-regulated promoters, we ﬁrst tested the
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inducibility of the different expression systems in a variety of
tumor cell lines, including HEK-293 human cells, murine LLC, and
murine B16-F10 melanoma cells.29 To address this, we employed
pHRSIN transfer vectors encoding the luciferase reporter gene
under the control of different inﬂammation-induced promoters:
the E-Selectin promoter (ESELp), the IL1–IL6 hybrid promoter (IL1–
IL6p), and the synthetic 6x NFkB promoter (NFkBp).15 As a control,
a pHRSIN vector expressing luciferase under the control of the
constitutive SFFVp was used. The different cell lines were
transduced with these lentivectors and then stimulated for 6 h,
harvested and cell extracts were made to measure luciferase
activity and protein content. We ﬁrst employed TNF plus IL1β as
we have previously shown that these proinﬂammatory cytokines
are able to induce these inﬂammation-regulated promoters in
other cell lines.15 As shown in Figure 2a, luciferase activity from
the constitutively active SFFVp was not affected by the treatment,
while proinﬂammatory treatment increased the luciferase
activity in the three transduced cell lines when the
inﬂammation-regulated promoters were employed. Notably not
all inﬂammation-inducible promoters responded similarly in the
different cell lines. In this regard, we observed that all promoters
efﬁciently responded to the inﬂammatory stimulus in LLC cells. By
contrast, transduced B16-F10 cells showed low luciferase activity
and low fold induction with the ESELp, while the IL1–IL6p failed to
induce any luciferase activity in response to the inﬂammation
stimulus. In these cells, the NFkBp was also efﬁciently stimulated
by TNF and IL1 (Figure 2a, middle). HEK-293 cells showed similar
results to those obtained with LLC cells, with the exception of the
IL1–IL6p, which failed to respond to the stimulus (Figure 2a, right).
When we compared the transcriptional inducibility of the different
inﬂammation-inducible promoters, we found that the NFkBp
displays the highest basal luciferase activity in all cell lines tested;
in all cases, the NFkB-controlled luciferase activity was further
increased upon proinﬂammatory stimulation. Importantly, the
ESELp displays very low basal luciferase activity in all cell lines
assayed, which was consistently increased after proinﬂammatory
stimulation, showing the highest fold induction in both LLC and
HEK-293 cell lines. The IL1–IL6p showed the lowest luciferase
activity with no, or modest, fold induction in all cell lines tested.
To further conﬁrm these results, we incubated LLC and
B16-F10 transduced cells with a cytokine cocktail-containing
media collected from lipopolysaccharide-treated RAW cells. We
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Figure 1. Murine IL12 is successfully expressed as a P2A self-processing polypeptide. (a) Schematic representation of the murine IL12-
encoding plasmids. The murine codon-optimized sequences encoding the IL12 subunits (p35 and p40) were ampliﬁed by PCR from the
muIL12opt plasmid and employed to generate the single ORF mup40opt-P2A-mup35opt sequence (muIL12opt-P2A). The sequence of the
P2A peptide (bold and underlined) ﬂanked by the linker (gray) and murine IL12-speciﬁc (bold) sequences are detailed. Arrowhead indicates
the cleavage site. (b, c) HEK-293 cells were cotransfected with a GFP-encoding reporter plasmid plus either the parental muIL12opt plasmid, a
control plasmid (Control), or the P2A-based muIL12 construct, muIL12opt-P2A. (b) At 48 h post-transfection, culture medium was collected
and assayed for IL12 by ELISA. The IL12 concentration was calculated based on a recombinant murine IL12 (p70) standard curve. (c) After
collecting the culture medium, transfected cells were treated with Brefeldin A (protein transport inhibitor) for 6 h. Cell extracts were analyzed
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found that treatment with these murine cytokine cocktails
mimicked the results obtained with TNF plus IL1β (Figure 2b).
As LLC express TLR4,30 lipopolysaccharide treatment was able to
increase the luciferase activity in LLC transduced cells (Figure 2b,
top). Altogether these results demonstrate that ESELp and
NFkBp are transcriptionally upregulated upon proinﬂammatory
treatment of transduced LLC and B16-F10 cells.
Induction of IFN-γ is one of the antitumoral activities of IL12. As
this cytokine will be present within the tumor, we tested whether
this cytokine was able to upregulate the inﬂammation-regulated
promoters. An IFN-γ-dependent induction would generate a
problematic activation loop in terms of therapeutic applications.
As shown in Figure 2c, IFN-γ did not induce the luciferase activity
under the control of these inﬂammation-regulated promoters.
Therefore, the transcriptional activity of these promoters will not
be affected by the presence of IFN-γ within the tumor
microenvironment.
The ESELp and NFkBp inﬂammation-regulated promoters are
upregulated within the tumor microenvironment
We decided to test whether these promoters were also induced in
the tumor microenvironment. For this we employed LVs encoding
the luciferase transgene under the control of the inﬂammation-
induced promoters (ESELp, NFkBp) or the constitutive viral
promoter (SFFVp) to transduce LLC cells (Figure 3). As in vivo
experiments last for several weeks and silencing of transgene
expression may occur, we ﬁrst tested if the promoter inducibility
was maintained. For this, we transduced LLC cells, kept them in
cell culture and treated them with either lipopolysaccharide or
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Figure 2. Inﬂammation-regulated promoters are induced upon proinﬂammatory stimulation of transduced LLC and B16-F10 tumor cells.
The indicated lentiviral vectors encoding the luciferase reporter transgene under the control of the inﬂammation-induced promoters (ESELp,
IL1–IL6p, NFkBp) or the constitutive viral promoter (SFFVp) were employed to transduce LLC (a–c), B16-F10 (a–c), and HEK-293 (a) cell lines
(MOI= 1.0). After serum deprivation, cells were incubated with tumor necrosis factor (TNF) (100 ngml− 1) plus IL1β (10 ngml− 1) (a, c), LPS
(b, c), supernatant from LPS-treated RAW cells (RAW SN) (b), or interferon-γ (c) for 6 h, and the luciferase activity was determined after cell
harvesting. Reporter gene expression is shown as relative light units (RLU) per microgram of protein (a, c) or fold induction (b). Numbers in
panel a indicate the fold induction. *Po0.05, **Po0.01, and ***Po0.001 versus untreated cells; n= 3. ESELp, E-selectin promoter; IL1β,
interleukin 1β; IL1–IL6p, IL1 enhancer–IL6 promoter; LLC, Lewis lung carcinoma; LPS, lipopolysaccharide; NFkBp, 6xNFkB sites; SFFVp, spleen
focus forming virus promoter.
Inﬂammation-regulated expression of murine IL12
C Lorenzo et al
5
© 2015 Nature America, Inc. Cancer Gene Therapy (2015), 1 – 10
77
TNF-α plus IL1β at different times (Figure 3a). We found that ESELp
and NFkBp were efﬁciently induced even at 38 days post-
transduction, a period of time longer than that needed for the
in vivo experiments. Therefore, we decided to test whether these
inﬂammation-regulated promoters were upregulated in vivo. For
this, LLC cells were transduced with the indicated luciferase-
encoding LVs and implanted subcutaneously into mice. Tumor
burden and bioluminescence (Figures 3b and c, respectively) were
monitored during 28 days. We found that the transduced cells
successfully engrafted after implantation. We observed that at late
time points the tumor volumes were smaller than those observed
when control cells were employed (i.e., non-transduced LLC).
Regarding the in vivo luciferase activity, the results show that
luciferase expression under the control of ESELp and NFkBp was
induced 21 days after implantation (Figure 3c). At the end of this
in vivo experiment (day 28), tumors were isolated and the
luciferase activity was measured in tumor homogenates. As shown
in Figure 3d, in the case of NFkBp none of the tumors displayed
luciferase activity. In the case of ESELp, only two out of four
tumors still showed very low luciferase activity. These results
indicate that these inﬂammation-regulated promoters are tran-
siently upregulated within the tumor environment. As transcrip-
tional activity of these promoters is upregulated by
proinﬂammatory cytokines, these results suggest that in LLC-
based tumors inﬂammation is transiently upregulated within
tumor microenvironment.
Efﬁcient murine IL12 release upon proinﬂammatory stimulation
Once we had determined the inducibility of the inﬂammation-
regulated promoters, we proceeded to clone the muIL12opt-P2A
coding sequence in the inﬂammation-regulated lentivectors
(Figure 4a), as inﬂammation is one of the main characteristics of
tumor environment and IL12 has shown potential as an anticancer
agent. We generated the lentiviral particles encoding the
muIL12opt-P2A under the control of the different inﬂammation-
regulated promoters (ESELp, IL1–IL6p, and NFkBp) or a constitu-
tive promoter (SFFVp) and used them to transduce HEK-293, LLC,
and B16-F10 tumor cells. As in the previous experiments,
transduced cells were treated for 6 h with TNF plus IL1β. After
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Figure 3. Intratumoral upregulation of inﬂammation-regulated promoters in vivo. The indicated lentiviral vectors encoding the luciferase
reporter transgene under the control of the inﬂammation-induced promoters (ESELp, NFkBp) or the constitutive viral promoter (SFFVp) were
employed to transduce LLC cells (MOI= 1.0). Transduced cells were either grown in cell culture (a) or implanted ectopically in mice (b–d).
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protein (μg). ESELp, E-selectin promoter; LLC, Lewis lung carcinoma; LPS, lipopolysaccharide; NFkBp, 6xNFkB sites; SFFVp, spleen focus forming
virus promoter.
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treatment, cell culture medium from transduced cells was
collected and the IL12 concentration was measured. As expected,
cells transduced with the constitutive strong viral promoter SFFVp
released high levels of IL12 (Figure 4b–d). Regarding the inducible
promoters, the lL12 levels detected mostly correlated with the
inducibility observed in the luciferase assays (Figure 2). Thus, the
HEK-293 and LLC cell lines showed inﬂammation-dependent
IL12 induction when ESELp and NFkBp were employed (Figure 4b
and d). In the case of B16-F10 cells, we only detected signiﬁcant
amounts of IL12 when NFkBp was employed (Figure 4c). Similar to
the results shown in Figure 2, NFkBp supported the highest fold
induction of IL12 expression in the three cell lines assayed.
However, ESELp showed the lowest basal activity while its activity
was consistently increased upon proinﬂammatory stimulation.
These features (low basal activity and high fold induction) are
particularly important for biomedical application to reduce toxicity
associated with constitutive and systemic IL12 release.
muIL12-P2A induces murine lymphoblast proliferation and IFN-γ
release
Although the fusion of P2A to muIL12 did not appear to adversely
affect expression of the IL12 subunits and the heterodimeric
interleukin is secreted correctly from the cells, thus suggesting its
proper folding, we performed a functional assay to test its
bioactivity. We collected supernatants from HEK-293 cells contain-
ing either the parental muIL12opt or the P2A-based IL12
(muIL12opt-P2A) and tested them in a proliferation assay using
ConA-stimulated murine lymphoblasts (Figure 5). As a positive
control, recombinant and puriﬁed murine IL12 (muIL12R) was
employed in these proliferation assays. The results show that all
murine IL12 samples employed were able to induce proliferation
of ConA-stimulated murine lymphoblasts in a dose-dependent
manner (Figure 5a). Similar results were obtained with α-CD3-
stimulated murine lymphoblasts (data not shown). Notably,
although similar amounts of IL12 were used, muIL12opt and the
P2A-based IL12 were more efﬁcient in inducing proliferation (2.1-
fold) than recombinant puriﬁed IL12 (1.6-fold); the difference
could be due to loss of speciﬁc activity during puriﬁcation. Finally,
to further characterize these cytokines we determined the half
maximal effective concentration (EC50) of each murine IL12. As
shown in Figure 5b, muIL12opt-P2A showed the lowest EC50
(0.16 ngml− 1), closely followed by the muIL12opt (0.27 ngml− 1).
As expected, the puriﬁed muIL12R showed a signiﬁcantly higher
EC50 (8.07 ngml− 1).
Treatment with IL12 induces IFN-γ release, which is essential for
the antitumor activity of IL12. Therefore, in addition to lympho-
blast proliferation, we also measured the amount of IFN-γ released
by ConA-stimulated murine lymphoblasts and further treated with
IL12. Freshly isolated splenocytes were ﬁrst stimulated with ConA
and then incubated for 48 h with increasing concentrations of
IL12. As shown in Figure 5c, we found that incubation with IL12
induced IFN-γ in a dose-dependent manner. As in the case of cell
proliferation, recombinant puriﬁed IL12 was less efﬁcient and the
amount of IFN-γ was lower than that induced by muIL12opt and
muIL12opt-P2A. Overall, these results conﬁrmed that 2A self-
processing murine IL12 is bioactive and efﬁciently induces
lymphoblast proliferation and IFN-γ release.
DISCUSSION
The production of IL12 requires the coordinated expression of p35
and p40 subunits to form the functional heterodimeric interleukin.
The biosynthesis of IL12 depends on the interaction of its p35 and
p40 subunits, not only to form the functional heterodimer but also
because these two subunits regulate each other. For example, it
has been reported that the p40 subunit stabilizes p35 and
promotes its secretion.19 In the present work, we have used an
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Figure 4. The P2A self-processing IL12 is released upon
proinﬂammatory stimulation of transduced murine tumor cells.
(a) Schematic representation of the different transfer plasmids
generated. The muIL12opt-P2A coding sequence was
cloned in constructs to place it under the control of the
inﬂammation-regulated promoters, ESELp, IL1–IL6p, and NFkB.
(b–d) The indicated transfer vector was employed to
generate lentiviral particles to transduce LLC (a), B16-F10 (b),
and HEK-293 (c) cells (MOI= 10.0 for LLC and B16-F10; MOI= 1.0
for HEK-293). After serum deprivation, cells were incubated
with tumor necrosis factor (TNF) (100 ng ml − 1) plus IL1β
(10 ng ml − 1) for 6 h, and supernatants were collected for IL12
detection by ELISA. The IL12 concentration was calculated based
on a recombinant murine IL12 (p70) standard curve and
expressed as picograms of IL12 per ml. One representative
experiment is shown. *Po0.05, **Po0.01, and ***Po0.001
versus untreated cells; n= 3. ELISA, enzyme-linked immunosor-
bent assay; ESELp, E-selectin promoter; LLC, Lewis lung carci-
noma; NFkBp, 6xNFkB sites; SFFVp, spleen focus forming virus
promoter.
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expression-optimized IL12 plasmid (muIL12opt) described by
Dr Felber and co-workers,19 which encodes signiﬁcantly higher
levels of bioactive IL12 compared to the wild-type IL12 sequences.
We have generated a P2A-based IL12 construct encoding both
IL12 subunits in a single coding sequence in order to achieve
concomitant, stoichiometric production of both IL12 subunits and
high levels of bioactive interleukin. The 2A peptide was ﬁrst
discovered in the foot-and-mouth disease virus, which encodes a
single ORF in which two of the gene products are separated by
the short 2A sequence, F2A (19 aa);26 it is now known that other
picornaviruses also have a 2A peptide, such as the porcine
teschovirus-1 (PTV1), whose 2A peptide (P2A) has been used in
this work. During its translation, P2A interacts with the exit tunnel
of the ribosome to induce ‘skipping’ of the last peptide bond at
the C-terminus of 2A, so that the ribosome is able to continue
translating the downstream gene product, after releasing the ﬁrst
protein fused at its C-terminus to 2A. This approach provides a
tool to allow the coordinated co-expression of multiple proteins
from a single coding sequence and enables the achievement of
stoichiometric production27 of the subunits. This is especially
important in the case of IL12, whose bioactive form requires
equimolar expression of the two separate genes encoding p40
and p35 and the subsequent formation of the heterodimeric
complex, since p40 homodimers are potent IL12 antagonists.18
This makes the P2A strategy more suitable for the expression of
heterocomplexes such as IL12 than other multicistronic strategies
such as use of internal ribosome entry sites, which allow
translation to be initiated from downstream translational start
codons but often with reduced efﬁciency, leading to unequal
expression of the gene products. In addition, this strategy reduces
the size of the vector since it eliminates the need of alternative
promoters and regulatory sequences. Additional advantages of
the P2A approach are that 2A-based exon skipping has been
observed to occur in all tested eukaryotic systems, and that the
fusion of the small size P2A sequence neither interferes with the
functionality of the chimeric protein nor displays immunogenicity
in immunocompetent individuals.31 Our results show that 2A
cleavage occurred at its C-terminus, similarly to its role in the
processing of PTV1 polypeptide, as we were able to detect the
mup40 subunit fused to P2A in the transient transfection
experiment in HEK-293 cells by western blotting (Figure 1c). The
cellular processing of muIL12opt was apparently successful in all
the tumor cell lines tested: HEK-293, LLC and B16-F10, as
transduced cells produced and released functional heterodimeric
IL12 (p70), measured by enzyme-linked immunosorbent assay
(Figure 4). IL12 bioactivity was further demonstrated in lympho-
cyte proliferation experiments (Figure 5). Thus, our results conﬁrm
that the IL12 polypeptides are processed normally and secreted
from the cell and that the P2A sequence employed does not
interfere with heterodimeric IL12 folding, secretion and activity.
Generally, IL12-based therapies can be divided into three
categories: active non-speciﬁc immunotherapy (aimed at activa-
tion of predominantly innate mechanisms), active speciﬁc
(vaccine) approach (directed mainly to the stimulation of adaptive
antitumor response) and gene therapy. Up to 58 clinical trials
based on IL12 therapy have been started or completed to date.7
Recombinant IL12 has shown relevant antitumor activity both in
experimental models and in humans. However, its clinical use has
been hampered by dose-limiting side effects after systemic
delivery of the recombinant protein. Hence, the rationale for the
new IL12-based gene therapy is that local expression of this
cytokine may result in enhanced antitumor activity and reduced
toxicity. In this regard, a number of local gene therapy approaches
have been undertaken in veterinary clinical oncology.32 By
employing viral and non-viral gene delivery methods local
antitumor effects have been achieved in cats, horses, and dogs.
They demonstrate that IL12-based gene therapy is an effective
approach. Altogether these results support and upgrade the
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Figure 5. Murine IL12 induces murine lymphoblast proliferation and
IFN-γ release. (a, b) Puriﬁed mononuclear cells (5 × 104) from spleens
of C57 mice (n= 4) were stimulated with concanavalin
A (ConA, 4 μgml− 1) for 30 h, and then co-stimulated with murine
IL12-containing supernatants from HEK-293 transfected cells with
either muIL12opt-P2A or muIL12opt. Commercially available
recombinant murine IL12 (muIL12R) was used as a positive control.
Forty-eight hours after muIL12 stimulation, increase in cell number
was determined using the CellTiter-Glo Luminiscent Assay from
Promega. (a) The proliferation ratio between co-stimulated (IL12
+ConA) and ConA only treated mononuclear cells (n= 4). *Po0.05,
**Po0.01, and ***Po0.001 versus lowest IL12 dose employed.
(b) EC50 value determination. GraphPad Prism (version 5.01) was
used for the analysis and for the EC50 value calculation. Samples
were measured in triplicates. Statistical analysis shows
mean± standard error of the mean (n= 4). (c) Puriﬁed mononuclear
cells (5 × 104) from spleens of C57 mice (n= 3) were stimulated
with concanavalin A (ConA, 4 μgml− 1) for 30 h, washed, and
then co-stimulated with murine IL12-containing supernatants as
above. Forty-eight hours later supernatants were collected and the
concentration of IFN-γ measured by enzyme-linked immunosorbent
assay. IFN-γ, interferon gamma; IL12, interleukin 12.
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antitumor IL12 features observed in preclinical experiments
performed in rodents. Most recently initiated IL12-based clinical
trials are focused on local tumor treatment by gene therapy.7
These strategies are trying not only to minimize the IL12-
dependent toxic effects but also to induce speciﬁc antitumor
mechanisms by overcoming the strong immunosuppressive
tumor microenvironment.33 In this regard it is important to
mention that the inﬂammation-regulated promoters ESELp and
NFkBp are still induced in the presence of IL10 (Garaulet et al15
and data not shown), a potent immunosuppressive cytokine
commonly expressed in tumors. Therefore, their transcriptional
regulation will not be hampered by the presence of this
immunosuppressive factor. Clinical trials based on intratumoral
IL12 expression have proven that local production of IL12 inside a
tumor can stimulate tumor inﬁltration by effector immune cells
and that in some cases this is followed by tumor regression.
Therefore IL12 is still considered as an anticancer cytokine and its
importance in cancer immunotherapy keeps growing.
Systemic expression of IL12 has proved to cause signiﬁcant
toxicity and negative side effects.7 Thus, a major challenge in the
treatment of cancer using IL12 is the development of expression
systems restricted to and tightly regulated by the tumor
environment, in order to conﬁne transgene expression only to
the tumor site. We have tested three different lentiviral expression
systems based on different inﬂammation-induced promoters
(ESELp, IL1–IL6p, and NFkBp) in different cell lines, including two
commonly employed in syngeneic mouse tumor models (LLC and
B16-F10). Our results show signiﬁcant differences in terms of
promoter activity, fold induction, and IL12 production among the
different cell lines and promoters (Figure 4). Among them, the IL12
concentration obtained with the ESELp-based system upon
stimulation (480 pgml− 1 in LLC; 160 pgml− 1 in HEK-293) might
be enough to induce IL12-dependent antitumor immunity. This
expression system would fulﬁll the requirements of an
inﬂammation-induced system as it produces very low IL12 in
basal conditions (90 pgml− 1 in LLC, 25 pgml− 1 in HEK-293), thus
preventing toxic side effects in the absence of inﬂammation. In
B16-F10 cells, the basal IL12 production of the NFkBp-based
system was very low (39 pgml− 1) while it was signiﬁcantly
increased after proinﬂammatory stimulation (666 pgml− 1); there-
fore, the NFkB-based system would be the best option for this cell
line. These long-term lentiviral expression systems might be useful
not only to address the impact of IL12 expression in the tumor
environment but also to achieve local IL12 release controlled by
the inﬂammation state of the tumor, hopefully avoiding toxic side
effects associated with systemic IL12 administration.
Recent preclinical studies in solid tumor models have shown
that the level of IL12 expression is essential for tumor clearance
and protection.11 For this, the authors isolated and characterized
IL12-producing tumor cell clones. Once the bioactivity of
muIL12opt-P2A has been conﬁrmed in cell culture-based assays
and the inducibility of the promoters has been tested in vivo, we
will test the bioactivity of the muIL12opt-P2A in mice by
employing IL12-producing clones from transduced LLC and B16-
F10 cells. We will employ them to perform syngenic tumor
experiments, in which LLC or B16-F10 clones transduced with the
selected inﬂammation-inducible lentivector encoding muIL12opt-
P2A will be subcutaneously implanted in mice to examine the
protective role of the induced IL12 expression in tumor growth. It
would be important to address the mechanisms implicated in this
effect and determine which immune cell populations are required
to trigger it. It will also be important to study whether long-term
protection can be established by immune memory, to ﬁnd out
how many IL12-secreting cells are able to protect mice from tumor
development and to determine how much IL12 is needed. These
experiments will constitute a proof-of-concept to study the
antitumoral efﬁcacy of our inducible LV systems after local
intratumoral administration.
Although gene therapy approaches exploiting the antitumoral
activity of IL12 have not yet achieved forecasted clinical success,
they shed some light to design future strategies. The most
relevant concerns to explain the disappointing results in those
trials were the duration and intensity of transgene expression, as
they employed short-term expression vectors expressing IL12
under the control of non-inducible promoters.6,34,35 Therefore,
new vectors with regulated, long-term production of IL12 might
have better results and deserve clinical testing. The LV-based
expression systems here described fulﬁll these two features, long
term and inducible transgene expression; therefore we think it is
worth employing them in preclinical experiments to test their
in vivo efﬁcacy after intratumoral administration. We will address
the therapeutic role of inducible IL12 expression in syngenic
tumor growth by employing the wild-type tumor cell lines, LLC
and B16-F10, followed by in vivo intratumoral injection of the
inﬂammation-regulated lentiviral systems encoding muIL12opt-
P2A. For future clinical applications, our expression systems can be
transferred to vector platforms safe enough for human
applications.
An important characteristic of IL12 is that it synergizes with
several other cytokines.36 The fact that IL12 as a monotherapy
displayed limited clinical efﬁcacy raised the investigation of
combined treatments. A number of combined approaches have
been tested, but only a few showed encouraging results.7
Nevertheless, despite these results, IL12 remains as a recognized
anticancer agent with a great potential for synergistic combina-
tions with other immunotherapies and/or conventional cancer
treatments.37,38
Finally, there is increasing evidence showing the importance of
host responses to viral vectors for successful experimental cancer
therapies. There is evidence of IL12 and IFN interplay in the
control of tumor growth.6,36 In this regard, it has recently been
shown by Melero and co-workers14 that the antitumor efﬁcacy of a
virally expressed murine IL12 was strongly dependent on the
induction of the IFN response. These results suggest the need of
viral vectors mimicking a viral infection to trigger an IFN response
needed to sustain efﬁcient IL12 antitumor activity.
In summary we have produced viral vectors expressing p2A-
dependent stoichiometric amounts of p40 and p35 IL12 subunits
under the control of inﬂammation-dependent promoters. These
vectors meet the criteria of (1) producing equimolar amounts of
IL12 subunits that are secreted as bioactive IL12 and (2) restricting
their expression to inﬂammation sites. In addition, the virus-
mimicking effect of these viral vectors would likely trigger the IFN
response needed for efﬁcient IL12-dependent immunotherapeutic
effects, improving its antitumor properties.
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4.4 Tumor cell transduction with a lentivector expressing a bioactive 
murine IL-12 as a self-processing P2A polypeptide driven by an 
inflammation-regulated promoter severely impairs tumor growth in 
vivo 
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4.4.1 Introduction 
 
The immune system can recognize and eliminate tumor cells, however sometimes the anti-
tumor immune response does not eradicate them and cancer arise. The inability to protect 
against tumors may be due to mechanisms of evasion, active suppression or sub-optimal 
activation of an immune response233. Cancer immunotherapy strategies try to activate or 
redirect the immune response against tumor cells. Cytokines are important players in both 
innate and adaptive immune responses and exert key effects on tumor biology234. In 
particular, cytokines involved in activation of immune effector mechanisms, including type 
I Interferons, GM-CSF, IL-2 and IL-12, are excellent candidates for cancer treatments. 
IL-12 is a heterodimeric protein composed of two subunits, p35 and p40, joined by a 
disulfide bond12. It is a potent mediator of anti-tumor immunity111 as it is a Th1-polarizing 
pro-inflammatory cytokine235 and interferes with angiogenesis236 and metastasis237. As 
systemic administration of IL-12 has anti-tumor activity but it is associated with toxic side 
effects, new IL-12 delivery methods are currently under development. In this regard, gene 
therapy approaches are a promising alternative to local IL-12 administration within the 
tumor environment142. In fact, viral and non-viral vectors have been employed to locally 
express IL-12 into the tumor mass in preclinical trials143-146,231. These gene therapy 
approaches either by themselves or in combination with other anti-tumor strategies have 
shown encouraging results. Viral vectors are immune-appealing tools as their virus-
mimicking effect may trigger an IFN-mediated response; in the case of a Semliki Forest 
virus vector (SFV), the virus-mediated IFN release was absolutely required for an IL-12 
efficient anti-tumoral effect147. Lentiviral vectors (LVs) have been reported to trigger a 
rapid and transient type I IFN response in mice which is dependent on functional vector 
particles238. 
Among the viral vectors, LVs are promising candidates for immunotherapeutic gene 
therapy approaches. LVs have been also extensively studied as anti-cancer vaccines due to 
DC activation through either TLR signaling or protein kinase R (PKR) phosphorylation at 
high MOIs239. In addition, LVs intrinsically induce Th1-polarizing immunogenicity240,241. In 
fact, IL-12-expressing LVs have been employed to transduce tumor cells and these 
transduced cells have been successfully used as autologous tumor vaccines145,242. We have 
cloned a codon optimized and P2A self-processing IL-12 (IL-12P2A) in LVs and transduced 
tumor cells commonly employed in syngeneic tumor models162. IL-12P2A was efficiently 
released by transduced cells and exerted bioactive effects on splenocytes ex vivo (i.e. cell 
proliferation and IFN-γ release). 
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Among other features tumor environment is characterized by inflammation. An 
appropriate system to control transgene expression in this pathological scenario would be 
an inflammation-regulated system: cytokine would be secreted upon inflammation, 
avoiding it constant release and minimizing side effect risk. We have developed several 
inflammation-regulated LV systems which are efficiently upregulated by acute 
inflammation in vivo160. In addition, we have found that they are also upregulated when 
transduced tumor cells are ectopically implanted in mice162. Therefore, we decided to 
clone IL-12P2A under these inflammation-inducible systems and test their putative 
immunotherapeutic effect in vivo. For this, we transduced Lewis Lung Carcinoma (LLC) 
cells with inducible LV systems and characterized isolated clones (proliferation and IL-
12P2A release). The in vitro selected clones were further ectopically implanted in mice to 
monitor tumor growth, mice survival and T lymphocyte activation. Our results show that 
mice implanted with tumor cells transduced with IL-12P2A expressing LVs under the 
NFκB inducible promoter (NFκBp) have a very high survival rate. The percentage of 
survival was even higher than that observed when IL-12P2A was under the control of a 
constitutively strong promoter (SFFVp). Importantly, NFκBp-dependent IL-12P2A 
expression caused a 60% of tumor regression. In both cases, the survival improvement 
correlated with a significant CD8+ T cell activation after implantation of tumor cells 
expressing IL-12P2A under either SFFVp or NFκBp. These results demonstrate that LLC 
cells transduced with the NFκBp-IL12P2A LV expression system severely impairs in vivo 
tumor growth and their implantation significantly activates CD8+ T lymphocytes. This 
system might be useful for direct LV administration into tumor cells as well as for in vivo 
anti-tumor vaccination. 
My personal contribution to this work consisted in performing the ectopic syngeneic 
mouse model and the subsequent analyses. 
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Abstract 
Interleukin 12 (IL-12) is a key cytokine for the initiation of Th1-dependent immune response and a promising 
anti-cancer agent. However, systemic IL-12 administration is hampered by undesired side-effects. New 
approaches are currently explored to reduce or minimize these adversities. We have previously shown that 
our inflammation-regulated lentiviral expression systems are induced in a solid tumor environment. In addition 
we have shown that a self-processing P2A murine IL-12 (IL-12P2A) efficiently stimulates murine lymphoblast 
proliferation and IFN-γ release ex vivo. In this work we tested the efficacy of these expression systems in a 
solid tumor model. For this we transduced Lewis Lung Carcinoma (LLC) cells, we isolated clones and 
characterized their proliferation and IL-12P2A release. We further subcutaneously injected selected clones 
into wild type C57/BL6 mice and analyzed the tumor cells growth and mice survival. Our results show that 
implantation of IL-12P2A-expressing cells reduced tumor growth. Notably cells transduced with the system 
that expresses IL-12P2A under the control of the inflammation-regulated system barely grew after 
implantation. In fact, up to 60% of tumor regression was observed, increasing significantly the survival rate of 
these animals. T-cell analysis showed that implantation of IL-12-producing cells activated CD8
+
 cells. 
Altogether, these results demonstrate that inducible IL-12P2A release under this inflammation-regulated 
promoter is able to activate CTLs and impair tumor growth; as a result, the overall survival is significantly 
increased. Therefore, this inflammation-regulated expression system might be useful for the development of 
new IL-12 delivery systems with less toxicity and more secure for clinical applications. 
 
 
Introduction 
 
The immune system can recognize and eliminate 
tumor cells, however sometimes the anti-tumor 
immune response does not eradicate them and cancer 
arise. The inability to protect against tumors may be 
due to mechanisms of evasion, active suppression or 
sub-optimal activation of an immune response1. 
Cancer immunotherapy strategies try to activate or 
redirect the immune response against tumor cells. 
Cytokines are important players in both innate and 
adaptive immune responses and exert key effects on 
tumor biology2. In particular, cytokines involved in 
activation of immune effector mechanisms, including 
type I Interferons, GM-CSF, IL-2 and IL-12, are 
excellent candidates for cancer treatments. 
IL-12 is a heterodimeric protein composed of two 
subunits, p35 and p40, joined by a disulfide bond3. It 
is a potent mediator of anti-tumor immunity4 as it is a 
Th1-polarizing pro-inflammatory cytokine5 and 
interferes with angiogenesis6 and metastasis7. As 
systemic administration of IL-12 has anti-tumor 
activity but it is associated with toxic side effects, new 
IL-12 delivery methods are currently under 
development. In this regard, gene therapy approaches 
are a promising alternative to local IL-12 
administration within the tumor environment8. In 
fact, viral and non-viral vectors have been employed 
to locally express IL-12 into the tumor mass in 
preclinical trials9-13. These gene therapy approaches 
either by themselves or in combination with other 
anti-tumor strategies have shown encouraging 
results. Viral vectors are immune-appealing tools as 
their virus-mimicking effect may trigger an IFN-
mediated response; in the case of a Semliki Forest 
virus vector (SFV), the virus-mediated IFN release 
was absolutely required for an IL-12 efficient anti-
tumoral effect14. Lentiviral vectors (LVs) have been 
reported to trigger a rapid and transient type I IFN 
response in mice which is dependent on functional 
vector particles15. 
Among the viral vectors, LVs are promising candidates 
for immunotherapeutic gene therapy approaches. LVs 
have been also extensively studied as anti-cancer 
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vaccines due to DC activation through either TLR 
signaling or protein kinase R (PKR) phosphorylation 
at high MOIs16. In addition LVs intrinsically induce 
Th1-polarizing immunogenicity17,18. In fact, IL-12-
expressing LVs have been employed to transduce 
tumor cells and these transduced cells have been 
successfully used as autologous tumor vaccines11,19. 
We have cloned a codon optimized and P2A self-
processing IL-12 (IL-12P2A) in LVs and transduced 
tumor cells commonly employed in syngeneic tumor 
models20. IL-12P2A was efficiently released by 
transduced cells and exerted bioactive effects on 
splenocytes ex vivo (i.e. cell proliferation and IFN-γ 
release). 
Among other features tumor environment is 
characterized by inflammation. An appropriate 
system to control the transgene expression in this 
pathological scenario would be an inflammation-
regulated system: cytokine would be secreted upon 
inflammation, avoiding it constant release and 
minimizing side effect risk. We have developed 
several inflammation-regulated LV systems which are 
efficiently upregulated by acute inflammation in 
vivo21. In addition, we have found that they are also 
upregulated when transduced tumor cells are 
ectopically implanted in mice20. Therefore, we decided 
to clone IL-12P2A under these inflammation-inducible 
systems and test their putative immunotherapeutic 
effect in vivo. For this, we transduced Lewis Lung 
Carcinoma (LLC) cells with inducible LV systems and 
characterized isolated clones (proliferation and IL-
12P2A release). The in vitro selected clones were 
further ectopically implanted in mice to monitor 
tumor growth, mice survival and T lymphocyte 
activation. Our results show that mice implanted with 
tumor cells transduced with IL-12P2A expressing LVs 
under the NFκB inducible promoter (NFκBp) have a 
very high survival rate. The percentage of survival 
was even higher than that observed when IL-12P2A 
was under the control of a constitutively strong 
promoter (SFFVp). Importantly NFκBp-dependent IL-
12P2A expression caused a 60% of tumor regression. 
In both cases, the survival improvement correlated 
with a significant CD8+ T cell activation after 
implantation of tumor cells expressing IL-12P2A 
under either SFFVp or NFκBp. These results 
demonstrate that LLC cells transduced with the 
NFκBp-IL12P2A LV expression system severely 
impairs in vivo tumor growth and their implantation 
significantly activates CD8+ T lymphocytes. This 
system might be useful for direct LV administration 
into tumor cells as well as for in vivo anti-tumor 
vaccination. 
 
Materials and Methods 
 
Cell culture 
Human Embryonic Kidney (HEK-293; ATCC #CRL-
1573) and murine Lewis Lung Carcinoma (LLC; ATCC 
#CRL-1642) cell lines were grown in Dulbecco´s 
modified Eagle´s medium supplemented with 10% 
fetal bovine serum (FBS; Sigma-Aldrich) and L-
glutamine (2 mM) plus antibiotics (100 U/ml 
penicillin and 100 µg/ml streptomycin).  
 
Second generation lentivector production and 
titration 
HEK-293 cells were transiently transfected by the 
calcium phosphate method 22. For viral particle 
production, the corresponding pHRSIN HIV 1-derived 
transfer vector was co-transfected with two helper 
plasmids, the 8.91 packaging vector 23 and pMD2-G 
(VSV-G containing plasmid; Addgene). Supernatants 
were collected 48 hours after transient transfection 
and cell debris was removed by centrifugation (10 
minutes, 740 x g, 4ºC). Viral particles were 
concentrated by ultracentrifugation in a swing bucket 
rotor for 2 hours at 121,986 x g at 4ºC (Ultraclear 
Tubes, SW28 rotor and L8-70 Ultracentrifuge; 
Beckman Coulter). After supernatant removal, viral 
particles were resuspended in phosphate-buffered 
(PBS) and stored at -70ºC. Total viral content was 
determined by quantitative PCR 24. 
 
Cell cloning and inducibility test assay 
LLC cells were transduced with the different lentiviral 
particles at the multiplicity of infection (MOI) of 100. 
After checking the transgene expression by western-
blotting and/or ELISA, transduced cells were seeded 
onto Terasaki plates at a density of 0.3 cells per well25. 
Wells containing a single cell were identified by visual 
inspection under a light microscope. Isolated clones 
were expanded and tested for either luciferase 
(luciferase activity) or IL-12 expression (Western-
blotting and ELISA). For ELISA assays, LLC clones 
(1.7x104 cells in 0.25ml) were seeded onto 24-wells at 
80% confluency, incubated for 2h in low-serum 
containing media (0.5% FBS) and then stimulated for 
6h with LPS (200ng/ml). For IL-12 analysis, 
supernatant was collected and IL-12 content measure 
by ELISA (Thermo Scientific). For IL-12 western-
blotting, a protein transport inhibitor (BD 
GolgiPlugTM, Biosciences) was added during LPS 
stimulation.  
Proliferation of the selected transduced LLC clones 
was analyzed by employing the cell proliferation 
reagent WST-1 (Roche) following manufacturer’s 
recommendations. Cell viability was monitored by 
periodically cell counting and trypan blue staining. 
Luciferase assay, Western Blotting and ELISA 
To determine luciferase activity Luc-expressing clones 
were collected after stimulation, washed with PBS and 
lysed with Reporter Lysis Buffer (RLB Promega). 
Supernatants were saved and employed to measure 
luciferase activity in a 20/20N luminometer (Turner 
BioSystems) and for protein quantification (Bradford; 
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Bio-Rad). Reporter gene expression is shown as 
relative light units (RLU) per microgram of protein. 
To determine IL-12 expression stimulated clones 
were harvested and lysed with Laemmli Buffer for 
Western Blot analysis. In brief, protein samples were 
separated on 12% polyacrylamide gels under 
reducing conditions and transferred to nitrocellulose 
membranes (Whatman). After blocking the 
membranes with 5% w/v skimmed milk in TBS-T 
(0.05% Tween-Tris Buffered Saline) for 1 hour at 
room temperature, the blots were incubated 
overnight at 4ºC with first antibody solution: rabbit 
polyclonal anti-2A peptide (0.05%, v/v; Millipore) or 
mouse monoclonal anti-α-tubulin (0.1%, v/v; Sigma-
Aldrich) in TBS-T with 5% skimmed milk. After 
several washes with TBS-T, blots were incubated with 
peroxidase-labeled goat anti-rabbit or anti-mouse IgG 
(0.02%, v/v; Pierce) in TBS-T with 5% skimmed milk 
for 1 hour at room temperature. The blots were then 
washed again with TBS-T and membrane-bound 
antibody was detected with ECL (enhanced 
chemiluminescence) detection reagent (GE 
Healthcare). 
To measure IL-12 release by transduced cell clones, 
cell culture supernatants were collected for detection 
by employing mouse IL12 ELISA Kit (Thermo 
Scientific; cat. #EMIL 122). Samples were measured in 
a microplate spectrophotometer (xMark; Bio-Rad) 
following manufacturer’s recommendations. 
Animals 
Six-week-old male C57/BL6 mice (Charles River, 
Burlington, MA) were fed lab chow and kept on a 12 
hours light/dark cycle. The animals were cared for 
according to the CNIO Animal Facility guidelines for 
the care and use of laboratory animals. 
In vivo tumor model 
Transduced LLC clones were grown in culture media, 
collected by centrifugation and washed with PBS. LLC 
cells (7.5x105 cells per animal) were resuspended in 
150 µl of PBS, embedded in matrigel (BD) and 
implanted subcutaneously into the right flank of the 
mouse. Tumor growth was monitored and tumor 
volume calculated (V= 4/3 πr3). Bioluminescence 
images were captured with an IVIS 200 in vivo 
imaging system (Caliper). For this, mice were i.p. 
injected with firefly luciferin (150 mg/kg; Promega), 
and anesthetized with isoflurane during the 
procedure. Living Imaging 3.0 software (Caliper) was 
employed for imaging analysis. 
Mononuclear spleen-derived population analyses 
Spleens from euthanized animal were mechanically 
disaggregated and mononuclear cells isolated by 
gradient centrifugation (Lympholyte-M, Cedarlane 
Laboratories, Burlington, NC). Analyses of the 
different populations were performed by incubating 
with the indicated specific antibodies conjugated with 
fluorophores (BD Biosciences, San Jose, CA):  CD4 
FITC/APC, CD8 FITC/PE, CD25 FITC/PE and CD69 
FIT/PE. Briefly, mononuclear cells (0.5-1 x 106) were 
incubated with γ-globuline (50 µg/ml) for 10 minutes 
at 4ºC, washed and then incubated with the 
corresponding specific antibody for 40 minutes at 4ºC. 
After several washes with PBS cells were analyzed by 
flow cytometry (BD FACSCanto II) employing the BD 
FACSDiva software (BD Biosciences). 
Statistical analysis 
Prism 5 for Windows (GraphPad Software Inc.; 
version 5.03) was employed for statistical analysis. 
Data shown were analyzed by t-test (unpaired, two-
tailed test) compared to control or untreated samples. 
Statistical significance was assigned at P<0.05. SD, 
standard deviation; SEM, standard error of the mean. 
Results 
Isolation and characterization of Luciferase- and 
IL-12P2A-producing LLC clones 
We have shown that transgene expression under our 
inflammation-regulated lentivector systems are 
induced in vitro and in vivo. In particular, we have 
recently demonstrated that luciferase activity of LLC 
cells transduced with the NFκB-based promoter 
(NFκBp) increased upon implantation in mice20. After 
these results, we decided to further test our 
expression systems in vivo. For this we isolated and 
characterized luciferase and IL-12P2A-expressing LLC 
clones in order to achieve a better understanding of 
the different promoter upregulation and transgene 
expression in these tumor cells. As shown in Figure 
1A, both inflammation-regulated promoters, ESELp 
and NFκBp, were upregulated (fold induction: 7.8 and 
10.4, respectively) after LPS treatment of the selected 
clones. We found that proliferation of these clones 
was not affected by transduction and luciferase 
activity, as their growth curves overlap with the one 
from non-transduced LLC cells (Figure 1B). We next 
focused on the isolation of IL-12P2A expressing 
clones. Our results have shown that NFκBp displayed 
the highest inducibility and the levels of IL-12P2A 
released upon upregulation of this promoter were 
similar to those observed when a strong viral 
promoter was employed (SFFVp)20. Therefore, we 
decided to isolate LLC clones expressing IL-12P2A 
under the control of either NFκBp or SFFVp. After 
cloning, we selected the clones based on the IL-12 
expression by western-blotting (Figure 1C). We then 
confirmed that IL-12P2A was efficiently released by 
measuring its content in the culture supernatants 
(Figure 1D). Selected clones showed constitutive and 
LPS-induced expression of IL-12P2A under the control 
of SFFVp and NFκBp, respectively. Next we 
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analyzed the proliferation and viability of these clones 
in comparison to wild type LLC cells. In terms of cell 
viability, we found no differences among clones and 
wild type cells (Table I). When the proliferation was 
analyzed through indirect metabolic activity 
quantification, growth curves overlapped, except for 
the SFFVp-IL12P2A clone (Figure 1 E,F); this clone 
displayed a slight growth rate decrease, suggesting 
that constitutive IL-12P2A expression might affect to 
this clone proliferation without affecting to its 
viability. 
 
Figure 1 
Characterization of luciferase- and IL-12P2A-expressing clones. (A,B) Isolated luciferase-expressing clones were tested for 
promoter inducibility and cell proliferation. (A) After serum deprivation, clones were incubated with LPS for 6 hours and 
luciferase activity was measured. Plot shows fold induction upon treatment. (B) Cell proliferation assays were performed 
through indirect metabolic activity quantification by incubation with WST-1 reagent followed by measure at 440 nm. Plot 
shows growth curves of the indicated clones. Non-transduced LLC were employed as a control. (C) IL-12P2A expressing clones 
were isolated, grown and, after serum deprivation, incubated with LPS for 6 hours in the presence of Brefeldin A (protein 
transport inhibitor). Cell extracts were analyzed by western blotting using either anti-P2A (top) or anti-α-tubulin (bottom) 
antibodies. (D) Supernatants from the IL-12P2A-expressing clones were collected and the IL-12 content measured by ELISA.  
(E and F) Cell proliferation assays were performed as in B. Plots show growth curves of the SFFVp (left) and NFκBp (right) 
containing clones. WST-1, water-soluble tetrazolium salt-1; ESELp, E-selectin promoter; NFκBp, 6xNFκBp sites; SFFVp, spleen 
focus-forming virus promoter; LPS, lipopolysaccharide. Plots show mean ± standard deviation.  ***P< 0.001. 
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Table I 
Clones viability percentage determination at 72h 
Clone Viability  
(% ± SD) 
Control 93.50 ± 1.68 
SFFVp-Luc 98.64 ± 0.59 
NFκBp-Luc 98.51 ± 0.70 
SFFVp-IL12P2A 97.28 ± 2.10 
NFκBp-IL12P2A 96.74 ± 0.66 
SD= standard deviation 
Local IL-12P2A release by the inflammation-
regulated expression system reduces tumor 
burden, increases mice survival and activates 
CD8+ T cells 
LLC clones isolated and characterized were employed 
for in vivo experiments. These cells were ectopically 
implanted into syngeneic mice (C57/BL6; n=5). 
Luciferase activity and tumor burden were monitored 
periodically. Bioluminiscence analysis confirmed the 
transcriptional activity of these promoters after in 
vivo implantation (Figure 2A); as NFκBp and ESELp 
are inflammation-regulated promoters, the results 
reveal that tumor environment is pro-inflammatory 
soon after implantation in this mouse model. To 
assess the anti-tumor activity of IL-12P2A, tumor 
sizes were monitored and the percentage of survival 
calculated (Figure 2 B,C). Animals were implanted 
with IL-12 expressing clones under the control of 
either SFFVp or NFκBp. As a control, a clone 
expressing luciferase under each promoter was also 
employed. Results clearly show that IL-12P2A 
expression by each promoter significantly reduced 
tumor sizes and increased the percentage of survival. 
Notably 3 out of 5 animals bearing NFκBp-IL-12P2A 
cells showed complete or partial tumor regression 
and stabilization, surviving for at least 60 days, when 
they were euthanized. This observation is very 
important as neither complete nor partial regression 
was detected when SFFVp-IL-12P2A cells were 
implanted. Finally, we studied the activation state of T 
lymphocytes isolated from spleens of euthanized mice 
(Figure 2D). Flow cytometry analysis showed that 
implantation of IL-12P2A expressing cells activates 
both CD4+ and CD8+ T cell populations, suggesting an 
acquired immune system activation due to IL-12 
expression. In the case of NFκBp, only the activation of 
CD8+ T cells was statistically significant. 
 
Discussion 
Recombinant IL-12 has shown relevant anti-tumor 
activity both in experimental models and in humans. 
However, its clinical use has been hampered by dose-
limiting side effects after systemic delivery of the 
recombinant protein. An interesting alternative to 
conventional drug treatments can be gene therapy 
approaches. In this regard, a number of local gene 
therapy approaches have been undertaken in 
veterinary clinical oncology 26 demonstrating that IL-
12 based gene therapy is an effective approach. Most 
recently initiated IL-12-based clinical trials are 
focused on local tumor treatment by gene therapy 27. 
Clinical trials based on intratumoral IL-12 expression 
have proven that local production of IL-12 inside a 
tumor can stimulate infiltration by effector immune 
cells and that in some cases this is followed by tumor 
regression. Our lentivector-based inflammation-
regulated expression systems would allow local 
expression of IL-12 controlled by the inflammatory 
state of the tumor microenvironment that might 
result in an enhanced anti-tumor activity with 
reduced toxicity.  
Our in vivo results show that the transcriptional 
activity of ESELp and NFκBp is regulated during 
tumor growth. Interestingly, ESELp-driven expression 
increased at day 8 post-implantation, reached the 
highest level at day 11-13 and then dropped 
gradually. In the case of NFκBp-driven expression, it is 
characterized by high transgene expression levels 
(100 times higher than ESELp-driven expression) and 
did not show a common activation pattern after 
implantation.  As NFκB pathway participates in both 
initiation and resolution of inflammation28, its 
complex regulation during tumor growth might 
account for the different expression patterns 
observed. 
Regarding IL-12P2A, its expression under the 
promoters tested reduces tumor growth causing 
improved survival rates. It is important to mention 
that the endpoint criterion for these experiments was 
the appearance of ulcers within the tumoral mass, and 
none of them suffered spontaneous death. 
Importantly, IL-12P2A expression under NFκBp 
showed a strong anti-tumoral effect, causing 1 partial 
and 2 complete tumor regressions. The NFκB pathway 
has a promoting role in most cancers 29 and here we 
show that it is possible to employ an NFκB-based 
promoter to drive transgene expression within tumor 
microenvironment. In particular, our experiments 
clearly show that NFκBp upregulation releases 
therapeutic levels of IL-12P2A. This expression 
system could be employed to control the local 
secretion of other immunotherapeutic agents with 
anti-tumor activity. In addition, it could be transfer to 
other vector platforms to be employed in 
inflammation-related diseases. 
The anti-tumor effects of IL-12 can be mediated by 
CD4+ and CD8+ T cells, depending on the tumor type 
and more importantly the delivery system 
employed11,19,30,31. In the case of implantation of IL-12-
secreting cells, both T-cell populations are required to 
eliminate tumor cells11. To determine whether T-cell 
activation was taking place after implantation of IL-
12P2A expressing cells, splenocytes from tumor- 
bearing mice were analyzed by flow cytometry.
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Figure 2 
Implantation of IL-12P2A expressing cells in mice causes smaller tumors, longer survival and CD8+ T cells activation. 
(A) One LLC clone expressing luciferase under the control of either the constitutive viral promoter SFFVp (left) or the 
inflammation-inducible promoters ESELp (middle) and NFκBp (right) were implanted ectopically in C57/BL6 mice (n=5 per 
group). Bioluminiscence was monitored three times per week and is represented as luciferase activity relative to tumor 
volume (Total flux/cm3). (B-D) IL-12P2A (blue) and Luciferase-expressing clones (black) under the control of either SFFVp (B) 
or NFκBp (C) were individually and ectopically implanted in C57/BL6 mice (n=5 per group). Tumor diameters were measured 
and total tumor volumes (left, one line per animal) and survival rates (right) were calculated. (D) Splenocytes from the 
indicated implanted mice were isolated and the activation state of CD4+ and CD8+ T cell populations analyzed by flow 
cytometry. Splenocytes from animals implanted with luciferase-expressing cells were employed as controls. ESELp, E-selectin 
promoter; NFκBp, 6xNFκBp sites; SFFVp, spleen focus-forming virus promoter. *P < 0.05, **P< 0.01, and ***P< 0.001. Standard 
error of the mean is represented. 
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We found that CD8+ T cell activation was statistically 
significant when IL-12P2A was expressed under 
either SFFVp or NFκBp. In the case of CD4+ T cell 
activation, the results were statistically significant 
only when IL-12P2A was constitutively expressed 
(SFFVp). As the NFκBp-IL-12P2A group showed the 
highest survival rate, and in these animals only CD8+ T 
cell population was significantly activated, these 
results highlight the crucial role of activated CD8+ T 
cells for the IL-12-dependent anti-tumor effect in this 
solid tumor model. Previous results have also shown 
that CD8+ T cells were the primary effectors in IL-12-
mediated anti-tumor immunity32,33. Further analysis 
of samples collected from these experiments (blood, 
spleen and tumor) as well as future experiments will 
allow us to confirm these observations. 
Once we have demonstrated the bioactivity of the 
muIL12opt-P2A in mice by employing IL-12P2A-
producing clones, our efforts will be directed to 
isolate, characterize and test in vivo an ESELp IL-12-
expressing cell clone. As we have showed, this 
promoter which is regulated by tumor-inflammation 
signals, produces the lowest levels of transgene 
expression, so potentially would be the best indicated 
to avoid side-effects. However is important to analyze 
whether these levels of IL-12 expression would be 
sufficient to produce anti-tumor effect. It will also be 
important to study whether long-term protection can 
be established by immune memory. 
Published results have shown that delivery of IL-12 by 
cancer cells is an effective route for immune activation 
both in leukemia and in solid tumor mouse models 
11,19. We have shown that subcutaneous implantation 
of IL-12P2A-expressing LLC clones results in tumor 
growth impairment, being the inflammation-regulated 
system the most efficient one. These experiments 
have proven that our inflammation-regulated system 
is efficiently expressed in LLC solid tumors. Therefore, 
we will further test the anti-tumoral efficacy of our 
inflammation-regulated LV systems by local 
intratumoral administration in different solid tumor 
models. These inducible promoters might represent 
excellent systems for the inflammation-regulated 
expression of different anti-tumor agents. For future 
clinical applications, our expression systems can be 
transferred to vector platforms safe enough for 
human applications. 
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5.1 Summary 
 
The inflammatory response is precisely controlled by the expression of cytokines whose 
local levels are directly related to the severity of the process. A major challenge in the 
treatment of chronic inflammatory diseases is the development of an expression system 
that is tightly regulated by the variable levels of these cytokines. We have described a long 
term lentiviral expression system based on the E-selectin promoter, which is locally 
induced by inflammatory stimuli in direct correlation with the intensity and duration of 
the inflammatory response. We have also generated lentivectors incorporating other 
previously described inflammation-inducible promoters, such as a hybrid human IL-6 
promoter joined to the enhancer region of the human IL-1 promoter (IL1-IL6p) and a 
chimeric promoter based on NFκB-binding sites (NFκBp); the latter is potently stimulated, 
reaching expression levels similar or even superior to those obtained with a constitutive 
strong viral promoter such as SFFVp. These promoters have been useful for monitoring 
and understanding the inflammatory course of locally zymosan-induced inflammation, the 
altered inflammatory response of glia in ALS model derived from OM and the 
inflammatory context after LLC cells implantation in mice. The different expression 
patterns developed by these promoters have allowed us to investigate the effect of 
inflammation-induced cytokine expression. The results indicate their potential for chronic 
inflammatory diseases gene therapy treatments, as they are regulated by the severity of 
the process and for cancer gene therapy treatments, where the tumor inflammatory 
microenvironment drives the expression of the therapeutic molecule. 
 
5.2 Inflammation-regulated lentiviral system for chronic inflammatory 
diseases 
 
Studies in animal models have shown that gene therapy is an alternative for the local 
treatment of chronic inflammatory diseases. One of the critical factors in gene transfer is 
the type of vector employed. Non-viral vectors commonly yield low gene transfer 
efficiency243,244. Among the viral vectors, adenoviruses are the most widely used, but they 
are poor candidates for the treatment of chronic inflammatory diseases because of the 
immune response associated with their application and the rapid loss of transgene 
expression due to lack of persistence of the viral genomes132,245. Adeno-associated viruses 
(AAV) have emerged as a very promising alternative, since although AAV vectors have 
limited cargo capacity, they stably transduce host cells and show low immunogenicity. 
However, recent studies have reported an inflammatory response after AAV application133-
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135. In addition, technical restrictions limit the scalability of AAV vectors, making it difficult 
to produce adequate viral titers246-248. As an alternative, lentivirus-derived expression 
systems have been employed in animal models of neuroinflammation139. LVs not only 
infect dividing and quiescent cells, but they also provide long term expression and show 
low immunogenicity. In addition, the biosafety profile of lentiviral vectors has been 
improved significantly by minimizing the regions of homology between vector and helper 
sequences (split configuration), and by using heterologous promoters249. Furthermore, the 
use of vesicular stomatitis virus glycoprotein (VSV-G) confers efficient transduction in a 
wide range of cell types from many species, and allows high titers of the lentiviral particles 
for clinical applications250,251. Our study suggests that LVs may also be a valuable 
alternative in the treatment of chronic inflammatory diseases. 
Several inflammation-inducible systems have been described recently, all of which are 
based on chimeric promoters. The precise in vivo regulation of these tailored promoters is 
still unknown. Our expression system is based on the proximal promoter region that 
controls the expression of the E-selectin gene. This gene is particularly attractive as it is 
induced early and transiently upon inflammation and its promoter region contains the 
binding sites for transcription factors activated by the early-induced pro-inflammatory 
cytokines TNF-α and IL-1. Compared to other described expression systems, the ESELp-
based system shows the highest transcriptional activity in endothelial cells. In addition, 
our expression system is highly stimulated in endothelial cells by the early-induced pro-
inflammatory cytokines TNF-α and IL-1. These results are important as activated 
endothelium plays an important role in inflammation initiation. We tested our expression 
system in an experimental model of chronic inflammation by administering repeated local 
injections of zymosan. ESELp-driven transgene expression is rapidly induced after 
zymosan administration, coinciding with the peak of inflammation 7 days after the first 
treatment, and is maintained until inflammation recedes. Compared to other 
inflammation-inducible systems, the ESELp-based is characterized by a low basal activity 
that after zymosan administration increased to levels similar to those observed with a 
strong viral promoter. The other expression systems analyzed showed either higher basal 
activity (NFκB-based system) or very low inducibility after inflammation (IL1-IL6p-based 
system). Our results show that ESELp-dependent transgene expression increases several 
fold, correlating with the severity of inflammation in the animal system tested.  
Since chronic inflammatory diseases are characterized by flare-ups and remission phases, 
it was important to test whether the promoter was silenced in vivo and whether transgene 
expression could be re-induced after a second zymosan boost. Transgene expression again 
correlated with inflammatory status after a second zymosan boost, showing no evidence 
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of promoter silencing. We therefore consider the ESELp a valuable tool for the 
development of gene expression systems for the treatment of chronic inflammatory 
diseases. The use of ESELp-based gene delivery systems to selectively express anti-
inflammatory agents in arthritis-affected joints might eliminate some of the problems of 
tolerability and compliance associated with systemic drug therapies. 
One important issue in locally applied gene therapy is to study the putative migration of 
transduced cells in vivo. In this regard, it has been demonstrated that LV injection into the 
mouse footpad transduces DCs which are able to migrate to the draining lymph nodes and 
spleen252. However, we only detected residual luciferase activity in the popliteal lymph 
nodes draining the infected paw, suggesting that transduced DCs remain in the local 
inflammatory focus160 (Garaulet G et al. Figure 3 f,g). This is in agreement with previously 
published results showing that IL-10 transgene expression modulates DC 
maturation253,254. The authors observed that DCs transduced with adenoviral vectors 
expressing IL-10 maintained an immature state characterized by low MHC class II, CD86, 
and IL-12 expression. The immaturity might affect to their migratory ability which would 
support our in vivo results. Further experiments should be performed to further 
characterize the impact of IL-10 expression on DC migration in vivo. 
The occurrence of unpredictable relapses complicates the treatment of chronic 
inflammatory diseases. Rheumatoid arthritis, the most frequent inflammatory rheumatic 
disorder, is a paradigm of chronic inflammatory diseases characterized by an imbalance of 
pro- and anti-inflammatory molecules. Although systemic administration of anti-
inflammatory agents is beneficial to patients with chronic RA, these treatments are limited 
by loss of efficiency and relapse after treatment cessation. There are also significant side 
effects associated with a prolonged systemic imbalance of the natural inflammatory 
response255,256. Viral vectors are promising candidates for gene therapy for local treatment 
of RA, and several clinical trials are underway257. However, there is still a need to develop 
new therapeutic approaches that provide prolonged remission from disease with limited 
side effects by targeting anti-inflammatory mediators to the diseased joints. The use of 
disease-regulated promoters to drive transgene expression might provide therapeutic 
levels of the anti-inflammatory agent exclusively during flare ups. In addition, 
administration of virus directly into arthritic joints should avoid the side effects associated 
with systemic administration and increase the site-specific effects of the therapeutic agent. 
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5.3 Therapeutic effect of murine IL-10 released by inflammation-inducible 
system 
 
It has been shown that local administration of recombinant IL-10 effectively reduces pro-
inflammatory cytokine activity in several animal models of human diseases; however, 
constant high levels of anti-inflammatory molecules might increase the risk of infection, 
therefore prolonged administration of IL-10 is limited by associated side effects. Our study 
demonstrates that activation of the LV-ESELp lentiviral expression system is regulated by 
the local level of inflammation. Moreover, the LV-ESELp system drives inflammation-
regulated IL-10 expression at levels sufficient to reduce acute inflammation induced by 
zymosan with no effect in the IL-10 serum levels. Although the LV-ESELp system releases 
considerably lower local concentrations of IL-10 than the constitutive expression vector 
LV-SFFVp, it is noteworthy that regulated IL-10 expression is as effective as constant 
expression in reducing inflammation in vivo. Furthermore, the inducible system is 
switched off during remission of the inflammation, thus avoiding the risks associated with 
a sustained release of IL-10. Altogether, these results suggest that local administration of 
LV-ESELp-IL10 should not increase animal susceptibility to opportunistic infections. As 
expected, the levels of inflammation and transgene induction are lower after the second 
bout than observed at disease onset. This endogenously-regulated system for the local 
expression of anti-inflammatory molecules provides a potential new approach for the local 
treatment of chronic inflammatory diseases. 
 
5.4 Inflammatory response in ALS cell model 
 
Besides the classical chronic inflammatory diseases, many data support the implication of 
neuroinflammation in neurodegenerative pathologies. Multiple lines of evidence have 
shown the immune system, including astrocytes and microglia, to be deleterious for motor 
neurons in ALS. Reactive astrocytes and microglia may release pro-inflammatory factors 
such as cytokines and chemokines which are harmful for the neighbouring cells258. 
However, their role as the primary cause of the disease remains undetermined. Our data 
indicate that there is no increased innate immune response of glia in ALS: using the 
established model of SOD1 overexpression in human astrocytes we did not observe 
increased pro-inflammatory response after LPS treatment; this result is similar when OM 
cells from healthy donors and those from ALS patients are compared. However, co-culture 
with motor neurons increases glial sensitivity to pro-inflammatory stimuli in ALS: we 
observed augmented NFκB-dependent reporter activity both in the SOD1-overexpressing 
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astrocyte model as well as in OM cells from ALS patients. Consistent with this, NF-κB 
activation has previously been observed in spinal cord astrocytes in ALS patients as well 
as in TDP-43 animal models where it was also demonstrated that the inhibition of NF-κB 
with Withaferin A reduced denervation in neuromuscular junctions259,260. These results 
indicate that alterations in the innate immune response of glia in ALS might be a 
consequence of their interaction with damaged neurons rather than the cause of initial 
neuronal damage. Nevertheless, once sensitized, the modified pro-inflammatory response 
of glia in ALS could further worsen the state of neighboring neurons. In agreement with 
this concept, previous work using a SOD1 transgenic mouse model demonstrated that 
microglia and T cells initially slow disease progression; but at later stages after 
accumulation of SOD1 protein, it contributes to acceleration of the disease261. Moreover, it 
has been shown in both ALS patients as well as in mouse models that activation of 
microglia and astrocytes takes place only after distal axon degeneration262. 
Thus, our inflammation-inducible LVs have been important to determine the activation of 
inflammatory responses in patient-derived OM when were co-cultured with human spinal 
cord neurons. This strategy reproduces, among others, this feature of the non-neuronal 
contribution to ALS and therefore shows the potential of OM cells as new cell model for 
ALS. 
 
5.5 Efficient expression of bioactive murine IL-12 as a self-processing P2A 
polypeptide 
 
The production of IL-12 requires the coordinated expression of p35 and p40 subunits to 
form the functional heterodimeric interleukin. The biosynthesis of IL-12 depends on the 
interaction of its p35 and p40 subunits, not only to form the functional heterodimer but 
also because these two subunits regulate each other. For example, it has been reported 
that the p40 subunit stabilizes p35 and promotes its secretion263. In the present work, we 
have used an expression-optimized IL-12 plasmid (muIL12opt) described by Dr. Felber 
and coworkers263, which encodes significantly higher levels of bioactive IL-12 compared to 
the wild-type IL-12 sequences. We have generated a P2A-based IL-12 construct encoding 
both IL-12 subunits in a single coding sequence in order to achieve concomitant, 
stoichiometric production of both IL-12 subunits and high levels of bioactive interleukin. 
The 2A peptide was first discovered in the foot-and-mouth disease virus (FMDV), which 
encodes a single ORF in which two of the gene products are separated by the short 2A 
sequence, F2A (19 aa) 264; it is now known that other picornaviruses also have a 2A 
peptide, such as the porcine teschovirus-1 (PTV1), whose 2A peptide (P2A) has been used 
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in this work. During its translation, P2A interacts with the exit tunnel of the ribosome to 
induce “skipping” of the last peptide bond at the C-terminus of 2A, so that the ribosome is 
able to continue translating the downstream gene product, after releasing the first protein 
fused at its C-terminus to 2A. This approach provides a tool to allow the coordinated co-
expression of multiple proteins from a single coding sequence and enables the 
achievement of stoichiometric production265 of the subunits. This is especially important 
in the case of IL-12, whose bioactive form requires equimolar expression of the two 
separate genes encoding p40 and p35 and the subsequent formation of the heterodimeric 
complex, since p40 homodimers are potent IL-12 antagonists232. This makes the P2A 
strategy more suitable for the expression of heterocomplexes such as IL-12 than other 
multicistronic strategies such as use of internal ribosome entry sites (IRES), which allow 
translation to be initiated from downstream translational start codons but often with 
reduced efficiency, leading to unequal expression of the gene products. In addition, this 
strategy reduces the size of the vector since it eliminates the need of alternative promoters 
and regulatory sequences. Additional advantages of the P2A approach are that 2A-based 
exon skipping has been observed to occur in all tested eukaryotic systems, and that the 
fusion of the small size P2A sequence neither interferes with the functionality of the 
chimeric protein nor displays immunogenicity in immunocompetent individuals266. Our 
results show that 2A cleavage occurred at its C-terminus, similarly to its role in the 
processing of PTV1 polypeptide, as we were able to detect the mup40 subunit fused to 
P2A in the transient transfection experiment in HEK-293 cells by western blotting 
(Lorenzo C et al. Figure 1c). The cellular processing of IL-12P2A was apparently successful 
in all the tumor cell lines tested: HEK-293, LLC and B16-F10, as transduced cells produced 
and released functional heterodimeric IL-12 (p70), measured by ELISA (Lorenzo C et al. 
Figure 4). IL-12P2A bioactivity was further demonstrated in lymphocyte proliferation 
experiments (Lorenzo C et al. Figure 5). Thus, our results confirm that the IL-12 
polypeptides are processed normally and secreted from the cell and that the P2A sequence 
employed does not interfere with heterodimeric IL-12 folding, secretion and activity. 
 
5.6 IL-12 expression driven by inflammation-inducible promoters in tumor 
cell lines 
 
Generally, IL-12 based therapies can be divided into three categories: active non-specific 
immunotherapy [aimed at activation of predominantly innate mechanisms], active specific 
(vaccine) approach [directed mainly to the stimulation of adaptive anti-tumor response] 
and gene therapy. Up to 58 clinical trials based on IL-12 therapy have been started or 
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completed to date113. Recombinant IL-12 has shown relevant anti-tumor activity both in 
experimental models and in humans. However, its clinical use has been hampered by dose-
limiting side effects after systemic delivery of the recombinant protein. Hence, the 
rationale for the new IL12-based gene therapy is that local expression of this cytokine may 
result in enhanced anti-tumor activity and reduced toxicity. In this regard, a number of 
local gene therapy approaches have been undertaken in veterinary clinical oncology267. By 
employing viral and non-viral gene delivery methods local anti-tumor effects have been 
achieved in cats, horses and dogs. They demonstrate that IL-12 based gene therapy is an 
effective approach. Altogether these results support and upgrade the antitumor IL-12 
features observed in preclinical experiments performed in rodents. Most recently initiated 
IL12-based clinical trials are focused on local tumor treatment by gene therapy113. These 
strategies are trying not only to minimize the IL12-dependent toxic effects but also to 
induce specific anti-tumor mechanisms by overcoming the strong immunosuppressive 
tumor microenvironment268. In this regard it is important to mention that the 
inflammation-regulated promoters ESELp and NFκBp are still induced in the presence of 
IL-10 [160 and data not shown], a potent immunosuppressive cytokine commonly 
expressed in tumors. Therefore, their transcriptional regulation will not be hampered by 
the presence of this immunosuppressive factor. Clinical trials based on intratumoral IL-12 
expression have proven that local production of IL-12 inside a tumor can stimulate 
infiltration by effector immune cells and that in some cases this is followed by tumor 
regression. Therefore IL-12 is still considered as an anti-cancer cytokine and its 
importance in cancer immunotherapy keeps growing. 
Systemic expression of IL-12 has proved to cause significant toxicity and negative side 
effects113. Thus, a major challenge in the treatment of cancer using IL-12 is the 
development of expression systems restricted to and tightly regulated by the tumor 
environment, in order to confine transgene expression only to the tumor site. We have 
tested three different lentiviral expression systems based on different inflammation-
induced promoters (ESELp, IL1-IL6p and NFκBp) in different cell lines, including two 
commonly employed in syngeneic mouse tumor models (LLC and B16-F10). Our results 
show significant differences in terms of promoter activity, fold induction and IL-12 
production among the different cell lines and promoters (Lorenzo et al. Figure 4). Among 
them, the IL-12 concentration obtained with the ESELp-based system upon stimulation 
(480 pg/ml in LLC; 160 pg/ml in HEK-293) might be enough to induce IL12-dependent 
anti-tumor immunity. This expression system would fulfil the requirements of an 
inflammation-induced system as it produces very low IL-12 in basal conditions (90 pg/ml 
in LLC, 25 pg/ml in HEK-293), thus preventing toxic side effects in the absence of 
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inflammation. In B16-F10 cells, the basal IL-12 production of the NFκBp-based system was 
very low (39 pg/ml) while it was significantly increased after pro-inflammatory 
stimulation (666 pg/ml); therefore, the NFκB-based system would be the best option for 
this cell line. These long term lentiviral expression systems might be useful not only to 
address the impact of IL-12 expression in the tumor environment but also to achieve local 
IL-12 release controlled by the inflammation state of the tumor, hopefully avoiding toxic 
side effects associated with systemic IL-12 administration. 
 
5.7 Inflammation-regulated promoters in a syngeneic tumor model 
 
Although gene therapy approaches exploiting the anti-tumoral activity of IL-12 have not 
yet achieved forecasted clinical success, they shed some light to design future strategies. 
The most relevant concerns to explain the disappointing results in those trials were the 
duration and intensity of transgene expression, as they employed short term expression 
vectors expressing IL-12 under the control of non-inducible promoters109,269,270. Therefore, 
new vectors with regulated long-term production of IL-12 might have better results and 
deserve clinical testing. The LV-based expression systems here described fulfil these two 
features, long term and inducible transgene expression. Recent preclinical studies in solid 
tumor models have shown that the level of IL-12 expression is essential for tumor 
clearance and protection145. For this, the authors isolated and characterized IL-12-
producing tumor cell clones. Once the bioactivity of IL-12P2A has been confirmed in cell 
culture-based assays and the inducibility of the promoters has been tested in vivo 162, we 
have tested the bioactivity of the IL-12P2A in mice by employing IL-12-producing clones 
from transduced LLC cells. ESELp and NFκBp showed early activation and tumor-
regulation of transgene expression in contrast to the non-inducible SFFVp expression. 
Interestingly, modulation of ESELp-driven expression begins with an increase starting at 
day 8 post-implant reaching a maximum around 11-13 days and followed by a constant 
fall. In contrast NFκBp-driven expression is characterized by high transgene levels (100 
times higher than ESELp-driven expression) and did not show a common activation 
pattern after implantation. As NFκB pathway participates in both initiation and resolution 
of inflammation271, its complex regulation during tumor growth might account for the 
different expression patterns observed. 
Regarding to IL-12P2A, its expression under the promoters tested reduced tumor cell 
growth in vivo; as a result the survival rate of the animals bearing IL-12P2A-expressing 
cells was significantly improved. It is important to indicate that the endpoint criterion was 
the detection of ulcerated areas within the tumor mass; none of them suffered 
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spontaneous death. Importantly, the results obtained with the NFκBp-based 
inflammation-inducible system were quite impressive as there were 1 partial and 2 
complete tumor regressions; these animals remained stable till the end of the experiment, 
up to 60 days post-implantation. The NFκB pathway has been recognized to play a 
promoting role in most cancers 31 and here we show that it is possible to make use of this 
NFκB-induced expression to drive transgene expression within tumor microenvironment 
and obtain a therapeutic effect by expressing IL-12. To determine whether T-cell 
activation was taking place after implantation of IL-12P2A expressing cells, splenocytes 
from tumor-bearing mice were analyzed by flow cytometry. We found that CD8+ T cell 
activation was statistically significant when IL-12P2A was expressed under either SFFVp 
or NFκBp. In the case of CD4+ T cell activation, the results were statistically significant only 
when IL-12P2A was constitutively expressed (SFFVp). As the NFκBp-IL-12P2A group 
showed the highest survival rate, and in these animals only CD8+ T cell population was 
significantly activated, these results highlight the crucial role of activated CD8+ T cells for 
the IL-12-dependent anti-tumor effect in this solid tumor model. This is in accordance 
with previous published results showing that CD8+ T cells were the primary effectors in 
IL-12-mediated anti-tumor immunity272,273. T cell activation in IL-12-expressing groups 
was confirmed by an increase in the percentage of CD69+ (one of the earliest cluster of 
differentiation expressed in activated T cells), and CD25+ (the α-chain of IL-2 receptor) 
cells, both surface proteins described as T cell activation markers 274,275. These results 
suggest that intratumor IL-12 expression triggers T cell responses that would be beneficial 
by hampering tumor progression.  
Systemic IL-12 administration causes significant toxicity and side effects 113. Samples and 
organs collected from this last in vivo experiment will allow to address this important 
question (i.e., toxicity and side effects) when our IL-12P2A expression systems were 
employed. The analysis of blood samples weekly collected will indicate the IL-12 
bloodstream levels, and will show whether the use of the inflammation-regulated 
promoter has any impact on IL-12 systemic levels. In addition tumor cell composition will 
be determined by looking for tumor infiltration of effector immune cells (macrophages, NK 
and T cells). Once we have demonstrated the bioactivity of IL-12P2A in mice by employing 
IL-12-producing LLC clones, our efforts will be directed to isolate, characterize and test in 
vivo LLC cell clones expressing IL-12P2A under ESELp. As we have shown that this 
promoter, which is regulated by tumor-inflammation, produces the lowest basal levels of 
transgene expression and a high fold induction upon stimulation, it would potentially be 
the best indicated to avoid side effects. However it is important to analyze whether these 
levels of IL-12 expression are therapeutic and have an anti-tumor effect.  It will also be 
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important to study whether long term protection can be established by immune memory. 
An important characteristic of IL-12 is that it synergizes with several other cytokines276. 
The fact that IL-12 as a monotherapy displayed limited clinical efficacy raised the 
investigation of combined treatments. A number of combined approaches have been 
tested, but only a few showed encouraging results113. Nevertheless, despite these results, 
IL-12 remains as a recognized anti-cancer agent with a great potential for synergistic 
combinations with other immunotherapies and/or conventional cancer treatments277,278.  
We have shown that subcutaneous implantation of IL-12P2A-expressing LLC clones 
results in tumor growth impairment, being the inflammation-regulated system the most 
efficient one. These experiments will constitute a proof-of-concept to study the anti-
tumoral efficacy of our inducible LV systems after local intratumoral administration. For 
future clinical applications, our expression systems can be transferred to vector platforms 
safe enough for human applications. Importantly, it has been recently shown that the virus 
mimicking effect of viral vectors would likely trigger the IFN-response needed for efficient 
IL-12 dependent immunotherapeutic effects, improving its anti-tumor properties 147. 
These inducible promoters might represent excellent systems for the inflammation-
regulated expression of different anti-tumor agents for future clinical applications. 
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6 Conclusions/Conclusiones 
  
107
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108
  
The conclusions drawn from this work can be summarized as follows: 
 
1. Lentiviral systems based on inflammation-inducible promoters respond to 
pro-inflammatory stimuli in vitro in different cell types such as immune, 
endothelial, glia and tumor cells. 
 
2. Local administration of the inflammation-regulated lentiviral system based 
on the human E-selectin promoter releases therapeutic levels of murine IL-
10 which attenuate acute inflammation induced by Zymosan injection. 
Promoter activation correlates with the inflammatory state within the 
affected area. 
 
3. Murine IL-12 expressed as a self-processing polypeptide based on the P2A 
peptide sequence (IL-12P2A) efficiently induces murine lymphoblast 
proliferation and IFN-γ release ex vivo. 
 
4. Subcutaneous implant of LLC cells transduced with the inflammation-
regulated lentiviral systems in mice stimulates transcription from their 
promoters. These results suggest the presence of an early pro-
inflammatory response within the tumor microenvironment. 
 
5. In the syngeneic model, the survival rates improve when tumor cells 
expressing IL-12P2A are implanted. In the case of the inflammation-
regulated inducible system based on the NFκB promoter, up to 60% of 
total or partial tumor regression was observed. 
 
6. Subcutaneous implant of LLC cells expressing IL-12P2A in mice increases 
the percentage of CD69 and CD25 positive cells within the CD8+ T cell 
population. These data suggest the activation of cytotoxic T lymphocytes 
that might contribute, at least in part, to the decrease of tumor growth rate 
in these animals. 
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Las conclusiones extraídas de este trabajo son las siguientes: 
 
1. Los sistemas lentivirales basados en promotores inducibles por 
inflamación responden in vitro a estímulos pro-inflamatorios en diferentes 
tipos celulares incluyendo células del sistema inmune, endoteliales, de la 
glía y tumorales. 
 
2. La administración local del sistema lentiviral regulado por inflamación 
basado en el promotor de la selectina E humana secreta niveles 
terapéuticos de IL-10 murina que disminuyen la inflamación aguda 
inducida por la inyección de Zymosan. La activación del promotor es 
proporcional al estadio inflamatorio de la zona afectada. 
 
3. La IL-12 murina expresada como un polipéptido auto-procesable 
empleando la secuencia del péptido P2A (IL-12P2A) induce en células 
aisladas de bazo de ratón tanto su proliferación como la producción de 
IFN-γ. 
 
4. El implante subcutáneo de células LLC transducidas con los sistemas 
lentivirales regulados por inflamación estimula la actividad transcripcional 
de sus promotores. Estos resultados sugieren la presencia temprana de un 
ambiente tumoral pro-inflamatorio post-implante. 
 
5. En el modelo de tumor singénico empleado, la tasa de supervivencia 
mejora cuando se implantan células tumorales que expresan IL-12P2A, 
llegando a observar una regresión total o parcial de la masa tumoral en un 
60% de los animales cuando se emplea el sistema lentiviral inducible por 
inflamación basado en el promotor NFκB. 
 
6. El implante subcutáneo de células LLC transducidas que expresan IL-
12P2A aumenta el porcentaje de linfocitos T CD8+ que expresan los 
marcadores de activación CD69 y CD25. Estos datos sugieren la activación 
de una respuesta inmune de linfocitos T citotóxicos que podría contribuir, 
al menos en parte, a la disminución de la tasa de crecimiento tumoral en 
estos animales. 
  
110
  
7 Bibliography 
  
111
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
112
  
1. Kumar V, Abbas A,K, Aster J,C. Robbins basic pathology 9th edition. ; 2012. 
2. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 
2010;140(6):805-820. 
3. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: The 
leukocyte adhesion cascade updated. Nature Reviews Immunology. 2007;7(9):678-689. 
4. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 
2014;41(5):694-707. 
5. Underhill D, Ozinsky A. Phagocytosis of microbes: Complexity in action. Annu Rev 
Immunol. 2002;20:825-852. 
6. Segal A. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197-223. 
7. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149-160. 
8. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. 
Nature Reviews Rheumatology. 2010;6(4):232-241. 
9. Charo I, Ransohoff R. Mechanisms of disease - the many roles of chemokines and 
chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621. 
10. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb 
Perspect Biol. 2009;1(6)(1943-0264 (Electronic)). 
11. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold 
Spring Harbor Perspectives in Biology. 2014;6(10):a016295. 
12. Vignali DAA, Kuchroo VK. IL-12 family cytokines: Immunological playmakers. Nat 
Immunol. 2012;13(8):722-728. 
13. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the 
IL-10 family of cytokines in inflammation and disease. Annual Review of Immunology, Vol 
29. 2011;29:71-109. 
14. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214(2):199-
210. 
15. Kirschfink M. Controlling the complement system in inflammation. 
Immunopharmacology. 1997;38(1-2):51-62. 
16. Medzhitov R. Origin and physiological roles of inflammation. Nature. 
2008;454(7203):428-435. 
17. Hatakeyama N, Matsuda N. Alert cell strategy: Mechanisms of inflammatory response 
and organ protection. Curr Pharm Des. 2014;20(36):5766-5778. 
18. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The 
pathogenesis of sepsis. Annual Review of Pathology: Mechanisms of Disease, Vol 6. 
2011;6:19-48. 
113
  
19. Nathan C, Ding A. Nonresolving inflammation. Cell. 2010;140(6):871-882. 
20. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: The 
molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol. 2009;27:621-
668. 
21. Tak PP, Firestein GS. NF-kappaB: A key role in inflammatory diseases. J Clin Invest. 
2001;107(1):7-11. 
22. Balkwill F, Mantovani A. Inflammation and cancer: Back to virchow? Lancet. 
2001;17(357(9255)):539-45. 
23. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 
2010;140(6):883-899. 
24. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 
2008;454(7203):436-444. 
25. de Martel C, Franceschi S. Infections and cancer: Established associations and new 
hypotheses. Critical Reviews in Oncology Hematology. 2009;70(3):183-194. 
26. Waldner MJ, Neurath MF. Colitis-associated cancer: The role of T cells in tumor 
development. Seminars in Immunopathology. 2009;31(2):249-256. 
27. Khasawneh J, Schulz MD, Walch A, et al. Inflammation and mitochondrial fatty acid 
beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A. 
2009;106(9):3354-3359. 
28. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung 
tumorigenesis by triggering IKK beta- and JNK1-dependent inflammation. Cancer Cell. 
2010;17(1):89-97. 
29. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for 
angiogenesis and macroscopic expansion of myc-induced pancreatic islet tumors. Nat Med. 
2007;13(10):1211-1218. 
30. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in 
tumor growth and angiogenesis. Cancer Cell. 2004;6(5):447-458. 
31. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappa B as the 
matchmaker. Nat Immunol. 2011;12(8):715-723. 
32. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: Role of 
STAT3 in the tumour microenvironment. Nature Reviews Immunology. 2007;7(1):41-51. 
33. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: A leading role for 
STAT3. Nature Reviews Cancer. 2009;9(11):798-809. 
34. Rius J, Guma M, Schachtrup C, et al. NF-kappa B links innate immunity to the hypoxic 
response through transcriptional regulation of HIF-1 alpha. Nature. 2008;453(7196):807-
U9. 
114
  
35. Eferl R, Wagner E. AP-1: A double-edged sword in tumorigenesis. Nature Reviews 
Cancer. 2003;3(11):859-868. 
36. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and 
angiogenesis. Proc Natl Acad Sci U S A. 2003;100(5):2645-2650. 
37. Grivennikov S, Karin M. Autocrine IL-6 signaling: A key event in tumorigenesis? Cancer 
Cell. 2008;13(1):7-9. 
38. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of 
intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 
2009;15(3):241-241. 
39. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: A potential target for the 
therapy of solid tumours. Lancet Oncology. 2003;4(9):565-573. 
40. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid-arthritis with 
chimeric monoclonal-antibodies to tumor-necrosis-factor-alpha. Arthritis Rheum. 
1993;36(12):1681-1690. 
41. Schett G, Elewaut D, McInnes IB, Dayer JM, Neurath MF. How cytokine networks fuel 
inflammation: Toward a cytokine-based disease taxonomy. Nat Med. 2013;19(7):822-824. 
42. Kopf M, Bachmann MF, Marsland BJ. Averting inflammation by targeting the cytokine 
environment. Nature Reviews Drug Discovery. 2010;9(9):703-718. 
43. Jacobs L, Herndon R, Freeman A, et al. Multicenter double-blind-study of effect of 
intrathecally administered natural human fibroblast interferon on exacerbations of 
multiple-sclerosis. Lancet. 1986;2(8521-2):1411-1413. 
44. Jacobs L. Intramuscular interferon beta-1a for disease progression in relapsing 
multiple sclerosis (vol 39, pg 285, 1996). Ann Neurol. 1996;40(3):480-480. 
45. Schwid SR, Panitch HS. Full results of the evidence of interferon dose-response-
european north american comparative efficacy (EVIDENCE) study: A multicenter, 
randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-
frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther. 2007;29(9):2031-
2048. 
46. Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V. Anti-TNF antibody 
therapy in rheumatoid arthritis and the risk of serious infections and malignancies - 
systematic review and meta-analysis of rare harmful effects in randomized controlled 
trials. Jama-Journal of the American Medical Association. 2006;295(19):2275-2285. 
47. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor 
necrosis factor blockade: Correction. Clinical Infectious Diseases. 2004;39(8):1254-1255. 
48. Fiorentino D, Bond M, Mosmann T. 2 types of mouse T-helper cell .4. Th2 clones 
secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 
1989;170(6):2081-2095. 
49. Spits H, Malefyt R. Functional-characterization of human il-10. Int Arch Allergy 
Immunol. 1992;99(1):8-15. 
115
  
50. Krause CD, Mei EW, Mirochnitchenko O, et al. Interactions among the components of 
the interleukin-10 receptor complex. Biochem Biophys Res Commun. 2006;340(2):377-385. 
51. Pestka S, Krause C, Sarkar D, Walter M, Shi Y, Fisher P. Interleukin-10 and related 
cytokines and receptors. Annu Rev Immunol. 2004;22:929-979. 
52. Lampropoulou V, Calderon-Gomez E, Roch T, et al. Suppressive functions of activated B 
cells in autoimmune diseases reveal the dual roles of toll-like receptors in immunity. 
Immunol Rev. 2010;233:146-161. 
53. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nature 
Reviews Immunology. 2010;10(3):170-181. 
54. Liu Y, Wei S, Ho A, Malefyt R, Moore K. Expression cloning and characterization of a 
human il-10 receptor. Journal of Immunology. 1994;152(4):1821-1829. 
55. Finbloom D, Winestock K. Il-10 induces the tyrosine phosphorylation of Tyk2 and Jak1 
and the differential assembly of Stat1-alpha and Stat3 complexes in human T-cells and 
monocytes. Journal of Immunology. 1995;155(3):1079-1090. 
56. Ho ASY, Wei SHY, Mui ALF, Miyajima A, Moore KW. Functional regions of the mouse 
interleukin-10 receptor cytoplasmic domain. Mol Cell Biol. 1995;15(9):5043-5053. 
57. Meraz M, White J, Sheehan K, et al. Targeted disruption of the STAT1 gene in mice 
reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 
1996;84(3):431-442. 
58. Takeda K, Clausen BE, Kaisho T, et al. Enhanced Th1 activity and development of 
chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 
1999;10(1):39-49. 
59. Filippi CM, von Herrath MG. IL-10 and the resolution of infections. J Pathol. 
2008;214(2):224-230. 
60. Mege J, Meghari S, Honstettre A, Capo C, Raoult D. The two faces of interleukin 10 in 
human infectious diseases. Lancet Infectious Diseases. 2006;6(9):557-569. 
61. O'Garra A, Vieira P, Vieira P, Goldfeld A. IL-10-producing and naturally occurring 
CD4(+) tregs: Limiting collateral damage. J Clin Invest. 2004;114(10):1372-1378. 
62. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice 
develop chronic enterocolitis. Cell. 1993;75(2):263-274. 
63. Curtale G, Mirolo M, Renzi TA, Rossato M, Bazzoni F, Locati M. Negative regulation of 
toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc Natl Acad Sci U S A. 
2013;110(28):11499-11504. 
64. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13(5):816-825. 
65. Moore KW, Malefyt RD, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 
receptor. Annu Rev Immunol. 2001;19:683-765. 
116
  
66. Sundstedt A, Hoiden I, Rosendahl A, Kalland T, vanRooijen N, Dohlsten M. 
Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. 
Journal of Immunology. 1997;158(1):180-186. 
67. Go NF, Castle BE, Barrett R, et al. Interleukin-10, a novel B-cell stimulatory factor - 
unresponsiveness of X-chromosome linked immunodeficiency-B cells. J Exp Med. 
1990;172(6):1625-1631. 
68. Rousset F, Garcia E, Defrance T, et al. Interleukin-10 is a potent growth and 
differentiation factor for activated human lymphocytes-B. Proc Natl Acad Sci U S A. 
1992;89(5):1890-1893. 
69. Briere F, Bridon J, Chevet D, et al. Interleukin-10 induces B-lymphocytes from iga-
deficient patients to secrete iga. J Clin Invest. 1994;94(1):97-104. 
70. Thompsonsnipes L, Dhar V, Bond M, Mosmann T, Moore K, Rennick D. Interleukin-10 - 
a novel stimulatory factor for mast-cells and their progenitors. J Exp Med. 
1991;173(2):507-510. 
71. Chen WF, Zlotnik A. Il-10 - a novel cytotoxic T-cell differentiation factor. Journal of 
Immunology. 1991;147(2):528-534. 
72. Groux H, Bigler M, de Vries J, Roncarolo M. Inhibitory and stimulatory effects of IL-10 
on human CD8(+) T cells. Journal of Immunology. 1998;160(7):3188-3193. 
73. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the 
immunoregulatory role of IL-10 secreted by antigen-presenting cells. Journal of 
Immunology. 1999;162(3):1723-1729. 
74. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. 
Trends Immunol. 2003;24(1):36-43. 
75. Oberholzer A, Oberholzer C, Moldawer LL. Inteyleukin-10: A complex role in the 
pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care 
Med. 2002;30(1):S58-S63. 
76. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following 
focal stroke. Neurosci Lett. 1998;251(3):189-192. 
77. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic 
encephalomyelitis in rats. Eur J Immunol. 1994;24(6):1434-1440. 
78. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by lactococcus lactis 
secreting interleukin-10. Science. 2000;289(5483):1352-1355. 
79. Asadullah K, Sterry W, Volk H. Interleukin-10 therapy - review of a new approach. 
Pharmacol Rev. 2003;55(2):241-269. 
80. Asadullah K, Friedrich M, Hanneken S, et al. Effects of systemic interleukin-10 therapy 
on psoriatic skin lesions: Histologic, immunohistologic, and molecular biology findings. J 
Invest Dermatol. 2001;116(5):721-727. 
117
  
81. Fuchs A, Granowitz E, Shapiro L, et al. Clinical, hematologic, and immunologic effects of 
interleukin-10 in humans. J Clin Immunol. 1996;16(5):291-303. 
82. Reich K. Response of psoriasis to interleukin-10 is associated with suppression of 
cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 
pathway and normalization of keratinocyte maturation. (vol 116, pg 319, 2001). J Invest 
Dermatol. 2001;116(5):829-829. 
83. Tilg H, van Montfrans C, van den Ende A, et al. Treatment of crohn's disease with 
recombinant human interleukin 10 induces the proinflammatory cytokine interferon 
gamma. Gut. 2002;50(2):191-195. 
84. Lauw F, Pajkrt D, Hack C, Kurimoto M, van Deventer S, van der Poll T. Proinflammatory 
effects of IL-10 during human endotoxemia. Journal of Immunology. 2000;165(5):2783-
2789. 
85. O'Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nature 
Reviews Immunology. 2007;7(6):425-428. 
86. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J 
Exp Med. 2007;204(2):239-243. 
87. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 
2011;144(5):646-674. 
88. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in 
cancer suppression and promotion. Science. 2011;331(6024):1565-1570. 
89. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer 
treatment. Nature Reviews Cancer. 2012;12(4):237-251. 
90. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. 
Immunity. 2013;39(1):1-10. 
91. Hodi FS. Improved survival with ipilimumab in patients with metastatic melanoma (vol 
363, pg 711, 2010). N Engl J Med. 2010;363(13):1290-1290. 
92. Chambers C, Kuhns M, Egen J, Allison J. CTLA-4-mediated inhibition in regulation of T 
cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev 
Immunol. 2001;19:565-594. 
93. Chemnitz J, Parry R, Nichols K, June C, Riley J. SHP-1 and SHP-2 associate with 
immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary 
human T cell stimulation, but only receptor ligation prevents T cell activation. Journal of 
Immunology. 2004;173(2):945-954. 
94. Parry R, Chemnitz J, Frauwirth K, et al. CTLA-4 and PD-1 receptors inhibit T-cell 
activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543-9553. 
95. Chen DS, Irving BA, Hodi FS. Molecular pathways: Next-generation immunotherapy-
inhibiting programmed death-ligand 1 and programmed death-1. Clinical Cancer Research. 
2012;18(24):6580-6587. 
118
  
96. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural-killer cell 
stimulatory factor (nksf), a cytokine with multiple biologic effects on human-lymphocytes. 
J Exp Med. 1989;170(3):827-845. 
97. Stern A, Podlaski F, Hulmes J, et al. Purification to homogeneity and partial 
characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid 
cells. Proc Natl Acad Sci U S A. 1990;87(17):6808-6812. 
98. Gubler U, Chua A, Schoenhaut D, et al. Coexpression of 2 distinct genes is required to 
generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci U S 
A. 1991;88(10):4143-4147. 
99. Presky D, Yang H, Minetti L, et al. A functional interleukin 12 receptor complex is 
composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A. 
1996;93(24):14002-14007. 
100. Gately M, Renzetti L, Magram J, et al. The interleukin-12/interleukin-12-receptor 
system: Role in normal and pathologic immune responses. Annu Rev Immunol. 
1998;16:495-521. 
101. Desai B, Quinn P, Wolitzky A, Mongini P, Chizzonite R, Gately M. Il-12 receptor .2. 
distribution and regulation of receptor expression. Journal of Immunology. 
1992;148(10):3125-3132. 
102. Rogge L, BarberisMaino L, Biffi M, et al. Selective expression of an interleukin-12 
receptor component by human T helper 1 cells. J Exp Med. 1997;185(5):825-831. 
103. Thierfelder W, vanDeursen J, Yamamoto K, et al. Requirement for Stat4 in interleukin-
12-mediated responses of natural killer and T cells. Nature. 1996;382(6587):171-174. 
104. Becker C, Wirtz S, Neurath M. Stepwise regulation of T(H)1 responses in 
autoimmunity: IL-12-related cytokines and their receptors. Inflamm Bowel Dis. 
2005;11(8):755-764. 
105. Afkarian M, Sedy J, Yang J, et al. T-bet is a STAT1-induced regulator of IL-12R 
expression in naive CD4(+) T cells. Nat Immunol. 2002;3(6):549-557. 
106. Mullen A, High F, Hutchins A, et al. Role of T-bet in commitment of T(H)1 cells before 
IL-12-dependent selection. Science. 2001;292(5523):1907-1910. 
107. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive 
immunity. Nature Reviews Immunology. 2003;3(2):133-146. 
108. Tahara H, Lotze M. Antitumor effects of interleukin-12 (il-12) - applications for the 
immunotherapy and gene-therapy of cancer. Gene Ther. 1995;2(2):96-106. 
109. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. 
Current Gene Therapy. 2005;5(6):573-581. 
110. Kerkar SP, Goldszmid RS, Muranski P, et al. IL-12 triggers a programmatic change in 
dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest. 
2011;121(12):4746-4757. 
119
  
111. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and 
immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155-168. 
112. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: Biological properties and 
clinical application. Clinical Cancer Research. 2007;13(16):4677-4685. 
113. Lasek W, Zagozdzon R, Jakobisiak M. Interleukin 12: Still a promising candidate for 
tumor immunotherapy? Cancer Immunology Immunotherapy. 2014;63(5):419-435. 
114. Kaufmann KB, Buning H, Galy A, Schambach A, Grez M. Gene therapy on the move. 
EMBO Mol Med. 2013;5(11):1642-1661. 
115. Giry-Laterriere M, Verhoeyen E, Salmon P. Lentiviral vectors. Methods Mol Biol. 
2011;737:183-209. 
116. Durand S, Cimarelli A. The inside out of lentiviral vectors. Viruses. 2011;3(2):132-159. 
117. Sinn PL, Sauter SL, McCray PB,Jr. Gene therapy progress and prospects: Development 
of improved lentiviral and retroviral vectors--design, biosafety, and production. Gene Ther. 
2005;12(14):1089-1098. 
118. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a 
conditional packaging system. J Virol. 1998;72(11):8463-8471. 
119. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of 
nondividing cells by a lentiviral vector. Science. 1996;272(5259):263-267. 
120. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and 
efficient in vivo gene delivery. J Virol. 1998;72(12):9873-9880. 
121. Cavazzana-Calvo M, Hacein-Bey S, Basile CD, et al. Gene therapy of human severe 
combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672. 
122. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 
activation after gene therapy of human beta-thalassaemia. Nature. 2010;467(7313):318-
U94. 
123. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the wiskott-
aldrich syndrome. N Engl J Med. 2010;363(20):1918-1927. 
124. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy 
in patients with wiskott-aldrich syndrome. Science. 2013;341(6148):865-U71. 
125. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic 
granulomatous disease by gene therapy, augmented by insertional activation of MDS1-
EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-409. 
126. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene 
therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 
2009;326(5954):818-823. 
120
  
127. Biffi A, Montini E, Lorioli L, et al. Lentiviral hematopoietic stem cell gene therapy 
benefits metachromatic leukodystrophy. Science. 2013;341(6148):864-U58. 
128. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have 
potent antitumor effects and can establish memory in patients with advanced leukemia. 
Science Translational Medicine. 2011;3(95):95ra73. 
129. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and 
regression of lymphoma in a patient treated with autologous T cells genetically engineered 
to recognize CD19. Blood. 2010;116(20):4099-4102. 
130. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T 
cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733. 
131. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a 
lentiviral vector-based gene therapy for parkinson's disease: A dose escalation, open-label, 
phase 1/2 trial. Lancet. 2014;383(9923):1138-1146. 
132. Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene transfer into 
normal rabbit arteries results in prolonged vascular cell activation, inflammation, and 
neointimal hyperplasia. J Clin Invest. 1995;96(6):2955-2965. 
133. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Current Gene 
Therapy. 2007;7(5):316-324. 
134. Zaiss AK, Cotter MJ, White LR, et al. Complement is an essential component of the 
immune response to adeno-associated virus vectors. J Virol. 2008;82(6):2727-2740. 
135. Peden CS, Manfredsson FP, Reimsnider SK, et al. Striatal readministration of rAAV 
vectors reveals an immune response against AAV2 capsids that can be circumvented. 
Molecular Therapy. 2009;17(3):524-537. 
136. Leung PSC, Dhirapong A, Wu P, Tao M. Gene therapy in autoimmune diseases: 
Challenges and opportunities. Autoimmunity Reviews. 2010;9(3):170-174. 
137. Kok M, Yamano S, Lodde B, et al. Local adeno-associated virus-mediated interleukin 
10 gene transfer has disease-modifying effects in a murine model of sjogren's syndrome. 
Hum Gene Ther. 2003;14(17):1605-1618. 
138. Guichelaar T, ten Brink CB, van Kooten PJ, et al. Autoantigen-specific IL-10-
transduced T cells suppress chronic arthritis by promoting the endogenous regulatory IL-
10 response. Journal of Immunology. 2008;180(3):1373-1381. 
139. van Strien ME, Mercier D, Drukarch B, et al. Anti-inflammatory effect by lentiviral-
mediated overexpression of IL-10 or IL-1 receptor antagonist in rat glial cells and 
macrophages. Gene Ther. 2010;17(5):662-671. 
140. He Z, Guo Q, Xiao M, He C, Zou W. Intrathecal lentivirus-mediated transfer of 
interleukin-10 attenuates chronic constriction injury-induced neuropathic pain through 
modulation of spinal high-mobility group box 1 in rats. Pain Physician. 2013;16(5):E615-
E625. 
121
  
141. Hirayama S, Sato M, Loisel-Meyer S, et al. Lentivirus IL-10 gene therapy down-
regulates IL-17 and attenuates mouse orthotopic lung allograft rejection. American Journal 
of Transplantation. 2013;13(6):1586-1593. 
142. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr 
Pharm Des. 2003;9(24):1981-1991. 
143. Freytag SO, Barton KN, Zhang Y. Efficacy of oncolytic adenovirus expressing suicide 
genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther. 
2013;20(12):1131-1139. 
144. Paul D, Qazilbash M, Song K, et al. Construction of a recombinant adeno-associated 
virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther. 
2000;7(2):308-315. 
145. Wei LZ, Xu Y, Nelles ME, et al. Localized interleukin-12 delivery for immunotherapy of 
solid tumours. J Cell Mol Med. 2013;17(11):1465-1474. 
146. Passer BJ, Cheema T, Wu S, Wu C, Rabkin SD, Martuza RL. Combination of vinblastine 
and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor 
and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 2013;20(1):17-24. 
147. Melero I, Quetglas JI, Reboredo M, et al. Strict requirement for vector-induced type I 
interferon in efficacious antitumor responses to virally encoded IL12. Cancer Res. 
2015;75(3):497-507. 
148. Brooks AR, Harkins RN, Wang PY, Qian HS, Liu PX, Rubanyi GM. Transcriptional 
silencing is associated with extensive methylation of the CMV promoter following 
adenoviral gene delivery to muscle. J Gene Med. 2004;6(4):395-404. 
149. Meilinger D, Fellinger K, Bultmann S, et al. Np95 interacts with de novo DNA 
methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic silencing of the viral 
CMV promoter in embryonic stem cells. EMBO Rep. 2009;10(11):1259-1264. 
150. Teschendorf C, Warrington KH, Siemann DW, Muzyczka N. Comparison of the EF-1 
alpha and the CMV promoter for engineering stable tumor cell lines using recombinant 
adeno-associated virus. Anticancer Res. 2002;22(6A):3325-3330. 
151. Herbst F, Ball CR, Tuorto F, et al. Extensive methylation of promoter sequences 
silences lentiviral transgene expression during stem cell differentiation in vivo. Molecular 
Therapy. 2012;20(5):1014-1021. 
152. Gossen M, Bujard H. Tight control of gene-expression in mammalian-cells by 
tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89(12):5547-5551. 
153. Pollock R, Clackson T. Dimerizer-regulated gene expression. Curr Opin Biotechnol. 
2002;13(5):459-467. 
154. Pollock R, Issner R, Zoller K, Natesan S, Rivera VM, Clackson T. Delivery of a stringent 
dimerizer-regulated gene expression system in a single retroviral vector. Proc Natl Acad 
Sci U S A. 2000;97(24):13221-13226. 
122
  
155. van de Loo FAJ. Inflammation-responsive promoters for fine-tuned gene therapy in 
rheumatoid arthritis. Curr Opin Mol Ther. 2004;6(5):537-545. 
156. Varley AW, Geiszler SM, Gaynor RB, Munford RS. A two-component expression 
system that responds to inflammatory stimuli in vivo. Nat Biotechnol. 1997;15(10):1002-
1006. 
157. van de Loo FAJ, de Hooge ASK, Smeets RL, et al. An inflammation-inducible adenoviral 
expression system for local treatment of the arthritic joint. Gene Ther. 2004;11(7):581-
590. 
158. Khoury M, Adriaansen J, Vervoordeldonk MJBM, et al. Inflammation-inducible anti-
TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated 
virus reduces arthritis. J Gene Med. 2007;9(7):596-604. 
159. Buckley SMK, Delhove JMKM, Perocheau DP, et al. In vivo bioimaging with tissue-
specific transcription factor activated luciferase reporters. Scientific Reports. 
2015;5:11842. 
160. Garaulet G, Alfranca A, Torrente M, et al. IL10 released by a new inflammation-
regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Molecular 
Therapy. 2013;21(1):119-130. 
161. Garcia-Escudero V, Rosales M, Luis Munoz J, et al. Patient-derived olfactory mucosa 
for study of the non-neuronal contribution to amyotrophic lateral sclerosis pathology. J 
Cell Mol Med. 2015;19(6):1284-1295. 
162. Lorenzo C, Perez-Chacon G, Garaulet G, Mallorquin Z, Zapata JM, Rodriguez A. Efficient 
expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by 
inflammation-regulated promoters in tumor cell lines. Cancer Gene Ther. 2015. 
163. Moore KW, Ogarra A, Malefyt RD, Vieira P, Mosmann TR. Interleukin-10. Annu Rev 
Immunol. 1993;11:165-190. 
164. van de Loo FAJ, van den Berg WB. Gene therapy for rheumatoid arthritis - lessons 
from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 
receptor antagonist as potential disease modulators. Rheumatic Disease Clinics of North 
America. 2002;28(1):127-+. 
165. Buchschacher GL, Wong-Staal F. Development of lentiviral vectors for gene therapy 
for human diseases. Blood. 2000;95(8):2499-2504. 
166. Roth S, Pulcini C, Vandenbos F, et al. Pulmonary localisation of hairy cell leukemia. 
Revue De Medecine Interne. 2002;23(10):870-872. 
167. Mayordomo L, Marenco JL, Gomez-Mateos J, Rejon E. Pulmonary miliary tuberculosis 
in a patient with anti-TNF-alpha treatment. Scand J Rheumatol. 2002;31(1):44-45. 
168. Martinez ON, Noiseux CR, Martin JAC, Lara VG. Reactivation tuberculosis in a patient 
with anti-TNF-alpha treatment. Am J Gastroenterol. 2001;96(5):1665-1666. 
169. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. 
Neurology. 2001;57(10):1885-1888. 
123
  
170. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration - 
the multistep paradigm. Cell. 1994;76(2):301-314. 
171. Keelan ET, Licence ST, Peters AM, Binns RM, Haskard DO. Characterization of E-
selectin expression in vivo with use of a radiolabeled monoclonal antibody. Am J Physiol. 
1994;266(1 Pt 2):H278-90. 
172. Jaggar RT, Chan HY, Harris AL, Bicknell R. Endothelial cell-specific expression of 
tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral 
delivery. Hum Gene Ther. 1997;8(18):2239-2247. 
173. Walton T, Wang JL, Ribas A, Barsky SH, Economou J, Nguyen M. Endothelium-specific 
expression of an E-selectin promoter recombinant adenoviral vector. Anticancer Res. 
1998;18(3A):1357-1360. 
174. Xu N, Rahman A, Minshall RD, Tiruppathi C, Malik AB. Beta(2)-integrin blockade 
driven by E-selectin promoter prevents neutrophil sequestration and lung injury in mice. 
Circ Res. 2000;87(3):254-260. 
175. Xu N, Gao XP, Minshall RD, Rahman A, Malik AB. Time-dependent reversal of sepsis-
induced PMN uptake and lung vascular injury by expression of CD18 antagonist. American 
Journal of Physiology-Lung Cellular and Molecular Physiology. 2002;282(4):L796-L802. 
176. Maxwell IH, Kaletta C, Naujoks K, Maxwell F. Targeting diphtheria toxin A-chain 
transcription to activated endothelial cells using an E-selectin promoter. Angiogenesis. 
2003;6(1):31-8. 
177. Rowland LP. Amyotrophic-lateral-sclerosis. Curr Opin Neurol. 1994;7(4):310-315. 
178. Calvo AC, Manzano R, Mendonca DMF, Munoz MJ, Zaragoza P, Osta R. Amyotrophic 
lateral sclerosis: A focus on disease progression. Biomed Research International. 
2014:925101. 
179. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. 
Nat Neurosci. 2014;17(1):17-23. 
180. Rosen DR. Mutations in cu/zn superoxide-dismutase gene are associated with familial 
amyotrophic-lateral-sclerosis (vol 362, pg 59, 1993). Nature. 1993;364(6435):362-362. 
181. Valentine JS, Doucette PA, Potter SZ. Copper-zinc superoxide dismutase and 
amyotrophic lateral sclerosis. Annu Rev Biochem. 2005;74:563-593. 
182. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC 
hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked 
FTD and ALS. Neuron. 2011;72(2):245-256. 
183. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat 
expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A 
cross-sectional study. Lancet Neurology. 2012;11(4):323-330. 
184. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 
is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268. 
124
  
185. Boillee S, Vande Velde C, Cleveland DW. ALS: A disease of motor neurons and their 
nonneuronal neighbors. Neuron. 2006;52(1):39-59. 
186. Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend 
survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302(5642):113-117. 
187. Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor 
neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci 
U S A. 2008;105(21):7594-7599. 
188. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect 
of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. 
2007;10(5):608-614. 
189. Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 
release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615-622. 
190. Marchetto MCN, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous 
effect of human SOD1(G37R) astrocytes on motor neurons derived from human 
embryonic stem cells. Cell Stem Cell. 2008;3(6):649-657. 
191. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. 
Muscle Nerve. 2002;26(4):459-470. 
192. Schiffer D, Cordera S, Cavalla P, Migheli A. Reactive astrogliosis of the spinal cord in 
amyotrophic lateral sclerosis. J Neurol Sci. 1996;139:27-33. 
193. Anneser JMH, Chahli C, Ince PG, Borasio GD, Shaw PJ. Glial proliferation and 
metabotropic glutamate receptor expression in amyotrophic lateral sclerosis. J 
Neuropathol Exp Neurol. 2004;63(8):831-840. 
194. Casula M, Iyer AM, Spliet WGM, et al. Toll-like receptor signaling in amyotrophic 
lateral sclerosis spinal cord tissue. Neuroscience. 2011;179:233-243. 
195. Wang R, Yang B, Zhang D. Activation of interferon signaling pathways in spinal cord 
astrocytes from an ALS mouse model. Glia. 2011;59(6):946-958. 
196. Baron P, Bussini S, Cardin V, et al. Production of monocyte chemoattractant protein-1 
in amyotrophic lateral sclerosis. Muscle Nerve. 2005;32(4):541-544. 
197. Tateishi T, Yamasaki R, Tanaka M, et al. CSF chemokine alterations related to the 
clinical course of amyotrophic lateral sclerosis. J Neuroimmunol. 2010;222(1-2):76-81. 
198. Poloni M, Facchetti D, Mai R, et al. Circulating levels of tumour necrosis factor-alpha 
and its soluble receptors are increased in the blood of patients with amyotrophic lateral 
sclerosis. Neurosci Lett. 2000;287(3):211-214. 
199. Keller AF, Gravel M, Kriz J. Live imaging of amyotrophic lateral sclerosis pathogenesis: 
Disease onset is characterized by marked induction of GFAP in schwann cells. Glia. 
2009;57(10):1130-1142. 
200. Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ. Microarray analysis of 
the cellular pathways involved in the adaptation to and progression of motor neuron 
125
  
injury in the SOD1 G93A mouse model of familial ALS. Journal of Neuroscience. 
2007;27(34):9201-9219. 
201. Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in 
neurodegenerative diseases: A similar pattern. Neurobiol Aging. 2009;30(5):759-768. 
202. Liu Y, Hao W, Dawson A, Liu S, Fassbender K. Expression of amyotrophic lateral 
sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J 
Biol Chem. 2009;284(6):3691-3699. 
203. Zhao W, Beers DR, Henkel JS, et al. Extracellular mutant SOD1 induces microglial-
mediated motoneuron injury. Glia. 2010;58(2):231-243. 
204. de Munck E, Munoz-Saez E, Miguel BG, et al. Beta-N-methylamino-L-alanine causes 
neurological and pathological phenotypes mimicking amyotrophic lateral sclerosis (ALS): 
The first step towards an experimental model for sporadic ALS. Environ Toxicol Pharmacol. 
2013;36(2):243-255. 
205. Ronnett GV, Leopold D, Cai XH, et al. Olfactory biopsies demonstrate a defect in 
neuronal development in rett's syndrome. Ann Neurol. 2003;54(2):206-218. 
206. Wolozin B, Zheng B, Loren D, et al. Beta/a4 domain of app - antigenic differences 
between cell-lines. J Neurosci Res. 1992;33(2):189-195. 
207. Abrams MT, Kaufmann WE, Rousseau F, et al. FMR1 gene expression in olfactory 
neuroblasts from two males with fragile X syndrome. Am J Med Genet. 1999;82(1):25-30. 
208. Feron F, Perry C, Hirning MH, McGrath J, Mackay-Sim A. Altered adhesion, 
proliferation and death in neural cultures from adults with schizophrenia. Schizophr Res. 
1999;40(3):211-218. 
209. Arnold SE, Han LY, Moberg PJ, et al. Dysregulation of olfactory receptor neuron 
lineage in schizophrenia. Arch Gen Psychiatry. 2001;58(9):829-835. 
210. McCurdy RD, Feron F, Perry C, et al. Cell cycle alterations in biopsied olfactory 
neuroepithelium in schizophrenia and bipolar I disorder using cell culture and gene 
expression analyses. Schizophr Res. 2006;82(2-3):163-173. 
211. Roisen FJ, Klueber KM, Lu CL, et al. Adult human olfactory stem cells. Brain Res. 
2001;890(1):11-22. 
212. Murrell W, Feron F, Wetzig A, et al. Multipotent stem cells from adult olfactory 
mucosa. Developmental Dynamics. 2005;233(2):496-515. 
213. Murrell W, Wetzig A, Donnellan M, et al. Olfactory mucosa is a potential source for 
autologous stem cell therapy for parkinson's disease. Stem Cells. 2008;26(8):2183-2192. 
214. Murrell W, Sanford E, Anderberg L, Cavanagh B, Mackay-Sim A. Olfactory stem cells 
can be induced to express chondrogenic phenotype in a rat intervertebral disc injury 
model. Spine Journal. 2009;9(7):585-594. 
215. Au E, Roskams AJ. Olfactory ensheathing cells of the lamina propria in vivo and in 
vitro. Glia. 2003;41(3):224-236. 
126
  
216. Doucette JR. The glial-cells in the nerve-fiber layer of the rat olfactory-bulb. Anat Rec. 
1984;210(2):385-391. 
217. Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell 
transplantation in human spinal cord injury. Brain. 2005;128:2951-2960. 
218. Lu J, Feron F, Ho SH, Mackay-Sim A, Waite PME. Transplantation of nasal olfactory 
tissue promotes partial recovery in paraplegic adult rats. Brain Res. 2001;889(1-2):344-
357. 
219. Morita E, Watanabe Y, Ishimoto M, et al. A novel cell transplantation protocol and its 
application to an ALS mouse model. Exp Neurol. 2008;213(2):431-438. 
220. Huang Z, Wang Y, Cao L, et al. Migratory properties of cultured olfactory ensheathing 
cells by single-cell migration assay. Cell Res. 2008;18(4):479-490. 
221. Vincent AJ, Taylor JM, Choi-Lundberg DL, West AK, Chuah MI. Genetic expression 
profile of olfactory ensheathing cells is distinct from that of schwann cells and astrocytes. 
Glia. 2005;51(2):132-147. 
222. Vincent AJ, Choi-Lundberg DL, Harris JA, West AK, Chuah MI. Bacteria and PAMPs 
activate nuclear factor kB and gro production in a subset of olfactory ensheathing cells and 
astrocytes but not in schwann cells. Glia. 2007;55(9):905-916. 
223. Doty R. Studies of olfactory dysfunction in major neurological disorders. Adv.Biosci. 
1994;93:593-602. 
224. Ozdener M, Rawson N. Olfactory dysfunction in neurodegenerative diseases. 
Eur.J.Gen.Med. 2004;1:1-11. 
225. Ahlskog JE, Waring SC, Petersen RC, et al. Olfactory dysfunction in guamanian ALS, 
parkinsonism, and dementia. Neurology. 1998;51(6):1672-1677. 
226. Federico G, Maremmani C, Cinquanta L, Baroncelli GI, Fattori B, Saggese G. Mucus of 
the human olfactory epithelium contains the insulin-like growth factor-I system which is 
altered in some neurodegenerative diseases. Brain Res. 1999;835(2):306-314. 
227. Matigian N, Abrahamsen G, Sutharsan R, et al. Disease-specific, neurosphere-derived 
cells as models for brain disorders. Disease Models & Mechanisms. 2010;3(11-12):785-798. 
228. Abrahamsen G, Fan Y, Matigian N, et al. A patient-derived stem cell model of 
hereditary spastic paraplegia with SPAST mutations. Disease Models & Mechanisms. 
2013;6(2):489-502. 
229. Ostrand-Rosenberg S. Immune surveillance: A balance between protumor and 
antitumor immunity. Curr Opin Genet Dev. 2008;18(1):11-18. 
230. Malmberg KJ, Ljunggren HG. Escape from immune- and nonimmune-mediated tumor 
surveillance. Semin Cancer Biol. 2006;16(1):16-31. 
231. Tietje A, Li J, Yu X, Wei Y. MULT1E/mIL-12: A novel bifunctional protein for natural 
killer cell activation. Gene Ther. 2014;21(5):468-475. 
127
  
232. Gillessen S, Carvajal D, Ling P, et al. Mouse interleukin-12 (il-12) P40 homodimer - a 
potent il-12 antagonist. Eur J Immunol. 1995;25(1):200-206. 
233. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-
1146. 
234. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nature Reviews 
Cancer. 2004;4(1):11-22. 
235. Germann T, Gately M, Schoenaut D, et al. Interleukin-12/t-cell stimulating factor, a 
cytokine with multiple effects on T-helper type-1 (Th1) but not on Th2 cells. Eur J 
Immunol. 1993;23(8):1762-1770. 
236. Voest EE, Kenyon BB, Oreilly MS, Truitt G, Damato RJ, Folkman J. Inhibition of 
angiogenesis in-vivo by interleukin-12. J Natl Cancer Inst. 1995;87(8):581-586. 
237. Kodama T, Takeda K, Shimozato O, et al. Perforin-dependent NK cell cytotoxicity is 
sufficient for anti-metastatic effect of IL-12. Eur J Immunol. 1999;29(4):1390-1396. 
238. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers 
a type I interferon response that restricts hepatocyte gene transfer and promotes vector 
clearance. Blood. 2007;109(7):2797-2805. 
239. Breckpot K, Aerts JL, Thielemans K. Lentiviral vectors for cancer immunotherapy: 
Transforming infectious particles into therapeutics. Gene Ther. 2007;14(11):847-862. 
240. Dullaers M, Van Meirvenne S, Heirman C, et al. Induction of effective therapeutic 
antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 
2006;13(7):630-640. 
241. Rowe HM, Lopes L, Ikeda Y, et al. Immunization with a lentiviral vector stimulates 
both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther. 2006;13(2):310-
319. 
242. Labbe A, Nelles M, Walia J, et al. IL-12 immunotherapy of murine leukaemia: 
Comparison of systemic versus gene modified cell therapy. J Cell Mol Med. 
2009;13(8B):1962-1976. 
243. Li S, Huang L. Nonviral gene therapy: Promises and challenges. Gene Ther. 
2000;7(1):31-34. 
244. Niidome T, Huang L. Gene therapy progress and prospects: Nonviral vectors. Gene 
Ther. 2002;9(24):1647-1652. 
245. Hiltunen MO, Turunen MP, Turunen AM, et al. Biodistribution of adenoviral vector to 
nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and 
periadventitial gene delivery methods. Faseb Journal. 2000;14(14):2230-2236. 
246. Pajusola K, Gruchala M, Joch H, Luscher TF, Yla-Herttuala S, Bueler H. Cell-type-
specific characteristics modulate the transduction efficiency of adeno-associated virus 
type 2 and restrain infection of endothelial cells. J Virol. 2002;76(22):11530-11540. 
128
  
247. Eslami MH, Gangadharan SP, Sui X, Rhynhart KK, Snyder RO, Conte MS. Gene delivery 
to in situ veins: Differential effects of adenovirus and adeno-associated viral vectors. 
Journal of Vascular Surgery. 2000;31(6):1149-1159. 
248. Vassalli G, Bueler H, Dudler J, von Segesser LK, Kappenberger L. Adeno-associated 
virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and 
arteries in vivo: A comparative study with adenovirus vectors. Int J Cardiol. 2003;90(2-
3):229-238. 
249. VandenDriessche T, Naldini L, Collen D, Chuah MKL. Oncoretroviral and lentiviral 
vector-mediated gene therapy. Gene Therapy Methods. 2002;346:573-589. 
250. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis-virus G 
glycoprotein pseudotyped retroviral vectors - concentration to very high-titer and efficient 
gene-transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A. 
1993;90(17):8033-8037. 
251. Bartz SR, Rogel ME, Emerman M. Human immunodeficiency virus type 1 cell cycle 
control: Vpr is cytostatic and mediates G(2) accumulation by a mechanism which differs 
from DNA damage checkpoint control. J Virol. 1996;70(4):2324-2331. 
252. Esslinger C, Chapatte L, Finke D, et al. In vivo administration of a lentiviral vaccine 
targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest. 
2003;111(11):1673-1681. 
253. Oberholzer A, Oberholzer C, Efron PA, et al. Functional modification of dendritic cells 
with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis. Shock. 
2005;23(6):507-515. 
254. Kushwah R, Oliver JR, Duan R, Zhang L, Keshavjee S, Hu J. Induction of immunological 
tolerance to adenoviral vectors by using a novel dendritic cell-based strategy. J Virol. 
2012;86(7):3422-3435. 
255. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF 
antibody therapy in rheumatoid arthritis and the risk of serious infections and 
malignancies - systematic review and meta-analysis of rare harmful effects in randomized 
controlled trials. Jama-Journal of the American Medical Association. 2006;295(19):2275-
2285. 
256. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N 
Engl J Med. 2006;355(7):704-712. 
257. Chan JMK, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM. Intraarticular gene 
transfer of TNFR : Fc suppresses experimental arthritis with reduced systemic distribution 
of the gene product. Molecular Therapy. 2002;6(6):727-736. 
258. Phani S, Re DB, Przedborski S. The role of the innate immune system in ALS. Frontiers 
in Pharmacology. 2012;3:UNSP 150. 
259. Migheli A, Piva R, Atzori C, Troost D, Schiffer D. C-jun, JNK/SAPK kinases and 
transcription factor NF-kappa B are selectively activated in astrocytes, but not motor 
neurons, in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1997;56(12):1314-
1322. 
129
  
260. Swarup V, Phaneuf D, Dupre N, et al. Deregulation of TDP-43 in amyotrophic lateral 
sclerosis triggers nuclear factor kappa B-mediated pathogenic pathways. J Exp Med. 
2011;208(12):2429-2447. 
261. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: The good, the bad, and the 
resting. Journal of Neuroimmune Pharmacology. 2009;4(4):389-398. 
262. Knippenberg S, Sipos J, Thau-Habermann N, et al. Altered expression of DJ-1 and 
PINK1 in sporadic ALS and in the SOD1(G93A) ALS mouse model. J Neuropathol Exp 
Neurol. 2013;72(11):1052-1061. 
263. Jalah R, Rosati M, Ganneru B, et al. The p40 subunit of interleukin (IL)-12 promotes 
stabilization and export of the p35 subunit IMPLICATIONS FOR IMPROVED IL-12 
CYTOKINE PRODUCTION. J Biol Chem. 2013;288(9):6763-6776. 
264. Ryan MD, King AMQ, Thomas GP. Cleavage of foot-and-mouth-disease virus 
polyprotein is mediated by residues located within a 19 amino-acid-sequence. J Gen Virol. 
1991;72:2727-2732. 
265. de Felipe P, Hughes LE, Ryan MD, Brown JD. Co-translational, intraribosomal cleavage 
of polypeptides by the foot-and-mouth disease virus 2A peptide. J Biol Chem. 
2003;278(13):11441-11448. 
266. Arber C, Abhyankar H, Heslop HE, et al. The immunogenicity of virus-derived 2A 
sequences in immunocompetent individuals. Gene Ther. 2013;20(9):958-962. 
267. Pavlin D, Cemazar M, Sersa G, Tozon N. IL-12 based gene therapy in veterinary 
medicine. Journal of Translational Medicine. 2012;10:234. 
268. Van der Jeught K, Bialkowski L, Daszkiewicz L, et al. Targeting the tumor 
microenvironment to enhance antitumor immune responses. Oncotarget. 2015;6(3):1359-
1381. 
269. Triozzi P, Strong T, Bucy R, et al. Intratumoral administration of a recombinant 
canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum 
Gene Ther. 2005;16(1):91-100. 
270. Rodriguez-Madoz J, Prieto J, Smerdou C. Semliki forest virus vectors engineered to 
express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. 
Molecular Therapy. 2005;12(1):153-163. 
271. Ruland J. Return to homeostasis: Downregulation of NF-kappa B responses. Nat 
Immunol. 2011;12(8):709-714. 
272. Mendiratta SK, Quezada A, Matar M, et al. Intratumoral delivery of IL-12 gene by 
polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent 
antitumor immunity. Gene Ther. 1999;6(5):833-839. 
273. Goyvaerts C, Broos K, Escors D, et al. The transduction pattern of IL-12-encoding 
lentiviral vectors shapes the immunological outcome. Eur J Immunol. 2015. 
274. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule 
induced following activation. Trends Immunol. 2005;26(3):136-140. 
130
  
275. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of 
the immune system. Nature Reviews Immunology. 2012;12(3):180-190. 
276. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Immunotherapy of cancer by IL-12-
based cytokine combinations. Expert Opinion on Biological Therapy. 2007;7(11):1705-
1721. 
277. Quetglas JI, Labiano S, Aznar MA, et al. Virotherapy with a semliki forest virus-based 
vector encoding IL12 synergizes with PD-1/PD-L1 blockade. Cancer Immunology Research. 
2015;3(5):449-454. 
278. Melero I, Berman DM, Angela Aznar M, Korman AJ, Perez Gracia JL, Haanen J. Evolving 
synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews 
Cancer. 2015;15(8):457-472. 
  
 
  
 
 
131
